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Type 2 Diabetes Mellitus: the need for better diagnosis and 
treatment 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by 
hyperglycemia with disturbances of carbohydrate, lipid and protein metabolism, 
involving decreased production of insulin and/or reduced sensitivity of the body 
tissues to insulin [1-4].  According to World Health Organization (WHO), T2DM is 
resulted from a defect in both insulin secretion and in insulin sensitivity, as well as 
β-cell dysfunction, β-cell loss and its progression [5]. T2DM is now found in almost 
every population and epidemiological evidence suggests that without effective 
prevention and intervention programmes, its prevalence will continue to increase 
globally [6]. Because of a lack of symptoms early on in the disease, a large 
proportion of these individuals remain undiagnosed; this proportion is estimated 
to be higher than 50% [7]. Moreover, it can lead to a number of serious medical 
complications (e.g. retinopathy, neuropathy, myocardial infarction, stroke), which 
are a major cause of morbidity, hospitalization and mortality in diabetic patients; 
and resulting in a financial burden for public health internationally [1, 5, 8]. 
Indeed, diabetes care already accounts for about 2–7% of the total national health 
care budgets of western European countries [9]. Thus, identification of early 
biomarkers for prediction and monitoring is needed for adequate screening 
diagnostics of T2DM [7]. 
T2DM and cardiovascular disease (CVD) are strongly associated with various 
common metabolic disturbances under the name of metabolic syndrome (MetS), 
including abdominal obesity, insulin resistance, dyslipidaemias, hypertension and 
a systemic proinflammatory state [10-12]. Several modifiable risk factors for 
T2DM have been identified such as obesity, physical inactivity, excessive calorie 
intake  and above mentioned MetS related disorders [10, 11]. Evidence shows 
that both lifestyle regulation and early pharmacotherapy during pre-diabetes are 
effective in slowing down the onset and progression of T2DM [2, 4, 13]. However, 
due to its multi-factorial causes (Figure 1) resulting from the interaction among a 
genetic predisposition, psychological, behavioral and environmental risk factors, 
the control of T2DM represents a considerable therapeutic challenge [2, 3, 5, 14] . 
Although life-style interventions for T2DM including appropriate diet, weight 
regulation and physical activity have demonstrated their efficacy to reduce cardio-
metabolic risks, these interventions are often disappointing on the longer term, 
resulting from the poor adherence and a lack of intensive health professional 
support.  
As a result, it is likely that the effect of lifestyle changes will be less in a real-life 
setting than in the published trials [5, 6]. Pharmacological intervention for the 
prevention of diabetes is therefore often recommended as a secondary 
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intervention to follow or to be used in combination with lifestyle intervention. 
However, the discovery of safe and effective drugs for the long-term treatment 
T2DM remains the challenge in diabetes research, predominantly owing to the 
continuing lack of understanding of the complex molecular pathogenesis and 
genetic basis of this disease [14]. The current treatments mainly focusing on 
restoring normoglycaemia generally require the use of anti-diabetic drugs; and 
none of these are able to correct all the anomalies involved in the complex 
pathogenesis of T2DM. They often fail after a few years of evolution of the 
disease and even insulin rarely achieve durable glycaemic control and can expose 
the patient to side effects, particularly hypoglycaemia and weight gain [5, 15]. It 
seems that either the current approach to treat hyperglycaemia in patients with 
T2DM does not affect the cardiovascular risk (at least not over the time course of 
the studies) or that current therapies exert off-target effects that neutralize any 
potential benefit of lowering glucose and/or do some harm [3, 15].  
Figure 1. A summary of multiple risk factors to cause T2DM 
Taken into account that the cardio-metabolic disorders in T2DM have diverse 
subtypes that involve changes in multiple molecular pathways, organs, tissue 
types and the central nervous system ( CNS) [5, 14, 16], the strategy for new drug 
development for T2DM should pursue as many promising leads as possible to 
establish a broad range, namely a system based and personalized way, to control 
the factors beyond glycaemia management (e.g. hypertension, dyslipidaemia, 
insulin resistance, obesity) with different mechanisms of action and potential 
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The discovery of novel biomarkers to dissect T2DM subtypes will help to improve 
its diagnosis as well will help to find new leads for actual disease modifying 
treatments. The attention should be drawn on the system biology based research 
into patient stratification with biomarkers which are disease-associated molecular 
changes in body tissues and fluids [19, 20]. If the correlation between diseases 
and changes in biomarkers could be established, the ability of health practitioners 
to diagnose T2DM and tailor treatments to individuals, so-called personalized 
healthcare solutions, would be radically improved [20].  
 
System level based searching for diagnostic biomarkers 
Systems biology and personalized medicine 
A biological entity, such as the whole organism of a human being, consists of 
myriads of cells which in turn contain many genes, transcripts, proteins, and 
metabolites. These molecules participate in specific networks and systems of 
interactions, and it is the aberrations in network behaviour that causes disease 
[21]. The discipline that seeks to reconstruct how molecules interact with each 
other in networks is systems biology, which  can be defined as ‘studying biology as 
an integrated system of genetic, protein, metabolite, cellular, and pathway events 
that are in flux and interdependent’ [21, 22]. Systems biology studies are typified 
by a shift from the more traditional reductionist approach towards more holistic 
approaches, with experimental strategies aimed at understanding interactions 
across multiple molecular entities [23].  
Actually the emergence of systems-based thinking across different scientific 
domains has occurred in the last century, yet systems biology often stayed 
unnoticed by the mainstream[24]. Only recently it has gained considerable 
momentum in the life science and pharmaceutical research, particularly due to 
the fact that the target-based drug discovery strategy became unproductive and 
thus more interest grew for the need to better understand biology in a different 
perspective [21, 24, 25]. More and more scientists and healthcare practitioners 
realized that the classical reductionism based interventions on ‘single compound 
focusing on a single target that links to a specific symptom’ have limitations for 
the multifactorial abnormalities such as T2DM, obesity, metabolic syndrome, 
cancer and cardiovascular diseases [24-27]. Evidence [6, 28-32] has shown that 
because of the lack of better diagnostics and therapies, these abnormalities 
become prevalent globally and put great medical and economic burden for society.  
Personalized medicine, which is defined as customized medical care for each 
patient’s unique condition, is regarded to make significant strides forward when a 
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systems approach is implemented to achieve the ultimate disease phenotyping 
and to develop novel therapeutics that address system-wide molecular 
perturbations caused by disease processes [33]. Personalized medicine, 
encompassing lifestyle, nutrition, psychology, environmental issues and medicine, 
is considered as the ultimate opportunity to improve healthcare; and it should 
depend on an understanding of systems biology and on systems-based developed 
interventions [33].  
Figure 2. The ‘Omics’ cascade and related research focuses.  
Novel diagnostic biomarkers as health indicators are urgently needed to move 
personalized medicine forward [33]. Moreover, stratifying patients on molecular 
biomarker profiles is a key step towards treatment response and non-response 
differentiation [33]. However, the current lack of knowledge of the complex 
underlying biochemistry in the system-based level often makes it difficult to 
develop or assess the value of potential biomarkers; as understanding biology 
requires knowledge of connectivity in systems and their self-organization and 
adaptation [24]. Several technologies developed in Life Sciences, particularly 
‘omics’ techniques, may offer a possibility to improve the identification of such 
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advance translational medicine, combination therapies, integrative medicine, and 
personalized medicine [33].  
 
-Omics, metabolomics and lipidomics 
Driven by recent technological advances in biology, analytical chemistry and 
bioinformatics, measuring and analyzing dozens and even more compounds 
simultaneously has become feasible. This development culminated in the 
emergence of the ‘omics’ science, with the most notable variants (downstream of 
genomics) being transcriptomics, proteomics, and metabolomics, which 
comprehensively study the expression of many gene transcripts, proteins, and 
metabolites respectively (Figure 2) [21].  
The ‘omics’ disciplines, widely applied in systems biology, allow researchers to 
achieve a ‘holistic’ view of the processes involved in the disease, and provide a 
complementary approach to the classical reductionist approach [21]. While 
genome approaches are powerful with regard to finding disease-associated 
patterns in the DNA, transcriptomics focuses on  global analysis of gene 
expression and proteomics on protein synthesis and cell signaling by measuring 
the complete proteome [34, 35].  The metabolome refers to the complete set of 
metabolites present in cells, body fluids and tissues. It is the endpoint of the 
“omics cascade” and thus the closest to phenotype [34, 36].  
Metabolomics is defined as ‘the comprehensive quantitative and qualitative 
analysis of all small molecules in a system (metabolome)’. It incorporates 
advanced analytical technologies to measure a molecular phenotype system 
readout and provides the ideal technology platform for the discovery of 
biomarker patterns associated with healthy and diseased states, for use in 
personalized health monitoring programs, and for the design of individualized 
interventions [33].  
Metabolomics dovetails with the philosophy of systems biology, because it 
provides a ‘top-down’, integrated view of biochemistry in complex organisms, as 
opposed to the traditional ‘bottom-up’ approach that investigates the network of 
interactions between genes, proteins and metabolites in individual cell types. A 
problem with systems biology is that each level of biological organization and 
control— genomics, gene expression, protein expression and metabolism — 
operates on a markedly different timescale from the others, making it difficult to 
find causal linkages [37]. Moreover, environmental and lifestyle influences on 
gene expression also make it hard to interpret genomic data, for example to 
predict an individual’s susceptibility to diseases. Metabolomics cuts through these 
problems by monitoring the global outcome of all the influencing factors, without 
Chapter  1 
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making assumptions about the effect of any single contribution to that outcome 
and thus the individual contributions can be teased out [37]. For this reason, 
metabolomics represents a rather exhaustive metabolic phenotyping technology, 
which will help in understanding metabolic diseases. 
A metabolomics study workflow is shown in Figure 3. For a good and valid 
metabolomics study, all steps, starting from the definition of the biological 
question until the experimental design up to the biostatistics, should be optimized; 
and finally the metabolites relevant to a specific phenotypic characteristic can be 
identified [34]. 
Figure 3. A metabolomics study workflow. 
Metabolomics is mainly conducted on biofluids such as urine or plasma, which are 
easily obtainable in mammalian studies. Because biofluids fulfill diverse biological 
purposes, their metabolic composition varies with their role and the functional 
integrity of the organ systems that are communicating with them, and ultimately 
with the physiological status of the whole organism [7]. Metabolomics studies of 
biofluids such as urine and plasma obtained from clinical trials have been applied 
successfully to investigate numerous diseases and metabolic processes [7, 38-49]. 
Furthermore, the approach of metabolomics has proven sensitive enough for the 
understanding of gene function in model organisms, including yeast, plants, and 
mice/rats [4, 7, 50-52]. This has led to the development of a number of screening 
assays in recent years to be used in drug development related to human diseases 
such as MetS, T2DM and cardiovascular disease, as well as its potential use in 
toxicology as part of the drug safety assessment process [7, 52].  
Lipidomics is a lipid-targeted metabolomics approach aiming at comprehensive 
analysis of the molecular species of lipids in biological samples. Recently,  
lipidomics has captured increased attention due to the well-recognized roles of 
lipids in numerous human diseases to which lipid-associated disorders contribute, 
such as diabetes, obesity, T2DM, atherosclerosis and MetS [53, 54].  
Indeed, historically T2DM was considered to revolve around a glucose-insulin axis 
while our current understanding of the pathogenesis of T2DM has shifted to the 
awareness that obesity, or more accurately, the products of excess adipose tissue, 
precede the perturbations of glucose metabolism [55]. It is now apparent that 
elevation of plasma free fatty acids (FFAs) plays a pivotal role in the development 
of T2DM by causing insulin resistance [55]. T2DM develops because pancreatic β-
General introduction and scope 
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cells eventually fail to produce enough insulin to compensate for insulin resistance 
[55]. T2DM is tightly associated with dyslipidemia, a cluster of interrelated plasma 
lipid and lipoprotein abnormalities, including reduced HDL cholesterol, a 
predominance of small dense LDL particles, and elevated triglycerides [56]. There 
is evidence that each of these dyslipidemic features is associated with increased 
risk of cardiovascular disease, the leading cause of death in patients with T2DM 
and there is no single drug can successfully regulate the dyslipidemia without 
long-term intolerance or side-effects [56, 57]. Therefore, measuring all or subsets 
of lipids in order to investigating lipid biochemistry using a lipidomics approach 
will not only provide a thorough perspective to study intervention induced lipid 
changes and metabolism in the complex biological system in health and disease, 
but will also assist in identifying potential biomarkers for establishing new 
preventive or therapeutic approaches for T2DM and its related cardio-metabolic 
disorders, especially dyslipidemia [54].  
 
Metabolomics and lipidomics in diabetes and metabolic syndrome 
research 
Metabolomics studies on both animal models and human with T2DM or MetS 
have been reported and yielded the “fingerprints” of the biochemical changes in 
plasma (blood) and urine that accompany diseased states.  
Several animal models have been developed and used extensively in studies of 
the pathophysiology of T2DM and its related metabolic abnormalities. The Zucker 
obese rat and Goto-kajizaki (GK) rat represent two pathogenic process of T2DM 
respectively, insulin resistance and hyperglycemia [4]. The urine metabolomics of 
both models rats demonstrates metabolic similarities between the two stages of 
T2DM, including reduced tricarboxylic acid (TCA) cycle and increased ketone 
bodies production. In addition, compared with Zucker obese rats, the GK rats have 
enhanced concentration of energy metabolites, which indicates energy metabolic 
changes produced in hyperglycemic stage more than in insulin resistant stage [4]. 
The db/db mouse model has autosomal recessive defects in the leptin receptor 
gene and produces clinical signs of leptin resistance, hyperphagia, obesity, and 
subsequent insulin resistance [58]. Profound changes in nucleotide metabolism 
including that of N - methylnicotinamide and N-methyl-2-pyridone-5-carboxamide, 
branched chain amino acids (BCAAs), nicotinamide metabolites and pantothenic 
acids were observed in such mouse model as compared with the controls [52, 58]. 
Kleemann et al. [59]used the ApoE*3 Leiden mouse model that expresses a 
mutation of the human ApoE*3 gene resulting in a slightly attenuated clearance 
of apoB containing particles via the LDL pathway, to elucidate the dynamics and 
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tissue-specificity of metabolic and inflammatory processes, the analysis of gene 
expression and metabolite levels in liver, white adipose tissue and muscle was 
performed. The results show that high fat diet induced insulin resistance is a time- 
and tissue-dependent process that starts in liver and proceeds in white adipose 
tissue. Insulin resistance development is paralleled by tissue-specific gene 
expression changes, metabolic adjustments, changes in lipid composition, and 
inflammatory responses in liver and WAT involving p65-NFkB and SOCS3. The 
biochemical pathways affected are numerous and different for the various tissues, 
indicating that the design of effective treatment regimens should be at an integral 
level rather than directed at a single target [59]. 
More and more metabolomics studies on human with T2DM, pre-diabetes and 
MetS have been published. Mass spectrometry techniques have been widely 
applied to obtain metabolite profiles of diabetic patients. The study designs can 
be generally summarized into three categories: 1) metabolomics differences 
between pre-/diseased group versus healthy controls; 2) the time-dependent 
metabolic profile before and after challenge test (e.g. oral glucose tolerance, lipid 
challenge) or drug intervention; and 3) Epidemiological –omics study. The 
between-group metabolomics differences are summarized in table 1. Highlighted 
metabolism biomarkers and pathways showed the related concentration 
differences between pre-diabetes/T2DM and the healthy controls [47, 49, 60-63]. 
The most applied challenge tests and interventions to study human system 
response related to metabolic profiling include oral glucose tolerance test, lipid 
challenge, dietary and drug interventions [42, 44, 48, 64-68]. The time dependent 
metabolite responses during the challenge or intervention period can be 
obviously detected, manifesting in multiple metabolic intermediates changes in 
different pathways. To name a few, the data reported the changes in fatty acids, 
animo acids, acylcarnitine levels, glutathione synthesis pathway, bile acids, urea 
cycle intermediates, and purine degradation products, etc. Finally, the European 
Union-funded projects, such as Molecular Phenotyping to Accelerate Genomic 
Epidemiology (MolPAGE) involving 17 partners from universities, pharmaceutical 
companies, and biotechnology companies. The MoLPAGE, formed in 2004, aims to 
tackle diabetes and vascular disease, at the level of genes, proteins, metabolites, 
and other biomarkers [7]. The ultimate goal of the MolPAGE project is to identify 
early diagnostic biomarkers that are able to highlight individuals likely to suffer 
from diabetes and vascular disease before they show any of the symptoms, 
biochemical abnormalities, or other features typically used in the diagnosis of 
these conditions, thus allowing more effective prevention programs and better 
treatment of the disease [7]. The results and data generated from this project are 
expected in the near future.  
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Table 1. A small summary of reported biomarkers/pathways of metabolomics 
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Together, in a clinical context, metabolomics offers the advantage of using readily 
available biofluids, i.e., urine and plasma to get information of the time-
dependent fluctuations of metabolites that occurs in response to disease, drug 
effects or other stimuli. This approach expands the number of metabolic markers 
available to the practitioner by an order of magnitude (otherwise not available 
through routine assays)[7, 37]. Metabolomics bears promise to enable 
characterization of early markers of disease and prognosis, as well as drug 
treatment efficacy and eventually personalized medicine [7].  
 




Although metabolomics-based systems analysis and phenotyping will be key, it 
still remains a challenge to stratify patients to provide a diagnosis considering the 
uniqueness and the interaction of person with his environment as a whole. 
Comparing the generated metabolite  or metabolic differences between healthy 
and T2DM can help us know more about multiple metabolites related pathway 
changes, yet not enough to stratify patients. The ‘challenge test’ to check people’s 
response to the stimuli is likely to provide early disease diagnosis [33], however, it 
often difficult to judge which challenge to apply and whether it is the right one. A 
complementary approach is to get diagnostic perspectives from other medicine 
systems which have already regarded the human being as a whole and provided 
personalized intervention to improve health. Indeed, system-level based diagnosis 
and personalized health has long been applied in  Chinese Medicine ( CM), in 
which personalized treatment have been the sole approach to medicine [33].  
 
Introduction of Chinese Medicine 
Chinese Medicine (CM) has developed its own health care concept with over 3000 
years of continuous practice and refinement through observation, testing and 
critical thinking [38]. Literally it means an art of healing that brings harmony and 
balance for human health, with an essential goal to maintain healthy condition 
and reach longevity with optimal quality of life.   
The concept of personalized health and system diagnostic principles has long been 
the basis of CM, in which the focus is the ‘diseased person’ instead of the 
‘person’s disease’ [69]; and the ‘disease process’ instead of the  ‘disease state’. 
CM provides emphasis on regulating the integrity of the human body and the 
interaction between human individuals and their environments, and it applies 
multiple natural therapeutic methods for disease management as well as health 
promotion [38].  The aim of CM is to restore the self-regulatory ability of the 
human system, instead of antagonizing specific pathogenetic targets [69]. Thus 
CM does not focus solely on the disease defined by pathological changes but the 
overall maladjustments of functional status called ‘syndrome type’ [69]. All 
diagnostic and therapeutic methods in CM are based on the differentiation of CM 
syndrome types [38], which can be defined as a functional status which is caused 
by the reaction to or interaction with environmental changes and pathogenic 
factors and it manifests as a group of correlated symptoms and its essence is the 
imbalance of the human system resulting in the perturbation of the metabolic or 
biological network [70] . In other words, patients suffering from the same disease 
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can be categorized into different CM syndrome types ( Figure 4) ; and the 
classification of CM syndrome types clusters certain symptoms together and 
provides an essential base for CM guided personalized treatment [38].  
Figure 4.  Patients with same disease can be categorized into different CM syndrome types 
and given personalized treatment accordingly.  
 
Chinese Medicine diagnostic principles 
Diagnosis in CM not based on objective instruments as in western medicine; 
instead it is achieved by using four diagnostic methods, 1) observation, 2) listening 
and smelling, 3) questioning and 4) pulse feeling, which are conceptual and rely 
entirely on clinical signs discerned by CM physicians ( Figure 5) [71]. CM physicians 
attempt to establish the health status through qualitative symptoms collection 
based on one’s appearance, behaviors, mental status, bio-rhythms, life style as 
well as his interaction and adaptation to both natural and social environment. In 
specific [18], ‘observation’ method focuses on the behavior, movement, figure, 
facial color, tongue,  throat and finger veins of a patient; with ‘listening and 
smelling’ method, CM physicians will evaluate the speech of a patient (e.g. pitch, 
tone, tempo), the way a patient is coughing or breathing and smell his breath and 
secretion (e.g. sweat). ‘Question’ is one the most important diagnostic techniques 
and CM physician will carefully ask and analyze the complaints and symptoms of a 
patient. Normally the following information will be covered [71]: medical history, 
response to cold/heat weather or food, sweat, symptoms of head, chest and body, 
pain, diet and appetite, sense organs, sleep quality and life style; for females there 
will be  questions related to menstrual cycle and pregnancy experiences. ‘Pulse 
feeling’ is an unique diagnostic method in CM, by feeling the rate, depth and 
tension of the pulse, CM physicians can speculate the health status of the whole 
system.  CM physicians will then cluster the symptoms/signs together according 
CM syndrome type 1 
Disease CM syndrome type 2 
CM syndrome type 3 
Treatment protocol 1 
Treatment protocol 2 
Treatment protocol 3 
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to CM diagnostic principles to get the CM syndrome type and provide 
personalized treatment. 
 
Figure5. CM diagnostic methods 
 
Combining Chinese Medicine and metabolomics to subtype T2DM 
CM is descriptive and phenomenological — it typically diagnoses patients using 
concepts based on the relationship between signs and symptoms, obtained via its 
four diagnostic methods [27]. It is said that CM diagnosis could be understood as a 
pattern recognition [71]. Patterns or syndrome types are manifestation profiles 
(relationships between signs and symptoms) already classified according to CM 
theories. It is based on pattern differentiation, together with the subject’s health 
CM diagnosis methods




















Symptoms collection and 
find their relationships
Categorize patients into different syndrome types
Provide personalized treatment
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status and environmental factors, that a CM physician designs and implements 
treatment. In contrast, Western-style, modern medicine has mainly used single 
biomarkers to describe disease states, for example diagnosing T2DM by 
measuring glucose levels. But there is a growing realization in the West that single 
biomarkers are not enough. A better approach is to look at patterns of biomarker 
responses to a challenge [27]. 
The concepts and practices of systems biology align very closely with CM. In CM 
theory, the concepts of the “whole” and the “system” rather than isolation are 
important, which well fits to systems biology perspectives. An emerging concept 
of health in the scientific literature describes an ability to adapt and self-manage 
in the face of social, physical and emotional challenges [27]. This perspective has 
long been central to the concept of health in CM, which further includes spiritual 
fulfilment and a sense of individual well-being. Systems biology is particularly 
useful when it comes to describing homeostasis — the regulation of a system’s 
internal environment to maintain a stable condition [27]. In turn, the ability to 
cope with changing environments and stress is encompassed in the principle of 
allostasis ─ the physiological or behavioural changes required to stabilize the 
biological system [27]. The data of systems biology based challenge or 
intervention to health will provide insight into the resilience of allostatic 
mechanisms, and hence into a person’s health, an approach similar as the tenets 
of CM.  
If we can correlate the CM diagnosed syndrome types to the metabolomics 
quantified clusters, it may help us stratify the patients and push personalized 
medicine forward (Figure 6). In addition to giving WM a basis for adopting some 
concepts of CM, systems biology is also pushing the convergence from the other 
direction. Increasingly, CM uses modern biochemical measurements and tools to 
refine or augment diagnostic descriptions. This is starting to facilitate the 
translation of CM concepts into Western concepts based on biochemical, pathway 
or regulatory processes [27]. Several studies [39, 43, 72, 73] combining 
metabolomics and CM syndrome types have revealed different molecular and 
metabolic patterns of patients with the WM diagnosed diseases, which provided 
new opportunities to improve patient stratification and personalized intervention.  
In China, the treatment for T2DM and/or its related metabolic disorder is often 
the mixture of both WM and CM strategies. Integration of CM and WM has 
accomplished better therapeutic effects for diabetics [74-77], manifesting as the 
improvement of insulin sensitivity, lipid profile and quality of life and the 
alleviation of diabetic foot ulcer; and the better tolerance and compliance with 
Western medication has been also reported. CM often provides patients with a 
multi-component herbal formula with tailored dosage based on the diagnosis, in 
order to obtain the multi-targets effects in the whole system to restore the self-
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adaptation ability. The idea is quite similar to the “combination therapy”, such as 
‘poly-pill’[78, 79] or ‘poly-meal’[80], proposed in western medical and scientific 
world. The evaluation of such multi-target effect used to be difficult, but with the 
systems biology based metabolomics approach, the fingerprints of whole 
spectrum of the active ingredients of an herbal and their concentrations can be 
quantified and their synergy effect in the system level [81] can be investigated. 
This might provide new possibilities to discover new drugs or other interventions 
for T2DM.  
 
Figure 6. Combine CM diagnosed syndrome types and metabolomics patterns after 
statistical pattern recognition techniques to search for the method to stratify patients  
 
Aim of this thesis 
The aim of this thesis is to apply a system biology based metabolomics approach, 
lipidomics in specific, to search for novel diagnostic markers or subtypes of T2DM 
in its early and late stages.  
The personalized diagnostic strategy of Chinese medicine will be combined with 
metabolomics to stratify the patients with T2DM or pre-diabetes; and explore the 
related metabolism changes and pathways. The multi-component preparations or 
drugs to treat cardio-metabolic disorders will be studied and assessed by 
metabolomics to understand the potential underlying multi-target or multi-
pathway effects. The idea is to investigate the pre-/diabetes and its related 
metabolic abnormalities such as obesity and dyslipidemia from a systems-based 
T2DM patients







Metabolomics pattern 1 Metabolomics pattern 2 Metabolomics pattern 3
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perspective and improve the understanding of the disease and its intervention to 
a personalized health direction. 
 
Outline of this thesis 
Each chapter addresses an aspect to realize the aim formulated in the thesis. In 
chapter 2, an explorative study of 50 pre-diabetic males is designed, combining 
GC-MS urine metabolomics with CM diagnosis to identify diagnostic biomarkers 
for pre-diabetic subtypes. Moreover, the inter-physician concordance of CM 
diagnoses is assessed. In chapter 3 and 4, the effects of rimonabant and a multi-
component preparation, both focus on regulating weight and having beneficial 
effects on dyslipidemia, were assessed  by lipidomics on mildly over-weighted 
ApoE*3Leiden.CETP Mice. In chapter 5, systems biology based metabolomics 
approaches are used to evaluate the therapeutic effects of ginseng roots grown 
for 3–6 years on the regulation of hyperglycemia and dyslipidemia in a Goto-
Kakizaki (GK) rat model with T2DM.  Chapter 6 reports the development of a fast 
plasma lipid analysis platform by nanospray chip-based mass spectrometry.  In 
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Abstract 
The prevalence of type 2 diabetes continuously increases globally. A personalized 
strategy applied in the pre-diabetic stage is vital for diabetic prevention and 
management. The personalized diagnosis of Chinese Medicine (CM) may help to 
stratify the diabetics. Metabolomics is regarded as a potential platform to provide 
biomarkers for disease-subtypes. We designed an explorative study of 50 pre-
diabetic males, combining GC-MS urine metabolomics with CM diagnosis in order 
to identify diagnostic biomarkers for pre-diabetic subtypes. Three CM physicians 
reached 85% diagnosis consistency resulting in the classification of 3 pre-diabetic 
groups. The urine metabolic patterns of group 1‘Qi-Yin deficiency’ and 2 ‘Qi-Yin 
deficiency with dampness’ (subtype A) and group 3 ‘Qi-Yin deficiency with 
stagnation’ (subtype B) were clearly discriminated. The majority of metabolites 
(51%), mainly sugars and amino acids, showed higher urine levels in subtype B 
compared with subtype A. This indicated more disturbances of carbohydrate 
metabolism and renal function in subtype B compared subtype A. No differences 
were found for hematological and biochemical parameters except for levels of 
glucose and γ-glutamyltransferase that were significantly higher in subtype B 
compared with subtype A. This study proved that combining metabolomics with 
CM diagnosis can reveal metabolic signatures for pre-diabetic subtypes. The 
identified urinary metabolites may be of special clinical relevance for non-invasive 
screening for subtypes of pre-diabetes, which could lead to an improvement of 














Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by 
hyperglycemia with disturbances of carbohydrates, fat and protein metabolism 
and its prevalence continuously increases globally[1-3]. Evidence shows that both 
lifestyle regulation and early pharmacotherapy during pre-diabetes are effective 
in slowing down the onset and progression of T2DM [1, 3, 4]. However, due to its 
multi-factorial causes resulting from the interaction between a genetic 
predisposition and behavioral and environmental risk factors, the control of T2DM 
represents a considerable therapeutic challenge[1, 2] and to diagnose and treat 
T2DM only based on the glucose level seems insufficient. Glycaemic control as 
evidenced by the reduction of glycated hemoglobin( HbA1c) with existing agents 
was found to have a weak and non-significant effect on the incidence of 
cardiovascular complications [1]. A more personalized and system based strategy 
to control the factors beyond glycaemia management (e.g. hypertension, 
dyslipidaemia, insulin resistance, obesity) is vital in reducing the diabetic 
morbidity and complications. The challenge towards personalized treatment is 
how to stratify patients to provide a diagnosis considering the uniqueness and the 
interaction of person with his environment as a whole [5].   
The concept of personalized health and system diagnostic principles is not new, as 
it has long been the basis of Chinese Medicine (CM), in which the focus is the 
‘diseased person’ instead of the ‘person’s disease’ [6]. CM does not focus solely 
on the disease defined by pathological changes but the overall maladjustments of 
functional status called ‘syndrome type’ [6]. The syndrome type is a functional 
status which is caused by the reaction to or interaction with environmental 
changes and pathogenic factors [7]. It is a manifestation profile of a group of  
signs and symptoms and its essence is the imbalance of the human system 
resulting in the perturbation of the metabolic or biological network [7]. CM aims 
to restore the self-regulatory ability of the human system, instead of antagonizing 
specific pathogenetic targets [6]. Metabolomics, defined as the “comprehensive 
quantitative and qualitative analysis of all small molecules in a system”, has been 
increasingly applied to study complex disease mechanisms to discover health-
disease associated mechanistic biomarkers and it is regarded as a unique bridge 
between different healthcare perspectives on personalized medicine [8]. Urine 
metabolomics is of special interest because the urine collection is non-invasive 
and it amplifies the circulating levels of metabolites by renal concentration, which 
consequently ensures urine a distinct representation of metabolic response [9].  
Several studies [10-13] combining metabolomics and CM syndrome types have 
revealed different molecular and metabolic patterns of patients with the Western 
Medicine (WM) diagnosed diseases, which provided new opportunities to 
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improve patient stratification and personalized intervention. In China, integration 
of CM and WM has accomplished better therapeutic effects for diabetics [14-17], 
manifesting as the improvement of insulin sensitivity, lipid profile and quality of 
life and the alleviation of diabetic foot ulcer. However, to implement CM diagnosis 
under WM system is not easy; as the diagnosis is not based on objective 
instruments. By using four diagnostic methods: observation, listening and 
smelling, question and pulse feeling (Figure 1), CM physicians attempt to establish 
the health status through qualitative symptoms collection based on one’s 
appearance, behaviors, mental status, bio-rhythms, life style as well as his 
interaction and adaptation to both natural and social environment. Specifically, 
‘observation’ method focuses on the behavior, movement, figure, facial color, 
tongue,  throat and finger veins of a patient; with ‘listening and smelling’ method, 
CM physicians will evaluate the speech of a patient (e.g. pitch, tone, tempo), the 
way a patient is coughing or breathing and smell his breath and secretion (e.g. 
sweat). ‘Question’ is one the most important diagnostic techniques and CM 
physician will carefully ask and analyze the complaints and symptoms of a patient. 
Normally the following information will be covered [18]: medical history, response 
to cold/heat weather or food, sweat, symptoms of head, chest and body, pain, 
diet and appetite, sense organs, sleep quality and life style; for females there will 
be  questions related to menstrual cycle and pregnancy experiences. ‘Pulse 
feeling’ is an unique diagnostic method in CM, by feeling the rate, depth and 
tension of the pulse, CM physicians can speculate the health status of the whole 
system.  CM physicians will then cluster the symptoms/signs together according 
to CM diagnostic principles to get the CM syndrome type and provide 
personalized treatment. Due to the fact that CM diagnosis is conceptual and relies 
entirely on clinical signs discerned by CM physicians, the inter-physician 
consistency on CM diagnosis is of importance to both scientific research and 
clinical practice [19].  
In this explorative study, we diagnosed 50 pre-diabetic males with CM syndrome 
types and applied urine metabolomics to search for biomarkers of pre-diabetic 
subtypes, with the following aims and hypotheses: (1) to assess the inter-
physician concordance of CM diagnoses; (2) to find the relationships between 
classifications of pre-diabetics according to CM diagnosis and metabolomics. We 
hypothesize that combining CM diagnosis with metabolomics could help us 
identify pre-diabetes subtypes with related urinary metabolic patterns. The latter 
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Figure 1. CM diagnosis and treatment paradigm. 
 
Experimental section 
Subjects and study design 
The study was conducted at TNO (Zeist, the Netherlands) and 69 overweight pre-
diabetic males were recruited from TNO’s candidate database. A pre-study 
screening comprised of a physical examination, clinical laboratory tests and the 
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evaluation of anamnesis and life style was performed in order to confirm that the 
recruited subjects have no other clinical abnormalities than pre-diabetes. Subjects 
were declared eligible when meeting the inclusion and exclusion criteria. Inclusion 
criteria: 1) males aged 30 –70 years; 2) Body Mass Index (BMI) 26 – 35 kg/m2; 3) 
pre-diabetes as determined by fasting glucose level of 6.1 – 6.9 mmol/L; 4) normal 
Dutch eating habits. Exclusion criteria: 1) smokers; 2) alcohol consumption ≥28 
units/week; 3) unexplained weight fluctuation of > 2kg in the month before the 
pre-study screening; 4) currently on CM therapies. Finally 50 overweight pre-
diabetic males, all of Dutch ancestry, were included in the study. All study subjects 
signed the informed consent and their baseline characteristics are summarized in 
Table 1. The study was approved by the Medical Ethics Committee of Tilburg 
(METOPP; Dutch acronym for medical ethical research in patients and volunteers).  
 
Table 1. Baseline characteristics of 50 pre-diabetic males 
Male (n = 50) Mean ± SD Range 
Age /years 57 ± 8 40 – 69 
Body weight /kg 94.2 ± 10.1 75.4 – 117.6 
BMI /kg m-
2
 28.8 ± 2.4 25.6 – 35.5 
BP systolic /mm Hg
-1 
137.7 ± 17.8 93 – 177 
BP diastolic /mm Hg
-1
 83.0 ± 10.1 56 – 104 
Waist circumference /cm 105.0 ± 8.1 92 – 128 
Blood glucose /mmol L
-1
 6.3 ± 0.3 5.9 – 6.9 
 
The study was designed as an explorative study without intervention (Figure 2). 
Fifty pre-diabetic males were diagnosed by three different CM physicians 
separately and in a randomized order. The CM physicians had to have least ≥ 5 
year CM training with a valid certificate and ≥ 10 year clinical experience in the 
Netherlands. Each CM examination took 15- 20 minutes and the physicians were 
not allowed to exchange ideas or know the diagnosis from each other. They were 
asked to apply CM diagnostic theories of organ and Qi-Blood-Fluid to give the 
personalized descriptions with percentage scaling to each subject. CM physicians 
first questioned subjects with symptoms and signs, then summarized and 
clustered these signs into CM diagnostic terms/syndromes (Figure 1). Finally CM 
physicians wrote down all the diagnosed syndromes, often 3-4 syndromes for 
each subject, and then based on severity and frequency of these syndromes 
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For example, the diagnosis was written down per subject by each physician in the 
form of “55% liver yang ascending, 35% yin deficiency and 10% liver qi 
stagnation”. CM diagnoses were considered consistent when ≥ 80% inter-
physician agreement was reached based on generalized procrustes analysis (GPA) 
results [20]. GPA is a multivariate exploratory technique that involves 
transformations (i.e., translation, rotation, reflection, isotropic rescaling) of 
individual data matrices to provide optimal comparability [20]. Subjects who were 
diagnosed differently by three CM physicians were excluded from further data 
analysis. The blood and the first void urine samples of study subjects were 
collected after an overnight fast (≥ 12 h). The blood samples were used for clinical 
laboratory measurements and urine samples for GC-MS metabolomics. The 
relationships between classifications of pre-diabetics according to CM diagnosis 
and metabolomics or clinical parameters were studied. 
 
Clinical parameter analysis 
Blood samples were obtained from antecubital vein of forearms and collected in 
tubes containing clot activator for serum and in anticoagulant tubes (Vacutainer 
Systems, Becton Dickinson, UK) of either K3EDTA or Li-heparin for plasma. The 
K3EDTA tubes were used for Hb1Ac determination while the Li-heparin tubes were 
used for the determination of glucose and lipids. Blood samples were centrifuged 
for 15 min at 2000 × g at 4 ºC within 30 min after collection. Samples were 
aliquoted and stored at -20°C till analysis. All biochemical determinations in blood 
were analyzed with enzymatic techniques on the Olympus analytical equipment 
(Olympus-Diagnostica, Germany), including the haematology profile and alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase 
(ALP), albumin, bilirubin, urea, creatinin, total- and high density lipoprotein-
cholesterol (HDL-C) and the ratio of total cholesterol and HDL-C, triacylglycerols, 
glucose.  
 
GC-MS of urinary metabolomics 
Urine sample preparation 
After collection, the first void spot urine samples were aliquoted and then stored 
in -20°C till gas chromatography–mass spectrometry (GC-MS) analysis. Urine 
samples were first thawed to room temperature, then homogenized by vortexing, 
and afterward centrifuged for 20min at 3500 RPM. One hundred µL urine sample 
of each study subject was added to 10 µL internal standard (IS) mixture (nr.1) 




final IS concentration of 10ng/µL in a clean PTFE vial. Afterwards the urine 
samples with IS mixture (nr.1) were frozen at -80 ºC and lyophilized or freeze 
dried. Subsequently, 10µL IS mixture (nr.2) consisting of alanine-D4 and glucose-
D7 with final IS concentration of 10 ng/µL were firstly added to the dried extracts. 
The dried extracts were then oximized with 20 µL of 16 mg/mL pyridine 
hydrochloride solution and 20 µL of 56mg/mL ethoxyamine hydrochloride 
solution in pyridine for 90 min at 40 °C, followed by adding 10 µL IS mixture (nr.3) 
consisting of DCHP, trifluoroacetyl- anthracene (TFAA) and DFBP with 
corresponding final concentrations of 18ng/ µL, 19 ng/µL and 20 ng/µL in IS nr.3. 
Finally, the extracts were silylated for 50 min at 40 ºC with 200 µL of MSTFA and 
centrifuged for 20 min at 3500 RPM.  
 
Instrument settings 
The derivatized (oximation and silylation) urine extracts were analyzed with an 
Agilent 6890 gas chromatograph coupled with an Agilent 5973 mass selective 
detector. The GC-MS method applied in the study can analyze a broad range of 
metabolites and was reported by Koek el al. [21]. The 1-μL aliquots of the extracts 
were injected into a HP5-MS capillary column (30 m × 250 μm i.d., 0.25-μm film 
thickness; J&W Scientific, Folson, CA) using PTV injection (Gerstel CIS4 injector) in 
the splitless mode. The temperature of the PTV was 70 ˚C during injection, and 0.6 
min after injection, the temperature was raised to 300 ˚C at a rate of 2 ˚C /s and 
held at 300 ˚C for 51 min. The initial GC oven temperature was 70 ˚C; 5 min after 
injection the GC oven temperature was increased with 6 ˚C /min to 325 ˚C and 
held for 3 min at 325 ˚C. Helium was used as a carrier gas and pressure 
programmed such that the helium flow was kept constant at a flow rate of 1.7 
mL/min. Detection was achieved with MS using electron impact ionization and full 
scan data acquisition (m/z 15-800).  
The performance of the applied GC-MS platform was assessed through the 
repeated analysis of the quality control (QC) samples. The QC samples, used to 
monitor the GC-MS response in time, were prepared by pooling aliquots of 50 
urine samples to represent the full biochemical diversity of the study samples and 
allow the calculation of the analytical precision for all metabolites measured. The 
QC sample data is also used to correct systematic errors such as batch to batch 
response differences by a single point calibration model [22, 23]. Twenty QC 
samples were processed exactly in the same way as the study samples and 
analyzed after every 2-3 study samples with double injections. Furthermore, 
method performance was carefully monitored using multiple internal standards 
and duplicate analysis of samples. 
 
Metabolomics with the personalized diagnosis reveals subtypes of pre-diabetes 
 38 
Metabolomics data preprocessing 
The GC-MS raw data was processed by Agilent ChemStation software. Only 
metabolites with 80% of the samples having a value were kept in the dataset. 
Data for each sample was corrected for the recovery of the IS for injection. Batch 
to batch differences in data were removed by synchronizing medians of QC-
samples per batch. Duplicate measurements were combined into a single 
measurement. When both analytical duplicates had a zero value or when both 
had a non-zero value, measurements were averaged. The single value was taken 
when only one of the duplicates was above zero. Metabolites with high 
imprecision (i.e. relative standard deviation ≥50%) were removed from the 
dataset. Finally, the GC-MS dataset contained 128 metabolites and 46 of which 
were identified.  
 
Data analysis 
In order to assess the inter-physician diagnostic consistency, generalized 
procrustes analysis (GPA) was performed [20]. GPA is a method for comparing 
shapes of objects, in which the shape of an object is defined in a mathematical 
context as all the remained geometrical information after location, scale and 
rotational effects being filtered out. Three objects (CM physicians) were defined in 
the study, namely a matrix with concept-scores for each of three CM physicians. 
Each matrix size was 50 (number of pre-diabetic males) × 26 (number of CM 
diagnostic terms with percentage scaling). To explore urinary metabolic patterns 
and its relation to CM diagnosed groups, an unsupervised Principal component 
analysis (PCA) [24] was carried out in MATLAB (version 7.7.0471, the Mathworks) 
with the PLS toolbox (version 5.0.3, Eigenvector Research, InC.). Partial least 
squares discriminant analysis (PLS-DA) [25] was further applied to identify the 
specific metabolites which contribute most to discriminate between the subtypes; 
and PLS-DA models were validated using double cross validation (DCV) [26]. To 
avoid the possibility that a few high-intensity variables dominate the final results 
[27], metabolomics dataset was standardized per variable, meaning that first the 
means of each variable were subtracted, and then all variables were divided by 
their standard deviation (SD). Statistical differences of blood clinical parameters 
and urine metabolite regulation between subtypes of pre-diabetics were assessed 
by univariate data analyses by SPSS 17.0 and the results are presented as means ± 
SD unless indicated otherwise, with p value < 0.05 as statistical significance. To 
correct for false positives, the multiple test correction (MTC) of Benjamini and 
Hochberg false discovery rate (FDR) analysis[28] was applied to adjust p values 





The diagnostic consistency of CM physicians and the CM syndrome types 
Twenty six CM diagnostic terms (data not shown) were used to provide the 
personalized descriptions for each subject. The GPA analysis revealed a diagnostic 
consensus proportion of 85% among three CM physicians. The residuals from GPA 
can provide information of the inter-physician diagnosis agreement for a subject. 
The higher the residual, the lower agreement the CM physicians have upon this 
subject. Six subjects with relatively high residuals (≥ 0.02) were excluded from 
further analysis. An example of subjects with high and low inter-physician 
diagnostic consistency is illustrated in Figure 3. The GPA residual value was low for 
subject 35 and high for subject 11. Obviously, the similar diagnoses of three CM 
physicians were given for subject 35 (Figure 3A) while different diagnoses were 
given for subject 11 (Figure 3B).  
The chief CM physician categorized the remaining 44 study subjects into three CM 
syndrome type groups: group 1 “Qi-Yin deficiency” (n= 15), group 2 “Qi-Yin 
deficiency with dampness” (n=20) and group 3 “Qi-Yin deficiency with stagnation” 
(n=9). The description and main symptoms under each syndrome type were 
summarized in Table 2. All subjects actually had symptoms of CM syndrome type 
“Qi-Yin deficiency”, mainly manifesting as fatigue, spontaneous or night sweat 
and afternoon heat. Only subjects in group 1 were diagnosed solely as “Qi-Yin 
deficiency” while subjects in group 2 and 3 had basic symptoms of “Qi-Yin 
deficiency” with additional CM pathological factors, either “dampness” or 
“stagnation”. 
 
Metabolomics patterns and the relevant clinical characteristics 
Metabolomics patterns 
The GC-MS urine metabolomics data matrix of 44 subjects × 128 metabolites was 
used for PCA. The first two principal components (PCs) were selected, which 
described 45.4% of the total variance of the urine metabolome for 3 CM groups 
(Figure 4). A clear separation was observed (gray line in Figure 4) of group 1 (Qi-
Yin deficiency) with group 2 (dampness) versus group 3 (stagnation). Thirteen out 
of 15 subjects (87%) of group 1 were clustered with subjects of group 2; while 
only three subjects numbered 22, 29 and 31 of group 1 were closer with subjects 
of group 3. Eight of 9 subjects of group 3 appeared at the right side of PCA score 
plot, except for subject 4 who was clustered with subjects diagnosed with 
‘dampness’ and ‘Qi-Yin deficiency’ (Figure 4). This separation in PCA indicated 
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underlying concentration differences of urine metabolites between two potential 
pre-diabetic subtypes: ‘group 1 plus 2’ (subtype A) versus ‘group 3’ (subtype B). 
PLS-DA with DCV was used to further identify urine metabolites that differed in 
concentrations between subtypes A and B. The DCV error rate was 11%, indicating 
that 5 out of 44 subjects were misclassified. Among top 10 metabolites that 
contributed most to discriminate between subtype A and B, only three were 
identified. Gluconic acid and tryptophan showed significantly higher 
concentration in subtype B subjects (Figure 5B) while D-xylose appeared no 
significant differences between the two subtypes (data not shown).  
Subsequently, quantitative differences in urine metabolites between subtypes A 
and B were tested by an independent t-test with MTC-FDR to correct for false 
positives.  This resulted in 65 out of 128 urine metabolites (51%) with significant 
higher concentrations (p = 0.00 − 0.02) and 38% metabolites with higher 
concentration trend in subtype B compared with subtype A (Figure 5A). Twenty 
four out of the 65 significantly changed metabolites could be identified, mainly 
sugars, amino acids and organic acids, and were ranked based on the coefficients 
of PLS-DA regression vector (Figure 5B).  The urine levels of these 24 metabolites 
were found to be 60 – 460% higher in subtype B compared to subtype A.  






Qi-Yin deficiency with  
Dampness 
(n= 20 ) 
Group 3 




Short of breath 
Palpitation 
Dizziness  
Spontaneous or night 
sweat 
Dry mouth and throat 
Thirsty 




The similar symptoms as “Qi-
Yin deficiency” plus symptoms 
below: 
Uncomfortable fullness of 
belly 
Inactive, lack of appetite 
Heaviness of  the body  
Obesity 
Edema 
Feels sick and vomiting; 
Bad breath 
The similar symptoms as 
“Qi-Yin deficiency” plus 
symptoms below: 
Chest oppression; 
Tingling in feet or limbs 
Dry skin 
Cold finger tips or toes  
Unexplained pain 
Light purple lips 

















Figure 3. Illustration of inter-physician diagnostic consistency. (A) Subject 35 was with a low GPA residual meaning consistent 
inter-physician diagnoses; (B) subject 11 was with a high GPA residual meaning discrepant inter-physician diagnoses. 
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Figure 4.  PCA score plot of urine metabolomics data reflecting pre-diabetic subtypes based 
on CM diagnosis. Three CM syndrome groups (n=44): group 1 ‘Qi-Yin deficiency’, group 2 
‘Qi-Yin deficiency with dampness’, group 3 ‘Qi-Yin deficiency with stagnation’. Group 3 was 
clearly separated from group 1 and 2. The gray line highlighted the separation between 
“group 1 plus 2” and “group 3”.  
 
Clinical characteristics 
Clinical characteristics of two pre-diabetic subtypes were analyzed by 
independent t-test. No significant differences were observed for parameters of 
haematology (data not shown) or physical examination including age, BMI, waist 
circumference and blood pressures (BP) (Table 3). Subtype B showed significant 
higher levels of fasting plasma glucose (p =0.04) and γ-glutamyltransferase (γ-GT) 
(p =0.03) as compared to subtype A (Table 3).  No other clinical parameters 






Figure 5. Urinary metabolite level differences between subtypes A and B. (A) The 
distribution of  urinary metabolite changes in subtype B (vs. subtype A); (B) Twenty four 
identified metabolites showed significantly higher urine levels in subtype B. The urinary 
metabolite level of subtype A was set to be 100% and relative changes of subtype B were 
illustrated in % compared with it (*p <0.05; ** p < 0.01; *** p <0.001 after MTC-FDR).  
The number before each metabolite refers to the ranking of metabolite based on 
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Table 3. Clinical characteristics of two PCA separated CM syndrome type groups  
 Subtype A 
Qi-Yin deficiency & 
Qi-Yin deficiency with 
Dampness 
(n= 35 ) 
Subtype B 





Age /years 56±8 58±7 NS 
BMI ( kg/m
2
) 28.8±2.1 29.1 ±3.4 NS 
Waist circumference / cm 105±7 105±12 NS 
Systolic BP (mm/Hg) 137±17 135 ± 22 NS 
Diastolic BP(mm/Hg) 83±9 81 ± 13 NS 
Glucose (mmol/L) 6.1 ±0.4 6.4±0.6 0.04 
Hb1Ac ( %) 5.8±0.3 5.9 ±0.3 NS 
TC (mmol/L) 5.7±0.9 5.8 ± 1.0 NS 
HDL-C (mmol/L) 1.3±0.3 1.2 ±0.2 NS 
LDL-C (mmol/L) 3.7±0.8 3.7 ±1.0 NS 
Ratio TC/HDL-C 4.7±1.1
 
4.8 ± 1.0 NS 
TG (mmol/L) 1.7 ±0.8 1.9 ± 0.9 NS 
ALP ( U/L) 79±20 72 ± 13 NS 
ALT ( U/L) 29±11
 
29 ± 10 NS 
AST( U/L) 23±5
 
22 ± 4 NS 
γ -GT( U/L) 36±15 50±20 0.03 
Urea (mmol/L) 6.1±1.5 6.1 ± 1.0 NS 
Creatinine (mmol/L) 93±13 87 ± 14 NS 
 
NS: No significance, p > 0.05 
   
 
Discussion 
This is an explorative study combining urine metabolomics with CM syndrome 
type diagnosis to search for different metabolic patterns in pre-diabetic subtypes. 
First of all, this study demonstrated that three CM physicians have reached a high 
(85%) diagnostic consistency. Taken into account the many different CM 




asked to apply CM theories of Organ and Qi-Blood-Fluid and to quantify the 
diagnoses in percentage scaling. In this way, the CM diagnostic theory was 
clarified and standardized in advance, which may increase the inter-physician 
diagnostic consistency. Zhang et al. [19] also reported that consensus on CM 
diagnostic criteria results in the improved agreement of diagnosis. Thus the 
standardization of CM diagnostic procedures including diagnostic principle 
selection and symptoms scaling can lead to a more quantitative and reproducible 
CM diagnosis.  
In real CM practice, there are many CM syndrome/pattern diagnostic principles 
and CM physicians are free to choose one or more of them to provide a syndrome 
diagnosis, in order to provide an optimal personalized treatment. The diagnostic 
terms under these principles can be translated into one another in certain extent. 
As shown in figure 6, most frequently used CM diagnostic terms of T2DM were 
summarized in different diagnostic principle levels. In the organ level, CM terms 
under ‘Organ’ diagnostic principle were listed and they can be translated to the 
relevant higher ‘functional level’. For example, the diagnostic terms in ‘Organ 
level’ such as ‘Lung stomach heat’ can be categorized under diagnostic term ‘Yin 
deficiency with excessive heat’ under ‘functional level’. According to the ‘Standard 
for diagnosis and therapeutic effect evaluation of diabetes mellitus’ established 
by Chinese integrative medicine academy diabetes committee in the year 2005 
[29], the T2DM and related disorders including metabolic syndrome and obesity 
were categorized into CM syndromes under CM ‘functional level’, which is based 
on the combination of ‘CM theories of Organ and Qi-Blood-Fluid’.  As for research 
reasons, the first step to understand the subtypes in ‘functional level’ is more 
practical. Followed this concept, three CM physicians in current study were asked 
to freely write down the CM diagnostic terms ranked with percentage scaling 
based on the severity and frequency of the syndrome, which is a purely 
personalized diagnosis for each patient (Figure 2). Then 44 subjects with high CM 
diagnosis agreement were set to the CM syndrome types in CM ‘functional level’ 
based on the relations of CM syndromes shown in figure 6. Therefore, the CM 
diagnostic strategy applied in the current study is semi-unsupervised. The fully 
unsupervised CM diagnosis need much more study subjects and will be 
investigated in the future. 
Furthermore, this study demonstrated that three different pre-diabetic syndrome 
types could be diagnosed based on CM principles: “Qi-Yin deficiency” (group 1), 
“Qi-Yin deficiency with dampness” (group 2) and “Qi-Yin deficiency with 
stagnation”. “Qi-Yin deficiency” can be described as abnormalities induced by 
hypermetabolism. Its symptoms showed certain similarities with “chronic fatigue 
syndrome” and/or “people with mild inflammatory status”. Its main complaints 
(Table 2) included fatigue, short of breath, dizziness, afternoon heat, 
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concentration problems and sleep disorders. “Qi-Yin deficiency” is regarded as the 
main CM syndrome type of T2DM in many Chinese national protocols and 
guidelines for diabetes management [29, 30]; while “stagnation” and “dampness” 
are two CM pathological factors closely associated with T2DM and diabetic 
complications [29, 30]. In CM theory, “dampness” refers to the imbalanced 
metabolism due to dysfunction of liquid and humor, usually by an over intake of 
Figure 6. Chinese Medicine syndrome type summary for T2DM and its related disorders 
including pre-diabetes, obesity and metabolic syndrome. 
 
raw, cold, greasy, or sweetened food [31]; while “stagnation” covers a wide range 
of abnormalities including blood circulation disturbance (especially 
microcirculation), metabolic and immune disorders, connective tissue 
pathological changes and some mental problems [32]. Chinese animal models 



































































related to these CM syndrome types might provide us with an idea of the 
underlying biological mechanisms. The animals model of “dampness” was built by 
feeding animal with high carbohydrate and fat diets in the warm and humid 
environment to induce the symptoms analogous to humans such as fatigue, 
appetite loss and reduction of Na+-K+-ATPase activity [31]. Animal models of 
“stagnation” were made by using repetitive external stimuli (e.g. electronic needle, 
noise, light) to induce pain, stress, increased blood noradrenalin levels, a 
sympathetic hyperfunction and microcirculatory disturbances [33]. In Chinese 
population, “dampness” was more prevalent in patients with fatty liver [34], 
hypertension [35] and diabetic angiopathic complications [36]. “Stagnation” or its 
related CM syndromes (e.g. Yang deficiency) refers to T2DM patients with higher 
occurrence of proliferative diabetic retinopathy [11] or cerebral infarction [37]. 
Although CM syndrome type based animal models have many more varieties[31-
33] and shall differ from real human situations, we still could infer that “dampness” 
is more associated with unhealthy life-style (i.e. intake of high energy diets) 
induced abnormalities; while “stagnation” may represent either catecholamines 
induced autonomic nervous system derangement or blood circulation problems.  
The most importantly, this study demonstrated that we were able to distinguish 
two out of three defined pre-diabetic subtypes based on their urinary metabolic 
patterns: subtype A: “Qi-Yin deficiency” (group 1) and “Qi-Yin deficiency with 
dampness” (group 2), subtype B: “Qi-Yin deficiency with stagnation”. Although the 
“Qi-Yin deficiency” group could not be clearly distinguished from the other two 
groups based on the urinary metabolome, its biological background could be 
reflected by understanding the other two groups as they shared the same basic 
complaints. Subtype A was highlighted by “dampness” symptoms such as 
heaviness of the body, obesity and oedema while subtype B by “stagnation” 
symptoms such as cold and tingling limbs and pain. The two pre-diabetic subtypes 
showed a clear separation by PCA and PLS-DA and 51% of the measured urinary 
metabolites were significantly different between these pre-diabetic subtypes. 
Subtype B showed higher urinary levels of metabolites compared to subtype A.  
Firstly, some metabolites (i.e. D-glucose, pyruvic acid, D-ribose, citric acid, D-
ribulose, L-cysteine, Meso-erythritol, nicotinamide) are related to carbohydrate 
and energy metabolism. The higher urinary concentrations of glucose and other 
sugars in subtype B may corroborate with a higher hyperglycemic status of these 
study subjects. The fasting plasma glucose level of subtype B also showed a 
significantly higher concentration (p =0.04) than that of subtype A (Table 3). There 
might be enhanced endogenous glucose production from gluconeogenesis and 
the urinary loss of tricarboxylic acid (TCA) cycle intermediates such as citric acid 
and pyruvic acid in subjects of subtype B may indicate increased hepatic 
gluconeogenesis to provide extra pyruvate as a substrate for glucose [38]. Meso-
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erythritol and nicotinamide can provide beneficial effects for diabetics as food 
supplements [39-42].  
Secondly, many amino acids (e.g. L-cysteine, L-serine, phenylalanine, tryptophan) 
were increased in the urine of subtype B. Pre-/diabetes is characterized by insulin 
resistance and catabolic/anabolic hormonal imbalance, which will affect the 
metabolism of the whole body. Insulin resistance can cause protein degradation 
and amino acid release [43, 44]. In addition to being used as substrate for 
gluconeogenesis, these amino acids are cleared from the circulation by the 
kidneys and thus appear in higher concentrations in the urine [43, 44]. We 
speculate that subtype B might have more insulin resistance or impaired insulin 
action compared with subtype A.  Moreover, L-serine, a non-essential amino acid, 
was reported to be excreted significantly more in the diabetics than in healthy 
controls [45]. Phenylalanine and tryptophan are essential amino acids which are 
either incorporated into proteins or broken down for energy and metabolic 
intermediates [46]. Tryptophan is the precursor of brain neurotransmitter 
serotonin and phenylalanine is the precursor of catecholamines which are 
adrenalin-like substances such as tyramine, dopamine, epinephrine and 
norepinephrine in the body [42]. Increased phenylalanine and tryptophan in urine 
might reflect the catecholamines related autonomic nervous system derangement 
[47-50]. Interestingly, “stagnation” animal modeling was also developed with the 
increased blood noradrenalin level.  
Finally, the higher urinary excretion of the majority of measured metabolites in 
subtype B subjects could indicate that they might have more potential 
disturbance of renal function; therefore they lost metabolites that are necessary 
for carbohydrate and energy metabolism. Specifically, hypoxanthine’s relation 
with renal problems has been well demonstrated. On one hand, when xanthine 
oxidase converts hypoxanthine to xanthine in the presence of molecular oxygen, 
superoxide radical is generated. Reactive oxygen species, which leads to a lipid 
peroxidation, protein denaturation and DNA oxidation, contributes to the 
microvascular dysfunction and exert direct renal tissue damage [51]. On the other 
hand, uric acid is the end product of hypoxanthine catabolism and could deposit 
in renal tissue and form kidney stones [51]. Increased urinary citric acids were 
observed in diabetics and created more risks of kidney stones [52-54].  
Clinical parameters did not show significant differences among the two pre-
diabetic subtypes, except for higher blood glucose and γ -GT in subtype B. 
Elevated γ -GT level is associated with diseases of the liver and pancreas as well as 
cardiovascular mortality [55, 56]. Though both are still within the clinical 
reference range, the potential diabetic related problems might be indicated, 
which need further investigation. This study is an early phase investigation on 




physicians. As such whilst this data is very promising, there needs to be larger 
investigations using more subjects and CM physicians to demonstrate the further 
reliability and external validity/ generalizability of this novel approach to 
diagnosing pre-diabetic subtypes. 
 
Conclusion 
This is the first study combining non-invasive GC-MS urine metabolomics with CM 
personalized diagnosis to find metabolic subtypes in pre-diabetics. This study 
demonstrated that 85% inter-physician consistency of CM diagnosis was reached 
when the diagnostic principles were standardized and symptom descriptions were 
clarified in advance. Based on 3 different CM syndrome groups, two pre-diabetic 
subtypes can be identified by urine metabolomics and had different urinary 
metabolic patterns. The subtype B excreted higher levels of sugars and amino 
acids compared to the subtype A, indicating more disturbances of carbohydrate 
metabolism and renal function. The identified urinary metabolites may be of 
special clinical relevance for easy and non-invasive screening for subtypes of 
pre/diabetes and uncovering the diabetic development and prognosis in some 
extent, which could lead to a better understanding and improvement of 
personalized interventions for diabetics. This study proved that the understanding 
and improvement of diagnosis plays a key role in bridging between CM and WM 
on personalized healthcare. Future studies are needed to validate the subtypes 
yielded in the current study and to assess the intervention response of these 
subtypes to metabolic or hyperglycemic drugs. 
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Abstract 
Lipids are known to play crucial roles in the development of life-style related risk 
factors such as obesity, dyslipoproteinemia, hypertension and diabetes. The first 
selective cannabinoid-1 receptor blocker rimonabant, an anorectic anti-obesity 
drug, was frequently used in conjunction with diet and exercise for patients with a 
body mass index greater than 30 kg/m² with associated risk factors such as type II 
diabetes and dyslipidaemia in the past. Less is known about the impact of this 
drug on the regulation of lipid metabolism in plasma and liver in the early stage of 
obesity.  
We designed a four-week parallel controlled intervention on apolipoprotein E3 
Leiden cholesteryl ester transfer protein (ApoE*3Leiden.CETP) transgenic mice 
with mild overweight and hypercholesterolemia. A liquid chromatography-linear 
ion trap-Fourier transform ion cyclotron resonance-mass spectrometric approach 
was employed to investigate plasma and liver lipid responses to the rimonabant 
intervention. Rimonabant was found to induce a significant body weight-loss 
(9.4%, p < 0.05) and a significant plasma total cholesterol reduction (24%, p < 0.05). 
Six plasma and three liver lipids in ApoE*3Leiden.CETP transgenic mice were 
detected to most significantly respond to rimonabant treatment. Distinct lipid 
patterns between the mice were observed for both plasma and liver samples in 
rimonabant treatment vs. non-treated controls. This study successfully applied, for 
the first time, systems biology based lipidomics approaches to evaluate treatment 
effects of rimonabant in the early stage of obesity.  
The effects of rimonabant on lipid metabolism and body weight reduction in early 














Obesity, a major risk factor for serious diet-related chronic diseases such as 
diabetes and cardiovascular disease, is commonly stated as critically important 
compositions of the metabolic syndrome [1, 2]. In recent decades, obesity has 
reached epidemic proportions globally due to the rapid economic growth, 
modernization and urbanization. The major causes of its rising epidemic are 
excessive consumption of energy-dense food high in saturated fats and sugars and 
reduced physical activity [3, 4]. Obesity is known to be associated with 
dyslipoproteinemia characterized by increased levels of plasma triacylglycerides 
(TG) and low density lipoprotein cholesterol (LDL-C) and decreased level of high 
density lipoprotein cholesterol (HDL-C) [5]. Chronic liver disease associated with 
obesity has been identified in adults since 1970s and soon after this condition was 
also reported in childhood and adolescence [6, 7]. Most commonly, non-alcoholic 
fatty liver is observed in obese subjects with liver disease. This disease is 
frequently caused by complex hepatocellular metabolic dysfunctions due to the 
impaired insulin action, leading to disordered metabolism of fat and free fatty 
acids and subsequent oxidant mediated damage to the hepatocytes [6].  
Traditionally, prevention and treatment of obesity focus on individual behavior 
interventions through increased regular exercise and a low-fat, low refined 
carbohydrate diet [4]. It has proven inadequate probably because the sociological 
factors are not taken into account. Medical treatment approaches for obesity have 
largely been developed in modern societies and appear to be effective on the 
short term [8, 9]. However, data reporting on long-term health outcome based on 
successful treatment strategies are very limited [10].  
Previously, it has been demonstrated that early obesity is associated with 
endothelial dysfunction in high-fat fed pigs [11]. The observed abnormalities such 
as mild dyslipidemia, vascular oxidative stress and hypertension indicated that the 
early phases of obesity play a key role in the progression of coronary 
atherosclerosis and cardiovascular events and can be considered as the center 
point of the metabolic syndrome [6, 11-13]. Collectively, effective strategies for 
prevention and recognition of overweight and obesity in an early stage are critical. 
Since lipids are involved in obesity-associated pathology, novel tools that enable a 
large-scale study of individual lipids in biological systems are highly demanded for 
understanding the potential pathogenic mechanisms. Lipidomics technology can 
provide an integrated view of lipid metabolites present in cells, tissues and 
biological fluids [14-16]. This tool can not only provide insights into the specific 
roles of lipids in monitoring health status, but will also assist in identifying 
potential preventive or biomarkers [17, 18]. The availability of novel analytical and 
advanced instrumental as well as powerful informatics technologies has facilitated 
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the characterization of global changes of lipids in metabolic conditions such as 
insulin resistance [19], obesity [20], atherosclerosis [21], diabetes [22], and 
hepatic steatosis [23] and has facilitated data integration in order to understand 
the biological system. 
Rimonabant, as the first selective cannabinoid-1 (CB1) receptor blocker, was 
proved to lead to reduced food intake, long-term maintained weight loss, and 
improved cardiovascular risk factors, manifesting as elevated plasma HDL-C, 
reduced plasma TG and inhibited insulin resistance in obese subjects [24-26]. In 
2008 the European Medicines Agency withdrew the drug from the market in 
countries where it was commercially approved and marketed because of the 
psychiatric side-effects (e.g. depression and even suicide attempt) [27]. The aim of 
the current study was to unravel the underlying effects of rimonabant on plasma 
and hepatic lipid metabolism in stages of early obesity.  
For this we used a double transgenic mouse model, i.e. apolipoprotein E3 Leiden 
cholesteryl ester transfer protein (ApoE*3Leiden.CETP) transgenic mice, that 
matches with human lipid metabolism as closely as possible. The presence of 
ApoE*3Leiden hampers the uptake of very low density lipoprotein 
(VLDL)-remnants by the liver thus leading to increased VLDL/LDL-C levels in the 
plasma. CETP is a plasma glycoprotein that is responsible for the transportation of 
cholesterol ester (ChoE) from HDL to apoB-containing lipoproteins (e.g. VLDL and 
LDL) in exchange of TG, leading to decreased HDL-C levels [28, 29]. This gene is not 
present in wild type mice. Since in wild type mice the plasma cholesterol (Cho) is 
almost completely confined to the HDL fraction while VLDL and LDL are virtually 
absent due to the lack of CETP, wild type mice hardly develop dyslipidemia and, as 
a consequence, atherosclerosis [30]. The ApoE*3Leiden.CETP mice, however, have 
a higher VLDL/LDL-C level and relatively low HDL-C level. Taken together, 
ApoE*3Leiden.CETP mice have a human-like atherogenic lipoprotein profile. They 
not only respond in a human-like manner to pharmaceutical interventions with 
respect to lipid lowering efficacy [31, 32] but also respond to HDL modulating 
therapy. Many studies proved that the ApoE*3Leiden.CETP transgenic mouse is a 
valuable model to investigate the pathogenesis of vascular atherosclerotic lesion 
development and the effect of combination therapies on dyslipidemia and 
atherosclerosis [33-38]. In this paper we reported the results of the study of 
large-scale lipids in plasma and liver tissues of 16 female ApoE*3Leiden.CETP mice, 
8 of which were subjected to a period of 4 weeks of rimonabant intervention and 
8 untreated animals. 
Based on our study, we proposed that the rimonabant treatment intervention on 
early obesity of ApoE*3Leiden.CETP mice would affect plasma and hepatic lipid 
metabolism relative to the non-treated controls, leading to increased HDL-C 





All animals received humane care conforming to the rules and regulations set 
forward by the Netherlands Law on Animal Experiments. All animal experiments 
were approved by an independent institutional ethical committee on animal care 
and experimentation (Dierexperimenten Commissie DEC of Netherlands 
Organization for Applied Scientific Research, Zeist, the Netherlands) with a permit 
No. of DEC2489. 
 
Animals 
ApoE*3Leiden.CETP transgenic mice, expressing a human CETP gene [34], were 
bred at TNO (Leiden). In this study, sixteen female ApoE*3Leiden.CETP mice were 
used. All mice were housed under standard conditions in conventional cages (4 
mice per cage) with free access to water and food. At the age of 6-10 weeks, mice 
were fed a semi-synthetic modified Western-type diet (Hope Farms, Woerden, 
Netherlands) containing 15% (w/w) saturated fat, 0.2% (w/w) Cho and 40% (w/w) 
sucrose as described by Nishina et al [39] as a 4 weeks run-in diet in order to get 
mildly elevated lipid levels (plasma Cho levels of about 14-18 mmol/L) and a 
moderate increase in body weight. Thereafter (t = week 0), mice were matched on 
body weight and plasma Cho and TG levels (after 4 h fasting) and set into 2 groups. 
Subsequently, mice received a Western-type diet (Hope Farms, Woerden, 
Netherlands) without or with rimonabant (Sanofi-Aventis Netherlands B.V., Gouda, 
The Netherlands) at a concentration of 10 mg/kg body weight/day for a period of 
4 weeks. Table 1 presents the study design and time points at which both 
biochemical parameter and lipidomics profiling measurements were done. 
 
Sacrifice and Sample Collection 
Animals were sacrificed with rapid asphyxiation with CO2 and opened 
longitudinally after 4-week intervention experiment. Blood was collected before 
start of the intervention (t = week 0) and just before sacrifice (t = week 4) via tail 
vein bleeding into CB 300 LH microvettes (Sarstedt, Nümbrecht, Germany), 
containing lithium heparin and were placed on ice immediately after blood 
collection.  
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Table 1. Study design and time points at which both biological parameters and lipidomic profiling were done 
Time points of experiment (week) -4 -3 -2 -1 0 1 2 3 4 
 Run-in period  
Intervention 
period 
           
Group 1, control ×  ×  × 
Group 2, rimonabant treatment ×  ×  × 
          
Randomization     ×     
Body weight and food intake     × × × × × 
Plasma cholesterol and triacylglyceride     ×    × 
Lipoprotein profile     ×    × 
HDL-C measurement     ×    × 
CETP level & activity     ×    × 
Sacrifice with plasma & liver collection for lipidomics         × 





Plasma samples were obtained after centrifugation of the blood samples for 10 
min at 6000 rpm at 4 C. Liver tissues were dissected on ice and immediately 
weighted before being snap-frozen in liquid nitrogen. Both the plasma and the 
tissue samples were stored at -80 C until use.  
 
Plasma biochemical analyses and lipoprotein profile analysis 
Plasma samples collected at t = week 0 and t = week 4 were assayed for total 
cholesterol (TC), total triacylglycerides (TG), HDL-C and lipoprotein profile. Plasma 
TC and TG were quantified using the commercially available enzymatic kits 236691 
and 11488872 (Roche Molecular Biochemicals, Indianapolic, IN, USA), respectively. 
Plasma HDL-C was quantified after precipitation of apoB-containing lipoproteins. 
Pooled lipoprotein profiles were measured by fast performance liquid 
chromatography (FPLC) using an AKTA apparatus (Amersham Biosciences). Cho, TG 
and Phospholipid (PL) levels were measured in the fractions of freshly obtained 
samples. PLs were determined in the FPLC fractions using kit “phospholipids B” 
(Instruchemie Co., The Netherlands). 
 
Measurement of cholesteryl ester transfer activity in plasma 
CETP level was measured in each animal using the commercially available 
enzymatic kit “RB-CETP” (Roar Biomedical, Inc.). The transfer of newly synthesized 
ChoE in plasma was assayed by a radioisotope method as described before [40]. 
Briefly, [3H] Cho mixed with bovine serine albumin was equilibrated with plasma 
free Cho for 24 h at 4 °C followed by incubation for 3 h at 37 °C. Subsequently, 
apoB-containing lipoproteins were precipitated by addition of heparin/MnCl2. 
Lipids were extracted from the precipitation and the labeled cholesteryl esters 
were separated from labeled unesterified Cho on silica columns and assayed by 
liquid scintillation counting.  
 
Lipidomics analyses 
Lipid extraction for plasma samples 
Briefly, 30 L of internal standard (IS) mixture containing LPC (17:0) at 1.5 g/mL, 
PE (34:0) at 5 g/mL, PC (34:0) at 5 g/mL and TG (51:0) at 5 g/mL in 2:1 of 
CH2Cl2 /MeOH and 30 L of IS mixture containing LPC (19:0) at 30 g/mL, PE (30:0) 
at 30 g/mL, PC (38:0) at 150 g/mL and TG (45:0) at 60 g/mL in 2:1 of CH2Cl2 
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/MeOH were added to 30 L of plasma which was placed in a new 2 mL eppendorf 
vial (Eppendorf, Hamburg, Germany). Following this, 180 L MeOH and 360 L 
CH2Cl2 were successively added. Thorough vortex was performed both before and 
after CH2Cl2 addition. Subsequently, 120 L water was added to form a two-phase 
system in which lipids were located in the bottom organic phase. After 10 min 
centrifugation at a rotation speed of 6000g at 10 C, 300 L of lipid extracts from 
the bottom layer were transferred into a new brown auto-sampler vial. The 
extracts were diluted 20 times with ACN/IPA/water (65:30:5, v/v/v) before LC-MS 
running. 
 
Lipid extraction for liver samples 
Sixty microliters of IS mixture containing LPC (17:0) at 1.5 g/mL, PE (34:0) at 7.5 
g/mL, PC (34:0) at 12.5 g/mL and TG (51:0) at 45 g/mL in 2:1 of CH2Cl2 /MeOH 
and 60 L of IS mixture containing LPC (19:0) at 18 g/mL, PE (30:0) at 90 g/mL, 
PC (38:0) at 150 g/mL and TG (45:0) at 480 g/mL in 2:1 of CH2Cl2 /MeOH were 
added to 10 mg of dry liver powder followed by addition of 160 L of MeOH 
containing 0.02% antioxidant butylated hydroxytoluene (BHT), and then 320 L of 
CH2Cl2 was added. The mixture was thoroughly vortexed for 1 min both before and 
after CH2Cl2 addition. After that, the resulted suspension was placed for 5 min in 
an ultrasonic bath at -4 C and then placed in a shaker followed by 45 min 
incessantly shaking at -4 C. A 10 min centrifugation at a rotation speed of 6000g 
at 10 C was needed before 500 L of the supernatant was transferred into a new 
2 ml eppendorf vial. Subsequently, 100 L of 0.9 % NaCl was added to the 
supernatant to give rise to a two-phase system: the nonlipid compounds were 
located in the upper aqueous phase, while most of the lipids were in the lower 
organic phase. After being centrifuged at 2000g for 10 min at 10 C, a total of 300 
L of lipid extract was collected from the bottom organic phase. Diluted the lipid 
extracts 40 with ACN/IPA/water (65:30:5, v/v/v); 10 L was loaded for LC-MS 
lipidomics analysis. 
 
LC-MS lipid profiling 
Diluted lipid extracts from both plasma and liver tissue samples were measured on 
a liquid chromatography-linear ion trap-Fourier transform ion cyclotron 
resonance-mass spectrometric (LC-FTMS) system equipped with a Surveyor HPLC 
MS pump, an autosampler (Thermo Fischer, San Jose, CA) and an Ascentis Express 
C8 2.1 × 150 mm (2.7 μm particle size) column (Sigma-Aldrich Chemie B.V., 
Zwijndrecht, The Netherlands). The binary solvent consisted of water/ACN (2:3, 10 
mM ammonium formate) and ACN/IPA (1:9, 10 mM ammonium formate). The LC 
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separation conditions were identical to those described previously [41]. The 
lipidomics profiling was carried out in the full ESI positive ion mode with a mass 
range of m/z 430-1500. The heated capillary was set at 300 C. The voltages of the 
sampling cone and capillary were 3.8 kV and 48 V, respectively. The tube lens was 
optimized to be 140 V. Nitrogen was used as sheath gas (60 units), auxiliary gas (5 
units) and sweep gas (3 units). The LC-MS data were acquired by Xcalibur (Thermo 
Fisher) with 200 ms maximum injection time. The number of μscans was 2. Both 
the ion trap and FT scan events were recorded during data acquisition.  
Specifically, samples of interest (i.e. plasma or liver samples) were randomly 
analyzed and the quality control (QC) samples, prepared by pooling of all plasma 
or liver samples, were regularly placed in the measurement sequence. Of note, 
plasma and liver samples were analyzed separately. 
 
Preprocessing of lipidomics data 
Lipid peaks including spiked IS such as LPC (17:0), LPC (19:0), PE (34:0), PE (30:0), 
PC (34:0), PC (38:0), TG (51:0) and TG (45:0) were extracted based on their 
expected retention time and accurate masses according to an in-house lipid 
database using LCquan v2.5 (Thermo Fisher). The peak area of each extracted lipid 
ion was calibrated by an appropriate IS. Duplicate measurements were combined 
into a single measurement after IS calibration. Data quality was assessed by 
calculating the relative standard deviation (RSD) of all calibrated lipid peaks in the 
QC samples. Peaks with a RSD larger than 20% were excluded leaving 131 lipids in 
the plasma lipidomics data set and 133 lipids in the liver lipidomics data set for 
subsequent data analyses. General information about the lipidomics protocol was 
provided in the Supplementary Text, Tables and Figures as Supporting Information.  
 
Statistical analysis 
Statistical significance of biochemical parameters was analyzed by independent 
student t-test. Lipidomics data were first analyzed by independent student t-test 
and later extended with Benjamini and Hochberg multiple testing corrections. 
Data were expressed as mean  SD unless otherwise stated. A value of p < 0.05 
was considered statistically significant.  
In order to visualize possible relations between the samples from treated and 
non-treated groups, principal component analysis (PCA) was carried out for the 
mean centered plus unit variance scaled plasma lipidomics data and liver 
lipidomics data, respectively using Matlab software (version 6.5.1, release 13, The 
Mathworks, 2003).  
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One control mouse (marked as 3733) was excluded from statistical data analyses 
throughout the article, because it did not respond to Western-type diet during 
run-in period and failed to reach hypercholesterolemia criteria essential for our 
experiment. We observed that the relative levels of most hepatic lipids were much 
lower in this mouse as compared to the other control mice. In this animal, the 
biochemical markers such as plasma TC, TG and liver weight were lowest among 
all control mice (data not shown).  
Results 
Food intake and body weight 
The variation in food intake and body weight during the 4 weeks of intervention is 
shown in Figure 1 A and B, respectively. The body weight was significantly reduced 
in mice on rimonabant compared to control throughout the whole intervention 
period. In total, the weight loss was 9.4% (p = 0.03) at the end of the experiment. 
This decline in body weight might be explained by reduced food intake in the 
initial states of the experiment, although statistical significance was not reached. 
 
Plasma cholesterol, triacylglycerides, HDL-C and lipoprotein profiles 
After a period of 4 weeks of intervention, plasma TC was significantly reduced by 
24% (p = 0.04) (Figure 2A) and plasma TG reached a reduction trend (e.g. 1.34  
0.96 vs. 2.35  1.34 mM, p = 0.11) in the rimonabant group as compared to the 
control mice (Figure 2B). As compared to the control, we could not see a 
significant increase in plasma HDL-C upon rimonabant intervention (Figure 2C).  
The 4-week rimonabant intervention led to decreased levels of Cho, TG and PLs in 
the VLDL for 1.5, 2.5 and 2 fold respectively (Figure 2 D-F) and to a slightly 
increased level of Cho in HDL particles (magnified part in Figure 2D). 
Concentrations for Cho and TG as well as PLs were unaffected in LDL particles, 
whereas TG and PL concentrations were unaffected in HDL particles. 
 
Rimonabant does not significantly affect plasma CETP activity 
The CETP level was constant during the intervention (Figure 3A). The four-week 
rimonabant intervention resulted in a non-significant change of plasma CETP 
activity (e.g. 90.8  27.0 vs. 70.6  33.3 nmol/mL/h, p = 0.22) as compared to the 





Figure 1. Food intake and body weight. The 4-week intervention effect of rimonabant on 
food intake (A) and body weight (B). * P < 0.05 vs. the control. Body weight per mouse and 
food intake per cage were measured at day 0, 2, 3, 4, 9, 11, 14, 21 and 28 respectively. 
Values are expressed as means  SD. P values correspond to the mean difference between 
the rimonabant group and the control group. 
 




Figure 2. Four-week intervention effect of rimonabant on plasma TC (A) and TG (B) as well 
as HDL-C (C) levels. Plasma TC, TG and HDL-C were measured at week 0 and 4. Values are 
shown as means  SD. *P < 0.05 vs. the control. P values correspond to the mean difference 
between the rimonabant and the control group; (D-F) alterations of Cho and TG as well as 
PLs in the pooled lipoprotein profiles on the rimonabant treatment as compared to the 
controls. Fractions 4-7 represent VLDL; fractions 8-9 represent intermediate-density 







Figure 3. Rimonabant does not significantly affect plasma CETP activity. Effect of 
rimonabant on plasma CETP level (A) and CETP activity (B) in ApoE*3Leiden.CETP mice at 
time points of t = week 0 and 4; (white bars: the control group; black bars: the rimonabant 
group). Values are means  SD. There were no statistically significant changes found in 
CETP level and CETP activity during the intervention treatment. 
 
Lipidomics reveals differences between nontreatment and rimonabant 
treatment mice for both plasma and liver samples 
To get an overview of existing patterns in the lipidomics data such as clusters of 
mice of nontreated controls and mice undergoing rimonabant treatment and 
which lipids contributed most to these clusters, we performed PCA for the plasma 
and liver lipidomics datasets, respectively. Figure 4 displays the PCA biplots (A, 
plasma samples; B, liver samples). In both plasma and liver the rimonabant 
treated group was separated well from the control group. Two rimonabant treated 
mice (marked as 3736 and 3758) deviated from the others within the group 
causing some overlap with the mice from the control liver group. The deviations of 
these two mice from other group members were further checked with data from 
biological parameters and lipidomics. The biological parameters revealed that 
among all rimonabant treated mice the liver weights of these two mice were the 
heaviest and the total plasma TG levels were the lowest (data not shown). The 
liver lipidomics data showed that the TG levels were more abundant in these two 
mice than other rimonabant treated mice. In addition, the loadings in the biplot 
(lipid species represented by colored symbols in Figure 4A and B) indicated that TG 
lipid species dominated the differentiation between non-treated controls and the 
rimonabant-treated mice for both plasma and liver lipidomics data sets. 




Figure 4. PCA biplots for the first two principal components of lipid profiling of plasma 
samples (A) and liver samples (B) in control animals (n = 7) and animals treated with 
rimonabant (n = 8). Both PCA models used mean centred plus unit variance scaled data. 
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Rimonabant significantly affects individual lipids in both plasma and liver 
of treated mice 
To investigate quantitative changes of lipids in the rimonabant intervention group 
as compared to the control, statistical significance for the mean difference of all 
identified lipids between the rimonabant group and the control group was tested 
using independent student t-test. It was found that 33 plasma and 25 liver lipid 
species out of 131 and 133 lipids respectively were significantly changed after the 
4-week rimonabant intervention as compared to the controls. Four lipids changed 
significantly upon rimonabant treatment in both plasma and liver, i.e. PE (36:3), TG 
(50:1), TG (52:2) and TG (56:7). Within these perturbed lipids, one interesting 
observation was that 31 out of 33 lipid species were significantly decreased in 
plasma samples whereas 22 out of 25 lipid species were significantly increased in 
liver samples in the rimonabant group versus the controls (Table 2 and 3).  
Remarkably, after multiple testing correction only 6 plasma lipids (LPC-18:1, 
LPC-18:2, LPE-20:4, PC-38:2, PE-38:2 and SPM-16:0) and 3 liver lipids (PC-40:4, 
ChoE-16:1 and TG-56:6) remained significant out of 33 and 25 plasma and liver 
lipids respectively (lipids with p values marked in bold in Table 2 and 3).  
 
Rimonabant significantly decreases the overall responses of plasma lipid 
classes  
The summation of the individually measured lipids into different lipid classes 
showed for plasma concentrationsa significant reduction of PE with 20% (p = 0.02), 
ChoE with 22% (p = 0.02) and TG with 46% (p = 0.04) in rimonabant treated mice 
vs. the control  (white bar graph in Figure 5); the summation of individually 
measured lipids into lipid classes of LPC, PC and SPM in plasma of mice receiving 
rimonabant treatment were comparable to those in untreated controls under the 
current LC-MS conditions. In total, the level of phospholipids in plasma samples 
was comparable in rimonabant treated mice vs. the control (data not shown). In 
liver tissues, none of the summation of the individually measured lipids within 
each of lipid classes was significantly changed after the rimonabant intervention in 
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Table 2. Significantly influenced lipid molecular species in plasma upon 
rimonabant treatment as compared to non-treated controls 
 




(mean ± SD) 
rimonabant 







 ()  
 () 
LPC (18:1) 0.2896 ± 0.0146 0.2414 ± 0.032 83 0.0030**  
LPC (18:2) 0.1402 ± 0.0105 0.1069 ± 0.0138 76 0.0002***  
LPC (20:3) 0.0264 ± 0.0023 0.0219 ± 0.0034 83 0.0109*  
LPE (20:4) 0.0022 ± 0.0001 0.0017 ± 0.0002 76 0.0001***  
PC (36:2) 0.0848 ± 0.0088 0.0738 ± 0.0059 87 0.0133*  
PC (38:2) 0.5067 ± 0.0589 0.3773 ± 0.0624 74 0.0012**  
PE (36:3) 0.7573 ± 0.1050 0.6087 ± 0.1137 80 0.0214*  
PE (38:2) 0.2678 ± 0.0457 0.2042 ± 0.0205 76 0.0035**  
PE (38:4) 0.1453 ± 0.0243 0.1126 ± 0.0146 77 0.0068**  
SPM (16:0) 0.0046 ± 0.0003 0.0054 ± 0.0004 118 0.0006***  
SPM (18:0) 0.0008 ± 0.0001 0.0010 ± 0.0001 122 0.0102*  
ChoE (18:1) 0.1869 ± 0.0171 0.9168 ± 0.2101 77 0.0180*  
*P < 0.05, **p < 0.01, ***p< 0.001 vs. the contrl.  
P values correspond to the mean difference between the rimonabant group and the control group. 





















(mean ± SD) 
rimonabant 







 ()  
 () 
TG (44:0) 0.0169 ± 0.0009 0.0151 ± 0.002 89 0.0437*  
TG (46:0) 0.0328 ± 0.0037 0.0273 ± 0.0047 83 0.0259*  
TG (46:1) 0.0127 ± 0.0038 0.0078 ± 0.0033 62 0.0198*  
TG (48:0) 0.0167 ± 0.0057 0.009 ± 0.0056 54 0.0202*  
TG (48:1) 0.0084 ± 0.0028 0.0048 ± 0.0032 57 0.0387*  
TG (48:2) 0.1037 ± 0.0302 0.0558 ± 0.0411 54 0.0247*  
TG (50:0) 0.0493 ± 0.0196 0.0251 ± 0.0197 51 0.0329*  
TG (50:1) 0.1568 ± 0.0685 0.0805 ± 0.0631 51 0.0429*  
TG (52:2) 1.0304 ± 0.4185 0.5248 ± 0.4136 51 0.0353*  
TG (52:6) 0.0025 ± 0.0008 0.0013 ± 0.001 52 0.0298*  
TG (54:2) 0.3189 ± 0.1698 0.1508 ± 0.1247 47 0.0459*  
TG (54:3) 0.9160 ± 0.3800 0.4568 ± 0.3700 50 0.0341*  
TG (54:4) 0.1780 ± 0.0750 0.0921 ± 0.0693 52 0.0382*  
TG (56:3) 0.1001 ± 0.0481 0.0453 ± 0.0314 45 0.0200*  
TG (56:4) 0.0765 ± 0.0328 0.0396 ± 0.0253 52 0.0289*  
TG (56:7) 0.3749 ± 0.1634 0.2055 ± 0.134 55 0.0459*  
TG (58:3) 0.0057 ± 0.0028 0.0029 ± 0.0017 52 0.0367*  
TG (58:4) 0.0051 ± 0.0022 0.0028 ± 0.0014 55 0.0290*  
TG (58:5) 0.0155 ± 0.0069 0.0084 ± 0.005 54 0.0384*  
TG (58:6) 0.0162 ± 0.0055 0.0098 ± 0.0044 60 0.0253*  
TG (58:7) 0.0264 ± 0.0091 0.016 ± 0.0078 60 0.0322*  
*P < 0.05, **p < 0.01, ***p< 0.001 vs. the contrl.  
P values correspond to the mean difference between the rimonabant group and the control group. 
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Table 3. Significantly influenced lipid molecular species in liver tissue upon 




(mean ± SD) 
rimonabant 
(mean ± SD) 
rimonabant 
 vs. control 
change (%) 
 p value 
()  
() 
PC (38:4) 2.160 ± 0.299 2.563 ± 0.319 119 0.0262*  
PC (40:4) 0.157 ± 0.012 0.196 ± 0.024 125 0.0018**  
PC (40:5) 0.834 ± 0.069 1.052 ± 0.184 126 0.0113*  
PC (40:6) 0.546 ± 0.048 0.668 ± 0.086 122 0.0054**  
PC (40:8) 0.272 ± 0.040 0.225 ± 0.036 83 0.0318*  
PE (34:1) 0.254 ± 0.038 0.308 ± 0.055 121 0.0484*  
PE (36:3) 0.529 ± 0.126 0.418 ± 0.066 79 0.0493*  
PE (38:6) 1.474 ± 0.079 1.785 ± 0.341 121 0.0355*  
PE (40:6) 0.563 ± 0.057 0.711 ± 0.125 126 0.0133*  
ChoE (16:1) 0.628 ± 0.232 1.078 ± 0.160 172 0.0007***  
ChoE (22:6) 0.043 ± 0.008 0.054 ± 0.005 127 0.0054**  
TG (50:1) 1.357 ± 0.363 1.773 ± 0.362 131 0.0450*  
TG (50:2) 1.779 ± 0.570 2.497 ± 0.636 140 0.0396*  
TG (50:3) 0.347 ± 0.132 0.581 ± 0.211 167 0.0251*  
TG (52:2) 7.234 ± 1.170 8.572 ± 1.160 118 0.0448*  
TG (52:4) 0.462 ± 0.116 0.679 ± 0.229 147 0.0411*  
TG (52:5) 0.526 ± 0.165 0.840 ± 0.346 160 0.0478*  
TG (54:5) 0.354 ± 0.078 0.504 ± 0.136 143 0.0235*  
TG (54:6) 0.616 ± 0.181 1.021 ± 0.305 166 0.0091**  
TG (54:7) 0.078 ± 0.025 0.141 ± 0.058 180 0.0195*  
TG (56:5) 0.517 ± 0.100 0.687 ± 0.151 133 0.0250*  
TG (56:6) 0.135 ± 0.027 0.209 ± 0.033 155 0.0005***  
TG (56:7) 1.047 ± 0.281 1.562 ± 0.558 149 0.0461*  
TG (56:8) 0.168 ± 0.049 0.274 ± 0.108 163 0.0326*  
TG (60:1) 0.015 ± 0.002 0.012 ± 0.002 83 0.0352*  
*P < 0.05, **p < 0.01, ***p< 0.001 vs. the contrl.  
P values correspond to the mean difference between the rimonabant group and the control group. 









Figure 5. Relative change of the summation of the individually measured lipids in different 
lipid classes based on the present LC-MS lipidomics data acquired from plasma and liver 
samples in the rimonabant group vs. the control. The summation of the individually 
measured lipids in each lipid class in the control is set to be 1. * P < 0.05 vs. the control. P 




Rimonabant, a selective CB1 receptor antagonist, is known for reducing body 
weight and improving cardiovascular risk factors in obese subjects[24, 26, 42-44]. 
However, studies of the obesity regulation effects of rimonabant mainly focus on 
the plasma/serum biochemical and lipid profile [45-47]. Less is known about the 
regulation of individual plasma and hepatic lipid species upon rimonabant 
treatment in obese subjects.  
The present study describes the rearrangement and relocalisation of lipids in an 
early obese ApoE*3Leiden.CETP mouse model with humanized lipoprotein 
metabolism exposed to a 4-week rimonabant intervention. Lipoprotein profiling 
and lipidomics approaches were used for this purpose.  
Throughout the experiment, food intake upon rimonabant dropped sharply during 
the first two days but quickly recovered to some extent during the first 3 weeks; 
since day 21, food intake has returned to nearly the levels in identical high-fat fed 
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mice without rimonabant treatment. Although the rapid return to high energy 
intake within 3 weeks, the rimonabant group exhibited a significant and 
maintained weight reduction throughout the intervention period as compared 
with the non-treated controls. Collectively, this body weight reduction may be 
attributed to 1) the transient reduction in energy intake; 2) a reduction in energy 
efficiency (i.e. wastage of energy) caused by interruption of cannabinoid signalling 
upon rimonabant treatment [48]. Notably, the 9.4% body weight reduction 
induced by rimonabant treatment in our study seems not to be comparable with 
the at least 20% body weight-loss induced by rimonabant reported in literature 
for obese mice and humans [43, 44]. However, it should not be neglected that the 
mouse model used was in the early stage of obesity with only mildly increased 
body weight and plasma Cho. 
Rimonabant intervention studies both in rodents and humans [24, 26, 45, 47, 49] 
have shown significant reduction of plasma TC and TG and a significant increase in 
HDL-C concentrations. Our 4-week rimonabant treatment of ApoE*3Leiden.CETP 
transgenic mice in early stage of obesity showed similar reduction of plasma TC 
and a reduction trend of plasma TG (Figure 2A and B). However, the treatment did 
not significantly increase levels of HDL-C (Figure 2C), which was probably due to 
our short intervention period combined with an early stage of obesity in our 
animal model. In line with these observations, plasma Cho and TG in VLDL were 
reduced, whereas Cho in HDL was slightly increased after the rimonabant 
intervention (Figure 2D and E). These effects may be mediated via adiponectin, a 
major adipocyte cytokine involved in the regulation of hyperglycaemia, 
hyperinsulinaemia, and fatty acid oxidation at the peripheral adipocyte level [42, 
50, 51]. Adiponectin release from adipocytes is known to be regulated by 
inhibition of CB1 [43, 52]. Furthermore, no significant reduction effect of 
rimonabant on CETP activity and levels was found in the ApoE*3Leiden mouse 
model.  
The LCMS-based plasma lipidomics analysis revealed a significant decrease of a 
large number of plasma lipids (Table 2) and a significant reduction in plasma PE, 
ChoE and TG lipid classes (Figure 5) after rimonabant intervention, indicating the 
beneficial effect of rimonabant on plasma lipid metabolism in early stage of 
obesity. Specifically, as ChoE, TG and phospholipids (e.g. PE) are the main 
components of VLDL particles, their reduction in plasma indicated a lower 
circulated VLDL induced by rimonabant, which is in line with the result of plasma 
lipoprotein profiles, i.e., the VLDL fractions of Cho, TG and PLs were all reduced in 
rimonabant group (Figure 2D-F). Evidence from animal studies and clinical trials 
indicated that the beneficial metabolic effects of rimonabant on plasma/serum 
lipid profiles are caused by the absence of basal endocannabinoid signaling, 
leading to reduced energy efficiency of food [24, 48, 53]. In addition, after 
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multiple testing corrections six plasma lipid species showed a most significant 
reduction in response to rimonabant except for SPM (16:0) which increased. 
Although it is unknown if these lipid compounds would be useful for 
understanding the pharmacological manipulation of rimonabant on improving 
obesity-related metabolic abnormalities under current experimental conditions, it 
may give hints point to an important role of individual lipid molecular species in 
rimonabant’s management of obesity.  
It is recognized that high-fat diet-induced obesity is highly associated with fatty 
liver due to the expression of hepatic CB1 receptor [49, 54]. Liver-specific deletion 
of CB1 or blockage of CB1 receptor was frequently used to protect against 
obesity-associated hepatic steatosis [45, 49, 53]. The results from available studies 
suggest that rimonabant, as a CB1 receptor antagonist, potentially has clinical 
applications in the treatment of high-fat diet-induced liver diseases [45, 53]. In the 
present study, down-regulation of lipids was not observed in liver tissues as in 
plasma after rimonabant treatment. It could be owing to the early stage of obesity 
in our animal model, which displays a mild increase in body weight and 
moderately elevated plasma Cho levels (14-18mmol/L). It also needs to be noted 
that our animal model is very different from those used in literature to investigate 
rimonabant’s management in high-fat diet-induced liver disease. Our 
ApoE*3Leiden.CETP mice express a natural mutation of the human APOE3 gene in 
addition to the human APOC1 gene. Introduction of these genes induces an 
attenuated clearance of apoB-containing lipoproteins via the LDL receptor 
pathway [34, 55]. Mice with such genetic background show mildly increased Cho 
and TG levels on a chow diet and a human-like lipoprotein profiles on high fat diet 
[56]. Taken collectively, we proposed that 4-week rimonabant treatment has 
moderate effect on liver lipid metabolism in the early stage of obesity of 
ApoE*3Leiden.CETP mice under current experimental conditions.  
This study shows that LC-MS lipidomics approaches hold promises for searching 
potential lipid biomarkers in relation to disease prevention and health promotion. 
Moreover, it was demonstrated that a 4-week rimonabant intervention improves 
body weight and cardiovascular risk factors during the early stage of obesity in 
ApoE*3Leiden.CETP mice. Finding of only limited amount of significant lipid 
changes may be attributed to the early stage of obesity in the animal model used. 
Taken together, it indicates that the effects of rimonabant on body weight and 
cardiovascular risk factors are moderate in the case of early stage obesity. 
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Synthetic lipid standards including lyso-phosphocholine (LPC-17:0, LPC-19:0), 
phosphatidylethanolamine (PE-30:0, PE-34:0), phosphatidylcholine (PC-34:0, 
PC-38:0) and triglyceride (TG-45:0, TG-51:0) were purchased from Avanti Polar 
Lipids, Inc. (Alabaster, AL, USA) and Sigma-Aldrich Chemie B.V. (Zwijndrecht, The 
Netherlands). ULC-MS grade of acetonitrile (ACN), methanol (MeOH), isopropanol 
(IPA), and water as well as LC-MS grade of dichloromethane (CH2Cl2) were 
obtained from Biosolve (Valkenswaard, The Netherlands). Ammonium formate 
(AmFm, 99.995%) was of LC-MS grade and purchased from Sigma-Aldrich Chemie 
(St. Louis, MO, USA). Rimonabant was purchased from Sanofi-Aventis Netherlands 
B.V. (Gouda, The Netherlands). 
 
Lipid standards for plasma lipidomics profile and liver lipidomics profile 
In brief, stock solutions of 8 lipid standards from 4 different lipid classes were 
separately prepared in a CH2Cl2 /MeOH mixture (2:1, v/v) for all standards except 
TG by weighing an exact amount of each lipid standard in new glass autosampler 
vials and stored at -20C until further use. The TG standard was dissolved in CH2Cl2 
instead of a CH2Cl2 /MeOH mixture due to its weak polarity.  
For LC-MS lipidomics analysis of study samples, the stock solutions were separated 
into two sets. Set 1 consist of LPC (19:0), PC (38:0), PE (30:0), and TG (45:0), which 
was used for quantification of less intermediate  high abundant lipids in the 
samples; set 2 consist of LPC (17:0), PC (34:0), PE (34:0) and TG (51:0), which was 
used for quantification of very low  low abundant lipids in the samples. The final 
working solution for each set was prepared by pipetting a certain volume of 
corresponding stock solutions, “thawed” to room temperature followed by 
thorough vortex, into a new glass autosampler vial and diluting it to appropriate 
concentrations with a CH2Cl2 /MeOH mixture (2:1, v/v). Detailed information for 
these standards is provided in Supplementary Tables S1. 
For method validation of LC-MS liver lipidomics profile, two sets of standard 
mixture were also used. Set 1 was used as internal standard (I.S.) mixture, 
consisting of LPC (17:0) at 30 g/mL, PC (34:0) at 180 g/mL, PE (34:0) at 120 
g/mL, and TG (51:0) at 90 g/mL in a CH2Cl2 /MeOH mixture (2:1, v/v); and set 2 
was used as “validation standard mixture” containing LPC (19:0), PC (38:0), PE 
(30:0), and TG (45:0) at the following C0-C8 concentration levels: LPC (19:0) at 0, 
0.1, 0.5, 1, 2.5, 10, 30, 90, 180 g/mL; PC (38:0) at 0, 0.5, 2.5, 5, 12.5, 50, 150, 450, 
900 g/mL; PE (30:0) and TG (45:0) at 0, 0.3, 1.5, 3, 7.5, 30, 90, 270, 540 g/mL. 
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From C1 to C8, the concentration was gradually increased, i.e., working solution of 
C8 was prepared first and then gradually diluted towards C7–C1. Three different 
concentrations (e.g. C4, C6 and C8, corresponding to low, medium and high 
concentration levels, respectively), were selected for evaluation of repeatability 
and calculation of recovery.  
 















LPC (17:0) 510.3557 [M + H]
+
 0.75 6 0.75 6 
PE (34:0) 720.5583 [M + H]
+
 1.05 20 1.80 30 
PC (34:0) 762.6025 [M + H]
+
 1.20 20 1.50 50 
TG (51:0) 866.8209 [M + NH4]
+
 1.25 20 2.25 180 
LPC (19:0) 538.3880 [M + H]
+
 0.90 120 0.75 72 
PE (30:0) 664.4927 [M + H]
+
 2.50 120 2.45 360 
PC (38:0) 818.6658 [M + H]
+
 3.50 600 3.75 600 
TG (45:0) 782.7264 [M + NH4]
+
 2.50 240 4.20 1920 
 
Liver samples for method validation of LC-MS liver lipidomics profile 
Liver tissues from five healthy male mice at age of 8-12 weeks with C57BL/6 
background were used for method validation of LC-MS liver lipidomics profile. 
These samples were kindly provided by Division of Toxicology, Leiden/Amsterdam 
Center for Drug Research, Leiden University (The Netherlands).  
 
Liver sample pre-processing 
The frozen liver samples stored at -80C were immediately put into a lyophilizer 
after taken out from the freezer and lyophilized for 48 hours for the purpose of full 
dryness. After lyophilization, the liver was placed on clean aluminum foil followed 
by folding of the aluminum foil in order to cover the liver within it. A hammer was 
then used to triturate the crisp dry liver, wrapped inside the aluminum foil. Ten 
milligrams of liver powder was weighed in a clean 1.5 mL eppendorf vial for the 
subsequent lipid extraction. Notably, the triturated liver tissues from 5 mice used 
for method validation were mixed homogeneously before use.  
 
Lipid extraction for method validation of liver lipid profiling 
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i) Spiking before sample preparation. Sixty microliters of I.S. mixture and 60 L of 
the validation standard mixture were added to 10 mg of dry liver powder followed 
by addition of 160 L of MeOH containing 0.02% antioxidant butylated 
hydroxytoluene (BHT), and then 320 L of CH2Cl2 was added. The mixture was 
vortexed for 1 min both before and after CH2Cl2 addition. After that, the resulted 
suspension was placed for 5 min in an ultrasonic bath at -4C and then placed in a 
shaker followed by 45 min incessantly shaking at -4C. Then 10 min centrifugation 
at a rotation speed of 6000g at 10C was needed before 500 L of the supernatant 
was transferred into a new 1.5 ml eppendorf vial. 100 L of 0.9 % NaCl was 
subsequently added to the supernatant to give rise to a two-phase system: the 
nonlipid compounds were located in the upper aqueous phase, while most of the 
lipids were in the lower organic phase. After being centrifuged at 2000g at 10 C 
for 10 min, a total of 300 L of lipid extract was collected from the bottom organic 
phase followed by addition of 60 L of a CH2Cl2/MeOH mixture (2:1, v/v). Diluted 
the lipid extracts 40 with ACN/IPA/water (65:30:5, v/v/v); 10 L was loaded for 
LC-MS lipidomics analysis. ii) Spiking after sample preparation. The same 
procedures as described for spiking before sample preparation were conducted 
except that 60 L of 2:1 CH2Cl2/MeOH instead of 60 L of validation standard 
mixture was added to 10 mg dry liver powder before sample preparation, while 60 
L of the validation standard mixture instead of 60 L 2:1 CH2Cl2/MeOH was 
added into the collected 300 L of liver lipid extract.  
     
QC samples 
For the purpose of monitoring the LC-MS response in time and assessing data 
quality, quality control (QC) samples, were obtained by pooling all plasma or liver 
samples. Sample preparation for QC samples was conducted as the same manner 
as study samples of interest. The number of QC samples (number of aliquots of 
pooled plasma or pooled liver samples) needed depends on the size of the study. 
In the present study, two injections of one QC sample are performed after every 
6th study sample injections. 
 
LC-MS chromatography 
Lipid extracts were performed on a liquid chromatography-linear ion trap-Fourier 
transform ion cyclotron resonance-mass spectrometric (LC-FTMS) system 
equipped with a Surveyor HPLC MS pump, an autosampler (Thermo Fischer, San 
Jose, CA) and an Ascentis Express C8 2.1 × 150 mm (2.7 μm particle size) column 
(Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). The binary gradient 
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system consisted of water/ACN (2:3, 10 mM ammonium formate) and ACN/IPA 
(1:9, 10 mM ammonium formate). The performance of the elution for the gradient 
was identical to that reported before [41]. The flow rate was 0.26 mL/min. The 
column oven was maintained at 55 °C and the temperature of the autosampler 
tray was 12 °C. The lipidomics profiling was carried out on Thermo Fischer linear 
ion trap-Fourier transform ion cyclotron resonance-mass spectrometry in the full 
ESI positive scan mode with a mass range of m/z 430-1500. IS of PC (34:0) was 
used to tune the mass spectrometry for optimizing the MS parameters. During 
tuning, 1 μg/mL of PC (34:0) at a flow rate of 10 μL/min from a Hamilton syringe 
pump and 30% A/70% B of elution at a flow rate of 250 μL/min from the Surveyor 
MS pump were continuously flowing into the LC-MS system. Finally, the optimized 
MS parameters are as following: the heated capillary was at 300C. The voltages of 
the sampling cone and capillary were 3.8 kV and 48 V, respectively. The tube lens 
was 140 V. Nitrogen was used as sheath gas (60 units), auxiliary gas (5 units) and 
sweep gas (3 units). The LC-MS data were acquired by Xcalibur (Thermo Fisher) 
with 200 ms maximum injection time. The number of  scans was 2. Both the ion 
trap and FT scan events were recorded during data acquisition.  
 
Data processing 
Lipid peaks including spiked internal standards (IS) were extracted based on their 
expected retention time and accurate masses according to an in-house lipid 
database using LCquan v2.5 (Thermo Fisher). The extracted lipid peaks were 
initially integrated by LCquan and manually corrected if needed. The parameters 
for the integration were peak detection algorithm, ICIS; smoothing points, 7; 
window, 60 s; view width, 3 min; baseline, 100; area noise factor, 5; peak noise 
factor, 10. The LCquan pre-processed data were exported as an Excel report. The 
standards, used for quantification, were picked out from the pre-processed Excel 
data sheet and the relative standard deviation (RSD) of their absolute peak areas 
from all injected samples was subsequently calculated to check the stability of the 
LC-MS system during the measurement. Lipids detected in study samples were 
quantified as the peak area ratios of lipids in study samples to lipid standards. 
Supplementary Table S2 showed the spiked concentration of 8 standards, the 
quantification strategies and RSD of absolute peak area of spiked standard from all 
injected samples. After quantification, duplicate measurements were combined 
into a single measurement. And then data quality was assessed by calculating the 
RSD of the peak area ratios of lipids in study samples to appropriate lipid 
standards in all QC samples. The summary of the calculation results is presented in 
Supplementary Table S3. Peaks with a %RSD more than 20% were excluded leaving 
131 lipids in plasma lipidomics data set and 133 lipids in liver lipidomics data set 
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for further data analysis.  
The lipidomics datasets were first analyzed by independent student t-test and late 
extended with Benjamini and Hochberg multiple testing corrections. P < 0.05 was 
considered to be statistically significant. In order to visualize possible relations 
between the samples from treated and non-treated groups, principal component 
analysis (PCA) was carried out for the mean centered plus unit variance scaled 
plasma lipidomics data set and liver lipidomics data set, respectively using Matlab 
software (version 6.5.1, release 13, The Mathworks, 2003). 
 
Table S2. The spiked concentrations of 8 standards used in lipidomics analyses and 
quantification strategies used for LC-MS lipidomics data analyses. 
Internal 
standards 





plasma liver plasma liver 
LPC 
(17:0) 
1.5 1.5 LPC, LPE 
very low  low 
13.6 14.7 
PE (34:0) 5 7.5 PE 23.9 26.3 
PC (34:0) 5 12.5 PC, SM 9.0 14.8 
TG (51:0) 5 45 ChoE, TG 12.2 13.0 
LPC 
(19:0) 
30 18 LPC 
less intermediate 
 high  
8.3 14.4 
PE (30:0) 30 90 PE 9.3 16.0 
PC (38:0) 150 150 PC, SM 10.8 13.6 
TG (45:0) 60 480 TG 11.0 11.4 
 
Table S3. The RSD of the peak area ratios of lipids in study samples to 
corresponding lipid standards calculated in all QC samples 
Plasma lipidomics dataset Liver lipidomics dataset 
% RSD Number of peaks % RSD Number of peaks 
0 - 5 45 0 - 5 71 
5 - 10 56 5 - 10 47 
10 - 15 19 10 - 15 8 
15 - 20 11 15 - 20 7 
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Causes and consequences of the complex changes in lipids occurring in the 
metabolic syndrome are only partly understood. Several interconnected processes 
are deteriorating, which implies that multi-target approaches might be more 
successful than strategies based on a limited number of surrogate markers. 
Preparations from Chinese Medicine (CM) systems have been handed down with 
documented clinical features similar as metabolic syndrome, which might help 
developing new intervention for metabolic syndrome. The progress in systems 
biology and specific animal models created possibilities to assess the effects of 
such preparations. Here we report the plasma and liver lipidomics results of the 
intervention effects of a preparation SUB885C in apolipoprotein E3 Leiden 
cholesteryl ester transfer protein (ApoE*3Leiden.CETP) mice. SUB885C was 
developed according to the principles of CM for treatment of metabolic syndrome. 
The cannabinoid receptor type 1 blocker rimonabant was included as a general 
control for the evaluation of weight and metabolic responses. 
ApoE*3Leiden.CETP mice with mild hypercholesterolemia were divided into 
SUB885C-, rimonabant- and non-treated control groups. SUB885C caused no 
weight loss, but significantly reduced plasma cholesterol (−49%, p <0.001), CETP 
levels (−31%, p <0.001), CETP activity (−74%, p <0.001) and increased HDL-C (39%, 
p <0.05). It influenced lipidomics classes of cholesterol esters and triglycerides the 
most. Rimonabant induced a weight loss (−9%, p <0.05), but only a moderate 
improvement of lipid profiles. In vitro, SUB885C extract caused adipolysis 
stimulation and adipogenesis inhibition in 3T3-L1 cells.  
SUB885C, a multi-components preparation, is able to produce anti-atherogenic 
changes in lipids of the ApoE*3Leiden.CETP mice, which are comparable to those 
obtained with compounds belonging to known drugs (e.g. rimonabant, 
atorvastatin, niacin). This study successfully illustrated the power of lipidomics in 
unraveling intervention effects and to help finding new targets or ingredients for 














The incidence of lifestyle-related cardiovascular and metabolic health 
complications, often collectively named metabolic syndrome, continues to 
increase world-wide [1, 2]. Although the major risk factors, including a sedentary 
lifestyle, overweight, unfavorable dietary habits and smoking are essentially 
modifiable, lifestyle measures often prove difficult and disappointing on the 
longer term. Because of the complex and multi-factorial manifestations of the 
metabolic syndrome, pharmacological strategies for primary prevention are 
increasingly focusing on the use of low-dose drug combinations. An example is the 
development of “polypill” concepts with a statin, one or more anti-hypertensive 
compounds and acetylsalicylic acid to reduce risks for cardiovascular disease in 
middle-aged individuals [3, 4]. At the same time it has been shown that dietary 
measures may be of comparable efficacy. Such a “polymeal” could provide a 
“more natural, safer and probably tastier alternative” than a polypill [5]. New 
insights and leads for dietary prevention or intervention can also be acquired from 
other healthcare systems like Chinese Medicine (CM). In CM [6],  the gap between 
food and drugs has always been small, and nutrition is seen as a normal part of 
prevention and healthcare. A remarkable high number of preparations have been 
handed down over the centuries with documented activity related to clinical 
features of what is now described as metabolic syndrome. The possibilities to 
analyze the subtle and multiple-pathway effects of such preparations have 
increased by the developments in systems biology-based metabolomics and 
specific animal models [7]. Here we report the plasma and liver lipidomic analysis 
of the effects of a CM preparation, SUB885C, in apolipoprotein E3 Leiden 
cholesteryl ester transfer protein (ApoE*3Leiden.CETP) transgenic mice. SUB885C 
is a multi-components preparation developed according to the principles of CM 
containing eight natural ingredients. The core formula is used in China for 
treatment of metabolic syndrome and early stage type 2 diabetes with obesity. A 
SUB885C intervention study [7] in prediabetic ApoE*3 Leiden mice has shown that 
SUB885C significantly improved insulin sensitivity as compared with non-treated 
controls. Meanwhile, several other anti-inflammatory and metabolic effects of the 
active ingredients in SUB885C have been reported [8-12]. Therefore, we 
hypothesized that SUB885C exerts a multi-target activity on lipid metabolism and 
insulin sensitivity. To investigate this, a parallel controlled intervention study was 
designed with female ApoE*3Leiden.CETP transgenic mice [13-16] showing mild 
hypercholesterolemia and overweight. The ApoE*3Leiden.CETP mouse model is 
obtained by cross-breeding ApoE*3Leiden mice with mice expressing human CETP. 
It has been shown to respond in a human-like manner to both lipid-lowering and 
high density lipoprotein cholesterol (HDL-C) raising interventions [13-19]. 
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Outcome parameters included body weight, food intake, plasma lipids and 
lipoproteins, and lipidomics of plasma and liver. Lipidomics measures all or 
subsets of lipids and provides a thorough perspective to study intervention 
induced lipid changes and metabolism in the complex biological system [7, 
20].The cannabinoid receptor type 1 (CB1) blocker rimonabant was included as a 
general control for the evaluation of weight and metabolic responses in the study. 
To further explore our findings, cell-based assays in 3T3-L1 adipocytes focusing on 
adipolytic and adipogenic activities of SUB885C were performed.  
 
Materials and Methods  
Ethics statement 
The experiments were performed according to the rules set by the Netherlands 
Law on Animal Experiments and approved by the Institutional Ethical Committee 
on Animal Care and Experimentation (Dierexperimenten Commissie DEC of 
Netherlands Organization for Applied Scientific Research, Zeist, the Netherlands) 
with a permit number of DEC2489. 
 
Materials and Chemicals 
Materials used for intervention studies 
SUB885C was provided by SU Biomedicine, The Netherlands. SUB885C consists of 
eight natural ingredients: Fructus Crataegi (Shan Zha), Folium Nelumbinis (He Ye), 
Folium Apocyni ( Luo Bu Ma Ye), Flos Rosae rugosae (Mei Gui Hua), Radix et 
Rhizoma Rhei (Da Huang), Depuratum mirabilitum (Mang Xiao, also known as 
mirabilite or Glauber’s salt), Thallus Sargassi (Hai Zao), and honey fried Radix 
Glycyrrhizae (Gan Cao). Above dry and sliced compounds were used for a water 
based decoction. After decoction and water solvent was dried into solid phase, it 
was used as the preparation for the intervention study. For the quality control of 
the preparation, the quantities of defined chemical markers were used for 
assessment according to pharmacopeia guideline. 
 
Chemicals and lipid internal standards 








phospholcholine (PC-34:0) and 1,2-dinonadecanoyl-sn-glycero-3-phospholcholine 
(PC-38:0) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 1,2,3-
tripentadecanoylglycerol (TG-45:0) and 1,2,3-triheptadecanoylglycerol (TG-51:0) 
were obtained from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). 
Ultra liquid chromatography-mass spectrometry (Ultra LC-MS) grade of 
acetonitrile (ACN), methanol (MeOH), isopropanol (IPA) and water as well as LC–
MS grade of dichloromethane (CH2Cl2) were purchased from Biosolve 
(Valkenswaard, The Netherlands). Phosphate Buffered Saline (PBS), and Hanks 
Balanced Salt Solution (HBBS) were supplied by Gibco. Isoproterenol, 10% sterile 
bovine serum albumin (BSA) solution, methanol and dimethyl sulfoxide (DMSO) 
were supplied by Sigma Aldrich. Plastic ware for tissue culture was supplied by 
Greiner Bio-One. The adipolysis assay kit was purchased fom Chemicon Int. 
(Temecula, CA). 
 
Intervention studies on mice 
Twenty-four female ApoE*3Leiden.CETP transgenic mice (age 610 weeks) were 
obtained from specific pathogen free (SPF) breading stock (TNO, Leiden, The 
Netherlands). The animals were fed a semi-synthetic modified Western-type diet 
(Hope Farms, The Netherlands), containing 0.2% cholesterol (Cho), 15% saturated 
fat and 40% sucrose as described by Nishina et al. [21], for a run-in period of 4 
weeks to get a mild hypercholesterolemia (plasma Cho levels of 1418 mmol/L) 
and body weight increase. Following this run-in period, mice were matched on 
body weight, plasma Cho and triglycerides (TG) levels (after 4 hours fasting) and 
divided in three groups of eight animals each (non-treated control, rimonabant- 
and SUB885C- treated). Preparations for intervention were given orally as admix 
to a Western-type diet for 4 weeks. Briefly, mice received the Western-type diet, 
without or with either SUB885C (SU Biomedicine, The Netherlands) at a 
concentration of 2% or rimonabant (Sanofi-Aventis, The Netherlands) at 10 mg/kg 
body weight/day. Flavoured sugar lumps were added to the diet of all groups to 
mask possible tastes of intervention preparations.  Body weight per mouse and 
food intake per cage was measured at intervention day 0, 2, 3, 4, 9, 11, 14, 21 and 
28. Blood was collected at the start of the intervention (week 0) and just before 
sacrifice of the mice (week 4) via tail vein bleeding using CB 300 LH microvettes 
(Sarstedt, Nümbrecht, Germany). Plasma samples were collected by 
centrifugation of the blood samples for 10 min at 6000 rpm at 4C. At the end of 
the intervention (week 4), animals were sacrificed with rapid asphyxiation using 
CO2. Livers were dissected on ice and samples were weighted and snap-frozen in 
liquid nitrogen. Both plasma and liver samples were stored at −80C until use.  




The 3T3-L1 preadipocyte cell line (ATCC) was used to study possible direct lipolysis 
or adipogenetic activity by SUB885C. The 3T3-L1 cells were cultured and 
differentiated from pre-adipocytes into full grown adipocytes as described by 
Niwano et al. [22]. Three hundred micrograms of SUB885C was extracted with 4 
ml methanol. After evaporation of the methanol, the extract was dissolved in 100 
μl DMSO. To study adipolysis the growth medium was removed from the cells and 
cells were washed twice with 1 ml HBSS per well. Then, to each well 250 μl HBSS 
was added containing 2% BSA and 2.5 μl of the diluted SUB885C extracts in DMSO. 
As a positive control, 2.5 μl of 1 mM isoproterenol in DMSO was added (final 
concentration 10 μM isoproterenol). For the negative controls, either 2.5 μl DMSO 
(DMSO control) or nothing (blank) was added. After 3 h incubation glycerol 
release was measured with a commercial adipolysis assay kit (Chemicon Int., 
Temecula, CA).  For the adipose conversion assay the addition of SUB885C started 
at the initiation of the cell differentiation. Together with the differentiation 
medium, SUB885C extract was added at different dilutions. At every medium 
replacement, fresh extract was added as well. After nine days of differentiation, 
the adipose conversion of the cells was analyzed by measuring the amount of fat 
produced. This was done by staining the fat with Oil Red O as described by 
Ramírez-Zacarías et al. [23]. 
 
Plasma biochemical analyses and lipoprotein profile analysis 
Plasma Cho, TG, HDL-C, lipoprotein profiles, CETP levels and activities and alanine 
aminotransferase (ALT) were measured at week 0 and week 4. Plasma total 
cholesterol (TC) and TG concentrations were determined in each animal using 
enzymatic kits (Roche Molecular Biochemicals, Indianapolis, Ind, USA). Pooled 
lipoprotein profiles were measured by fast performance liquid chromatography 
(FPLC) using an AKTA apparatus (Amersham Biosciences). TC, TG and phospholipid 
levels were measured in the fractions of freshly obtained samples. Phospholipids 
were determined in the FPLC fractions using a phospholipids B kit (Instruchemie 
Co., The Netherlands). Plasma HDL was determined by quantification of HDL-C in 
plasma after precipitation of apoB-containing lipoproteins. Thus, 10 μl of heparin 
(LEO Pharma, The Netherlands) and 10 μl of 0.2 mol/L MnCl2 were added to 20 μl 
plasma, and mixtures were incubated for 20 min at room temperature and 
centrifuged for 15 minutes at 13000g at 4°C. Plasma ALT was measured in pooled 
samples using a Boehringer Reflotron system. CETP levels were measured per 
mouse using RB-CETP kits from Roar Biomedical, Inc. Endogenous CETP activity 




for 24 h with plasma cholesterol at 4°C followed by incubation at 37°C for 3 h. 
Subsequently, apoB-containing lipoproteins were precipitated by addition of 
heparin/MnCl2. Lipids were extracted from the precipitate and labeled cholesteryl 
esters were separated from labeled unesterified cholesterol on silica columns and 
assayed by liquid scintillation counting. 
 
Lipidomics analyses 
Lipid extraction for plasma samples 
Plasma samples were thawed to room temperature and extracted with 2:1 of 
CH2Cl2/MeOH as described previously [25]. Briefly, 30 µl of heparin plasma was 
placed in a 2 ml vial (Eppendorf, Hamburg, Germany). Thirty microliters of the 
internal standard (IS) mixture consisting of LPC-19:0, PE-30:0, PC-38:0 and TG-45:0 
with corresponding concentrations of 30, 30, 150 and 60 µg/ml was first added, 
followed by 190 µl of MeOH and then 380 µl of CH2Cl2. The mixture was 
thoroughly vortexed both before and after CH2Cl2 addition. Afterwards, 120 µl of 
water was added and thoroughly vortexed. After centrifuging for 10 min at 6000g 
at 10ºC, 300 µl of the lower organic phase was transferred into a new 
autosampler vial and stored at −20 ºC until analysis. For LC-MS analysis, 25 µl of 
the lipid extract was diluted with 475 µl ACN/IPA/water 65/30/5 (v/v/v) and 10 µl 
was injected. 
 
Lipid extraction for liver samples 
The frozen liver samples stored at −80C were lyophilized and ground into powder. 
Ten milligrams of liver powder was weighed in a clean 1.5 ml eppendorf vial for 
the subsequent lipid extraction. Liver lipid extraction was achieved by liquid-liquid 
extraction (LLE) with a CH2Cl2/MeOH mixture (2:1, v/v) based on the method of 
Bligh and Dyer [26] with some modifications. Briefly, 60 µl of IS were added to 10 
mg of dry liver powder followed by addition of 180 µl of MeOH containing 0.02% 
antioxidant butylated hydroxytoluene (BHT), and then 360 µl of CH2Cl2 was added. 
The mixture was vortexed for 1 min both before and after CH2Cl2 addition. 
Afterwards, the resulting suspension was placed for 5 min in an ultrasonic bath at 
4C and then put in a shaker followed by 45 min incessantly shaking at 4C. 
Thereafter 10 min centrifugation at a rotation speed of 6000g at 10C was applied 
before 500 µl of the supernatant was transferred into a new 1.5 ml eppendorf vial. 
One hundred microliters of 0.9% NaCl was subsequently added to the supernatant 
to get a two-phase system where most of the lipids were in the lower organic 
phase. After being centrifuged at 2000g at 10C for 10 min, a total of 300 µl of 
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lipid extract was collected from the bottom organic phase. The final extract was 
diluted 40 times by injection solvent as described previously [25] and then 10 µl 
was injected for LC-MS analysis.  
 
LC-MS lipid profiling 
LC-MS analysis was performed on a hybrid liquid chromatography-linear ion trap-
Fourier transform ion cyclotron resonance-mass spectrometric system (LC-FTMS) 
consisting of a Surveyor HPLC MS pump and an autosampler (Thermo Fisher) 
equipped with an Ascentis Express C8 2.1 × 150 mm (2.7 μm particle size) column 
(Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). The LC-MS method 
used has been described previously by Hu et al. [25]. With this method, seven 
different lipid classes including both polar lipids such as lyso-phosphatidylcholine 
(LPC), lyso-phosphoethanolamine (LPE), phosphatidylcholine (PC), 
phosphoethanolamine (PE), sphingomyelin (SPM) and non-polar lipids such as 
cholesterol esters (ChEs) and TG were eluted from the column ionized with 
electrospray ionization in the positive ion mode. The MS detection was performed 
in the full scan mode with a range of mass to charge ratio (m/z) 400-1500. The 
identification of the detected lipid peaks was performed as described previously 
[25] and the current accurate mass data acquired by FT and linear-ion-trap 
MS/MS fragmentation. For those peaks without MS/MS fragmentations, 
identification was based on the observed accurate m/z and the relative retention 
times of specific m/z peaks.  Forty-eight plasma samples (week 0 and week 4) and 
24 liver samples (week 4) from ApoE*3.CETP transgenic mice of three groups 
were prepared in duplicate and injected once according to the procedures 
described above. The performance of the applied lipid profiling platform was 
assessed through the repeated analysis of the quality control (QC) samples [27]. 
The QC samples, used to monitor the LC-MS response in time, were prepared by 
pooling aliquots of 48 plasma samples for plasma lipidomics and 24 liver samples 
for liver lipidomics respectively to represent the full biochemical diversity of the 
study samples and allow the calculation of the analytical precision for all lipids 
measured. The QC sample data is also used to correct systematic errors such as 
batch to batch response differences by a single point calibration model [28, 29]. 
Ten QC plasma samples and 5 QC liver samples were processed exactly in the 
same way as the study samples. In total 106 plasma samples including 96 study 
samples and 10 QC samples and 53 liver samples including 48 study samples and 5 
QC samples were injected into the LC-MS system. The study samples were 
randomly analyzed and the QC samples were placed at regular intervals in the 




performance was carefully monitored using multiple IS and duplicate analysis of 
QC samples. Of note, plasma and liver samples were analyzed separately. 
 
Lipidomics data processing 
In total, 140 plasma lipid peaks and 137 hepatic lipid peaks were identified and 
selected as target lipids based on retention time and m/z of peaks processed by 
LC-Quan 2.5 (Thermo Fisher). The peak detection algorithm was used for peak 
integration using the following parameters: ICIS; smoothing points, 7; window, 30 
s; view width, 3 min; baseline, 40; area noise factor, 5; peak noise factor, 1045. 
Data for each mouse was normalized for the recovery of the IS for injection. Batch 
to batch differences in the data were removed by synchronizing the medians 
values of the QC samples per batch. Data was used only if the duplicates 
corresponded after visual inspection and the duplicates were averaged.  
 
Statistical data analysis 
One mouse (number 3733) in the control group was excluded from data analyses, 
because it did not respond to the diet during the run-in period and failed the 
inclusion criteria for hypercholesterolemia. Univariate data analyses were done by 
SPSS 17.0 and the results are presented as means ± standard deviation (SD) unless 
indicated otherwise. Statistical differences of biochemical parameters and 
lipidomics regulation at the end of the intervention of the three groups were 
analyzed parametrically by one-way analysis of variance (ANOVA). Data were log 
transformed if homogeneity of variance assumption was rejected. The Dunnett 
post hoc method was used to identify which treatment was significantly different 
from the control. One-tailed and two-tailed tests were used for biochemistry 
parameters and the lipidomics data respectively, with p values < 0.05 as statistical 
significance. To correct for false positives, the multiple test correction (MTC) of 
Benjamini and Hochberg false discovery rate (FDR) analysis was applied to adjust 
p values derived from the univariate results of the lipidomics data. To avoid the 
possibility that a few high-intensity variables dominate the final results [30], 
plasma and liver lipidomics datasets were autoscaled per variable, meaning that 
first the means of each variable were subtracted, and then all variables were 
divided by their SD. To find treatment dependent lipidomics grouping effects, 
both lipidomics datasets were analyzed by Principal Component Analysis (PCA) [31] 
in MATLAB (version 7.7.0471, the Mathworks) with the PLS toolbox (version 5.0.3, 
Eigenvector Research, InC.). PCA was used to find patterns in the data such as 
clusters of mice (scores) of non-treated controls and undergoing the treatments; 
and to identify which lipids contributed most to these clusters (loadings).  Partial 
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least squares discriminant analysis (PLS-DA) [32] was further applied to identify 
the specific metabolites which contribute most to discriminate between the 
subtypes; and PLS-DA models were validated using double cross validation (DCV) 
[33]. Week 4 lipidomics were used for data analysis because (1) the study interest 
is in the effect of SUB885C in the end of the intervention and all baseline 
parameters are homogeneous among the three groups; (2) liver lipidomics results 
are only available at week 4. Finally data matrices of 15 mice (7 controls, 8 
SUB885C) ×140 lipids for plasma lipidomics and 15 mice × 137 lipids for liver 
lipidomics were used for multivariate data analysis.   
 
Results 
SUB885C does not influence food intake or body weight in 
ApoE*3Leiden.CETP mice 
Compared to the controls, SUB885C did not have an effect on food intake in 
ApoE*3Leiden.CETP mice until day 20, and did not affect mean body weight 
(Figure 1).  After day 21, an increase in food intake was observed with SUB885C. 
According to published results in the same experiment [34], mice treated with 
rimonabant showed a reduced food intake with a pronounced dip at day 2. A 
significant reduction of mean body weight of approximately 9% remained visible 
until the end of the intervention [34].  
 
SUB885C decreases plasma cholesterol, triglycerides and increases HDL-C  
SUB885C treatment of ApoE*3Leiden.CETP mice caused a significant decrease in 
plasma Cho by 49% (8±1 mM versus 15±2 mM, p<0.001) after 4 weeks as 
compared to the controls (Figure 2A). During the 4 week intervention period 
plasma TG levels in both the SUB885C treated group and in control mice were 
significantly reduced by 67% (1.4 ± 0.5 mM versus 4 ± 2 mM, p<0.01) and 46% (2 ± 
1 mM versus 4 ± 2 mM, p< 0.01), respectively (data not shown).  At week 4, TG 
levels in the SUB885C group tended to be lower compared to the control mice 
(Figure 2A), but this difference did not reach significance (1.4±0.5 mM versus 2±1 
mM, p = 0.06). Plasma HDL-C in the SUB885C group was significantly increased by 
39% (1.1±0.3 mmol/L versus 0.8±0.3 mmol/L, p<0.05) as compared to that of the 
controls in week 4. Lipoprotein fraction analyses showed that SUB885C treatment 
caused a 3-fold decrease of very low density lipoprotein-cholestol (VLDL-C) and 
2.5 fold of VLDL-TGs and VLDL-phospholipids, as compared to those of the control 






Figure 1. Food intake and body weight. (A) Food intake (per cage) and (B) body weight (per 
mouse) were recorded and measured at day 0, 2, 3, 4, 9, 11, 14, 21 and 28 for SUB885C-
treated mice and control (*p <0.05 vs. control).  
In ApoE*3Leiden.CETP mice, the reduction of plasma TC was caused by the 
decrease of (V)LDL-C; while the increase of plasma HDL-C was in line with the 
obvious increase in HDL-C fraction. 
Based on previous published results [34], rimonabant treatment of 
ApoE*3Leiden.CETP mice induced a significant decrease of plasma Cho with 24% 
(p <0.05) when compared with that of the controls. However, there were no 
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adverse signs were observed during the study and ALT levels of all three groups 
were in the reference range. 
 
SUB885C decreases plasma CETP level and activity  
Four weeks of SUB885C intervention (Figure 2A) of ApoE*3Leiden.CETP mice 
caused a significant decrease in CETP level by 31% (22 ± 2 µg/mL versus 31±4 
µg/mL, p<0.001) and CETP activity by 74% (24 ± 11 µg/mL versus 91±27 µg/mL, 
p<0.001) as compared to the controls. However, rimonabant did not significantly 
affect the CETP level or the CETP activity in the same experimental setting [34]. 
 
Lipidomics reveals detailed lipid changes caused by SUB885C  
Two Principal Components (PCs) were selected for plasma and liver lipidomics. 
These PCs described 67% and 57% of the total variance of the plasma- and liver-
lipidomics, respectively (Figure 3A and B). In both PCA biplots, a separation was 
observed between control- and SUB885C treated-mice, indicating major changes 
of measured plasma and liver lipids between two groups. The loadings in the 
biplots (lipid species represented by colored symbols in Figure 3A and B) indicated 
that the lipids separating the SUB885C treated-mice from the control mice were 
TG, ChE and SPM.   PLS-DA with DCV was used to further investigate the main 
discriminating lipids between SUB885C and control groups. The DCV error rates in 
both plasma and liver were 20%, indicating that 3 out of 15 mice were 
misclassified. Among 30 main discriminating lipids between the control and 
SUB885C treated mice, ChEs, SPMs, PCs, TGs contributed most for the separation 
in plasma while SPMs, PCs, TGs contributed most in liver (Table S1 Supporting 
information). 
 
Lipidomics reveals detailed lipid changes caused by SUB885C  
Two Principal Components (PCs) were selected for plasma and liver lipidomics. 
These PCs described 67% and 57% of the total variance of the plasma- and liver-
lipidomics, respectively (Figure 3A and B). In both PCA biplots, a separation was 
observed between control- and SUB885C treated-mice, indicating major changes 
of measured plasma and liver lipids between two groups. The loadings in the 
biplots (lipid species represented by colored symbols in Figure 3A and B) indicated 





Figure 2. Plasma lipid, CETP and lipoprotein. Plasma concentrations are shown for TC, TG, HDL-C, CETP level and activity (A) of the 
SUB885C-, rimonabant- and non-treated mice at week 4 (concentrations in the control group are set to be 100% and relative 
changes of treated groups were illustrated in % compared with the control, *p < 0.05, ** p < 0.01, *** p < 0.001). Alterations of 
Cho (B), TG (C) and phospholipids (D) in the pooled lipoprotein profiles of the SUB885C- and non-treated mice at week 4. Fractions 
47 as VLDL; 89 as IDL; 1015 as LDL and 1623 as HDL. 
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TG, ChE and SPM.   PLS-DA with DCV was used to further investigate the main 
discriminating lipids between SUB885C and control groups. The DCV error rates in 
both plasma and liver were 20%, indicating that 3 out of 15 mice were 
misclassified. Among 30 main discriminating lipids between the control and 
SUB885C treated mice, ChEs, SPMs, PCs, TGs contributed most for the separation 
in plasma while SPMs, PCs, TGs contributed most in liver ( Supporting information 
Table S1). 
Quantitative differences in liver and plasma lipids between the SUB885C 
treatment group and untreated controls were statistically further analyzed by 
ANOVA with a two-tailed Dunnett post hoc method. SUB885C caused a significant 
reduction of plasma lipid classes of SPM, ChE, and TG by −28% (p<0.001), −46% 
(p<0.001), and −60% (p<0.01) compared to the controls, respectively. It caused a 
12% reduction (p<0.05) of total liver SPM, without significant influence on total 
liver TG or ChE lipids.  It was found that 86 (61%) plasma and 22 (16%) liver lipids 
out of 140 and 137 lipids respectively were significantly changed after the 4-week 
SUB885C intervention as compared to the controls.  Fifteen lipids changed 
significantly under SUB885C intervention in both plasma and liver, including LPC 
(18:2), PC (36:5), PE (34:2), SPM (22:1), SPM (24:1), ChE (18:2), ChE (20:4), TG 
(50:1), TG (54:0), ether TG (TG-O) (50:0), TG-O (50:1), TG-O (50:2), TG-O (52:1),TG-
O (52:2) and TG-O (58:2) (Supporting information Table S2 and S3). The 
correlation analysis, data with normal distribution by Pearson's and without by 
Spearman's, was performed to evaluate whether there is a relation between the 
concentrations of these lipids in plasma and liver. Only TG-O (50:0) showed a 
positive correlation between its concentration of plasma and liver; the others 
showed no correlation (data not shown). 
After MTC analysis, 70 out of 86 plasma lipids and 3 out of 22 hepatic lipids 
remained significant (p = 0.00−0.02, p values marked in bold) by SUB885C 
intervention (Supporting information Table S2 and S3). All three significantly 
changed hepatic lipids and 68 out of 70 (97 %) significantly changed plasma lipids 
were down regulated by SUB885C treatment. In plasma, SUB885C caused a 
significant reduction of 80% neutral lipids including ChE and TG, 50% SPM, 17% 
LPC and 14% PE. Three out of 5 significantly changed plasma PC (14%) by SUB885C 
was down-regulated (Table 1). In liver, SUB885C caused a significantly reduction 
of 17% ChE and 3% TG, but no obvious changes in phospholipids. Thus SUB885C It 








Figure 3. Lipidomics of plasma and liver reveals differences between non-treated and 
SUB885C-treated mice. Principle component analyses (PCA) of plasma and liver lipidomics 
datasets were applied to differentiate the non-treated controls (n = 7) and the SUB885C 
treated mice (n = 8). PCA biplots for (A) plasma samples and (B) liver samples.   
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Table 1. Significantly changed lipids in each lipid class 
Plasma 
Lipid class 
All measured lipids 
(n) 
Sig. changed lipids 
(n, % in each lipid class) 
Sig. reduced lipids 
(n, % in each lipid class) 
LPC 12 3   (17%) 3   (17%) 
LPE 2 0 0 
PC 36 5   (14%) 3   (8%) 
PE 7 1   (14%) 1   (14%) 
SPM 14 7   (50%) 7   (50%) 
ChE 10 8   (80%) 8   (80%) 
TG 59 47   (80%) 47   (80%) 
Total 140 70 (50%)  
Liver 
lipid class 
All measured lipids 
(n) 
Sig. changed lipids 
(n, % in each lipid class) 
Sig. reduced lipids 
(n, % in each lipid class) 
LPC 9 0 0 
LPE 2 0 0 
PC 29 0 0 
PE 19 0 0 
SPM 13 0 0 
ChE 6 1   (17%) 1   (17%) 
TG 59 2   (3%) 2   (3%) 
Total 137 3   (2%)  
 
Compared with the results of rimonabant induced lipid changes from the previous 
publication [34],  twenty four plasma lipids including LPC (18:2), PC (38:2), SPM 
(16:0), ChE (18:1), TG (46:0), TG (46:1), TG (48:0), TG (48:1), TG (48:2), TG (50:0), 
TG (50:1), TG (52:2), TG (52:6), TG (54:2), TG (54:3), TG (54:4) TG (56:3), TG (56:4), 
TG (56:7), TG (58:3), TG (58:4), TG (58:5), TG (58:6), TG (58:7) were significantly 
changed by both SUB885C and rimonabant, all of which were down regulated 
except for SPM (16:0) that SUB885C induced a down-regulation while rimonabant 
a up-regulation. After MTC, only LPC (18:2) and PC (38:2) remained significant in 
both SUB885C and rimonabant groups; while all lipids except for SPM (16:0), TG 
(56:3) and TG (58:5) still remained significant under SUB885C intervention.  Two 
liver lipids, PE (36:3) and TG (50:1), were significantly changed by SUB885C and 
rimonabant. The former was down-regulated by both treatments while the latter 
was down-regulated by SUB885C but up-regulated by rimonabant. Both lipids did 






SUB885C is able to stimulate adipolysis and inhibit adipogenesis in vitro 
To investigate SUB885C’s effect on adipolysis, the release of glycerol in the 
medium was measured after incubation of 3T3-L1 adipocytes with SUB885C. The 
positive control isoproterenol, a non-selective agonist of the β-adrenergic 
receptors, is known to increase the hydrolysis of TG [22, 35] and to stimulate 
adipolysis in 3T3-L1 adipocytes [22] (Figure 4A). When at a 500 × dilution, 
SUB885C extract caused a 22% higher glycerol release as compared to 
isoproterenol at a concentration of 20 µM. When SUB885C extract was 2500 × 
diluted, glycerol release was 20% lower than 20 µM isoproterenol, yet still higher 
than DMSO and Blank.  
The effect of SUB885C on lipid accumulation in 3T3-L1 adipocytes was 
investigated during their differentiation process. As positive control the cytokine 
tumor necrosis factor-α (TNF-α) was used, which interferes with adipocyte 
differentiation [22]. SUB885C was found to dose-dependently inhibit in vitro 
adipogenesis (Figure 4B). At 5000 × dilution there was 30% lipid inhibition in the 
cells as compared to the control (0.1% DMSO). At 1000 × dilution there was 45% 
lipid inhibition and at 500 × dilution there was 100% lipid inhibition in the cells. 
This was similar for TNF-α at a concentration of 2 ng/ml.   
The appearance of 3T3-L1 cells cultured for 9 days in the presence of SUB885C 
extract was shown in Figure 4C. The number of nuclei did not differ much among 
the 0.1% DMSO control, 500 × and 1000 × diluted SUB885C extracts. With 500 × 
dilution (top row) there was a decrease in the amount of nuclei, indicating toxicity 
induced cell loss, which was in line with the phase contrast picture of microscope 
with the 500 × dilution (bottom row). The other dilutions did not show a clear 
effect on the cell morphology. TNF-α, as a control, did not show any effect on 
nuclei numbers and a densely packed cell layer. Inhibition of lipid accumulation in 
3T3-L1 cells after exposure to SUB885C extract could be clearly seen at 1000 × and 
500 × dilutions.  
 
Discussion 
Causes and consequences of the complex changes in lipid patterns occurring 
during development of the metabolic syndrome are still only partly understood. 
Several interconnected processes are deteriorating which implies that in the end 
multi-target approaches might be more successful than prevention or 
intervention strategies based on a limited number of surrogate markers.  




Figure 4. Adipolytic and adipogenic activities of SUB885C in 3T3-L1 adipocytes. (A) Glycerol 
release as the result of adipolysis in 3T3-L1 adipocytes after incubation with SUB885C 
(500× and 2500× diluted) and 20 μM isoproterenol dissolved in DMSO with 1% as final 
concentration. (B) Inhibition of adipose conversion in differentiating 3T3-L1 adipocytes by 
SUB885C. (C) Morphological analysis of the differentiated 3T3-L1 adipocytes. The cells 
were treated with 20 µg/ml DAPI (top row), which stained the nuclei of the cells and gave 
an indication of cell numbers. The phase contrast of the microscope showed the outlines of 
the cells (bottom row) and gave an overview of cell density and morphology. The 
magnification is on the left.  
Results of the present study illustrated that a metabolomics-based analysis of the 
effects of a multi-component preparation can be used to study potential target 
processes or novel ingredients. Preparations having their origin in other 
healthcare systems such as CM have been shown to provide interesting starting 
points [36-42]. In a previous study it was found that SUB885C improved insulin 
sensitivity compared to control in pre-diabetic ApoE*3Leiden mice fed with a high 
fat diet for 10 weeks [7]. The ApoE*3Leiden.CETP mouse model used in the 
present study is a cross-bred of the ApoE*3Leiden mouse with mice expressing 
human CETP [16]. This further shifts the distribution of Cho from HDL to VLDL/LDL, 




Cho efflux, and produces a strong pro-atherogenic condition [43]. The model has 
shown its value for the evaluation of interventions that reduce plasma lipids or 
increase HDL-C [14, 15, 17, 34, 44].  
In the present study, SUB885C showed multiple effects to improve metabolic 
parameters and lipid patterns, which were summarized in figure 5. Specifically, 
SUB885C treatment induced a increase of plasma HDL-C, which was accompanied 
with a decrease of (V)LDL levels. Both effects are commonly regarded as anti-
atherogenic [14, 17]. Levels and activity of CETP, an important regulator of HDL 
metabolism, were found to be decreased, which may be related to the reduced 
levels of VLDL-TG, a substrate for CETP [44]. Taken together, the effects of 
SUB885C on HDL-C may be due to: 1) a decreased CETP activity and CETP level; 2) 
a reduced level of (V)LDL, an acceptor for HDL-ChE, which would reduce CETP 
transfer activity by decreasing the transfer of ChE from HDLs to TG–enriched 
lipoproteins, and more ChE-enriched HDL particles remain; 3) improved insulin 
sensitivity. SUB885C significantly reduced plasma TC, which likely reflected the 
reduction of (V)LDL-C concentrations in the SUB885C treated mice.  
During the intervention period total plasma TG levels when measured 
enzymatically decreased significantly in both the control and the SUB885C groups. 
At the end of intervention TG level tended to be lower in the SUB885 group 
compared to that of the control mice, but mainly due to a relatively large within 
group variance this did not reach significance. With the lipidomics, however, we 
found a significant reduction of 60% of total plasma TG (p<0.01) as compared to 
that of the controls. This supports our observation that SUB885C treatment 
induced a TG-lowering effect.  SUB885C particularly modulated a wide range of 
lipids such as TGs, ChEs and SPMs in plasma while in the liver only a few of these 
lipids were influenced (Table 1). After the correlation analysis of significantly 
changed lipids both in plasma and liver, only TG-O (50:0) showed a positive 
correlation and others not. Instead of a redistribution of lipids between plasma 
and liver, the effects of SUB885C might relate more to plasma lipoprotein 
metabolism. Based on the fact that the reduced lipids (i.e. ChE, SPM and TG) in 
plasma are core lipids of the lipoprotein particle, it seems conceivable that the 
circulating lipoprotein particles in plasma were reduced by SUB885C due to its 
influence on lipoprotein regulators such as CETP whose activities are mainly in 
plasma. This hypothesis is confirmed by the fact that SUB885C (not rimonabant) 
significantly reduced the level and activity of CETP (Figure 2A) in 
ApoE*3Leiden.CETP mice. 
In Table 2, some of the overall effects of SUB885C were compared with those of 
the drugs (i.e. rimonabant, atorvastatin, torcetrapib, niacin and tesaglitazer) that 
were used for modulating plasma lipid profiles obtained in the 
ApoE*3Leiden.CETP mouse model. 













CETP levels   ↓
HDL-C ↑ 






Figure 5. The summary of SUB885C effects. The effects of SUB885C were illustrated both in 
vitro and in ApoE*3Leiden.CETP mice with biochemical and lipidomics measurements. The 
improvement for insulin sensitivity was result from Wang et al. [7]. 
Although detailed comparisons cannot be made due to different study designs, 
effects of SUB885C on these variables appear to be comparable to those of the 
drugs investigated. Compared with the side-effects induced by these drugs, 
including psychiatric abnormalities (rimonabant) [45, 46], severe flushing (niacin) 
[44], headache (atorvastatin), increased risks of  cardiovascular morbidity and 
mortality (torcetrapib) [14, 47], the elevated serum creatinine and associated 
decreases in glomerular filtration rate (tesaglitazer) [48]; the reported side-effects 
of the active compounds in SUB885C are scarce. Only herbs containing 




[12]. Thus, SUB885C might have a higher benefit-risk ratio than other therapeutic 
interventions.  
In contrast to rimonabant, SUB885C did not reduce body weight or food intake 
during the 4-week intervention period. Rimonabant is a CB1 inverse agonist, 
which has been developed and briefly marketed for weight management and 
improvement of symptoms of the metabolic syndrome. Shortly after its 
introduction in Europe it was withdrawn because of its central side-effects such as 
depression and other psychiatric abnormalities [45, 46]. It is now commonly 
assumed that its action on the central CB1 receptors produces a relatively rapid 
but transient decrease of appetite [49]. In our study this was observed as a sharp 
dip in food intake around day 2 (Figure 1). In addition, rimonabant acts on 
peripheral CB1 receptors leading to a more sustained reduction of body weight 
and beneficial effects on a number of symptoms of the metabolic syndrome [50-
52]. Binding studies using a cell membrane preparation expressing the human 
cannabinoid CB1 receptor showed that a SUB885C total extract was able to 
displace bound radioactive ligand 3H-CP55940 (data not shown). This could 
indicate that one or more compounds present in the mixture have affinity for CB1 
receptors. However, more data are needed to confirm this. The lack of the effect 
of SUB885C on body weight and food intake at least suggests that there is no 
dominating overall effect on the central or peripheral regulation of food-intake or 
energy regulation.  
The in vitro results showed that SUB885C is able to stimulate lipolysis and inhibit 
adipogenesis in 3T3-L1 cells. At this stage it is difficult to speculate on a possible 
mechanism and its relevance for the overall in vivo effects of the preparation 
since there are several compounds classes that produce such effects, including, 
but not limited to CB1 blockers [22, 42, 53].   
Further studies are needed to reveal the pathways and processes modulated by 
SUB885C in more detail. Effects of the individual active components in SUB885C 
have been studied. For example, extracts of Fructus crataegi (Hawthorn berries) 
are used in CM for treatment of several cardiovascular problems and have been 
reported to possess anti-inflammatory properties and to modulate mitochondrial 
functioning [8, 11]. Flos Rosae rugosae (rose flower) extract has been reported to 
increase the activities of antioxidant enzymes and to reduce lipid peroxidation 
[10]. Radix et Rhizoma Rhei (rhubarb root) and Radix Glycyrrhizae (licorice root) 
have been reported to produce inhibition of fatty acid synthase, thus contributing  
to weight reduction [12]. Radix et Rhizoma Rhei contains emodin which is known 
as an inhibitor of 11 β-hydroxysteroid dehydrogenase type 1 and has been shown 
to ameliorate metabolic disorders in diet-induced obese mice [9].  
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Table 2. Effects on lipid parameters of SUB885C and existing drugs in the ApoE*3Leiden.CETP female mice model 
 SUB885C Rimonabant [34] Atorvastatin [15] Torcetrapib [14] Niacin [44] Tesaglitazer [17] 
Mice age 6-10 wk 6-10 wk   12 wk 18 wk 




























Study period 4 wk 4 wk 6wk 14 wk 3 wk 8 wk 
TC -49% -24% -33% -20% -44 - 68% 
* 
-55% 
TG -41% ( NS) -43% (NS) NS  -57 - 77% 
*
 -71% 
HDL-C + 39% +12% (NS) +52% +30% +77- 87% 
*
 +38% 
(V)LDL-C - 67% -33% -88% -26% -52 - 79% 
*
 - 80% 
CETP level -31% -4% ( NS) -29% ( NS) + 33% -24 - 45% 
*
 -42% 
CETP activity -74% -22% (NS) -36% -73% -24 - 52% 
*
 -56% 
Basic diet for ApoE*3Leiden.CETP female mice during run-in and study period: Western type diet with 15% w/w fat plus 
different content of cholesterol
 . 
 




This enzyme is now receiving considerable interest as a pharmacological target in 
metabolic syndrome [49]. Folium apocyni is obtained from leaves of Apocynum 
venetum L. (Venetian dogbane) and used in CM to prepare herbal teas against 
various cardiovascular and other problems.   
In conclusion, our study has shown that a CM principle-based multi-components 
preparation is able to produce anti-atherogenic changes in lipid spectra of the 
ApoE*3Leiden.CETP mouse model, which are comparable to those obtained with 
compounds belonging to known drug classes. Our data also illustrate the power of 
lipidomics in unraveling effects in detail and to help finding new targets or 
ingredients. These findings can be used to develop new preparations at the 
nutrition-pharma interface that can be used to prevent metabolic syndrome or 
ameliorate its first symptoms. Forthcoming studies should include dose-titrations 
and studies on lipid fluxes in human volunteers.  
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Table S1. Thirty lipids contributed most to discriminate between control and SUB885C 
treated mice in plasma and liver 
Ranking * Plasma lipids Liver lipids 
1 ChE (18:1) PC (34:3) 
2 ChE (18:1)-Dimeric LPC (16:0) 
3 ChE (18:2) SPM (20:0) 
4 PC (38:6) TG (52:6) 
5 ChE (18:3)-Dimeric TG (52:3) 
6 ChE  (18:3) SPM (15:0) 
7 PC (36:6) PC (40:5) 
8 PC (38:4) PC (36:5) 
9 PC (40:5) TG (52:2) 
10 PE-O (38:5) TG (50:2) 
11 PC-O (42:6) ChE (22:6) 
12 SPM  (24:2) TG (50:1) 
13 ChE  (18:2)-Dimeric PE (38:6) 
14 PE (38:2) SPM (22:1) 
15 PE (38:4) PC (40:8) 
16 SPM (14:0) TG (50:3) 
17 SPM (22:1) PC (36:1) 
18 SPM (18:1) TG (50:0) 
19 SPM (18:0) PC (38:6) 
20 SPM (24:1) LPE (20:4) 
21 PC (40:4) PC (38:3) 
22 SPM (15:0) PC-O (38:4) 
23 SPM (22:0) TG (52:1) 
24 PC (40:7) PC (40:7) 
25 PE (36:3) PE (34:1) 
26 SPM (23:0) PC-O (34:1) 
27 TG (54:5) TG (52:5) 
28 TG (46:1) SPM (22:0) 
29 TG (50:3) PE (38:3) 
30 SPM (20:0) PC-O (36:4) 
*
 The ranking is calculated based on the coefficients of PLSDA regression vector. 
Eight gray highlighted lipids are similar lipids present in both plasma and liver for the discrimination 
between control and treated mice.  
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Table S2. Lipid molecular species are significantly influenced in plasma upon 
SUB885C treatment as compared to non-treated controls 




(mean ± SD) 
SUB885C 






 ()  
 () 
LPC (14:0) 0.0008 ± 0.0001 0.0007 ± 0.0001 15 <0.05  
LPC (18:2) 0.14 ± 0.01 0.12 ± 0.01 16 <0.01  
LPC -O(18:1) 0.0033 ± 0.0008 0.0024 ± 0.0003 28 <0.05  
PC (32:0) 0.0034 ± 0.0004 0.0029 ± 0.0003 16 <0.01  
PC (36:5) 0.0006 ± 0.0001 0.0007 ± 0.0001 34 <0.05  
PC (38:2) 0.51 ± 0.06 0.36 ± 0.04 29 <0.001  
PC (38:4) 0.020 ± 0.003 0.029 ± 0.007 43 <0.05  
PC (38:6) 0.010 ± 0.002 0.014 ± 0.003 31 <0.05  
PC (40:7) 0.0025 ± 0.0003 0.0030± 0.0004 22 <0.05  
PC-O (34:3) 0.00006 ± 0.00001 0.00005 ± 0.00001 17 <0.05  
PC-O (38:7) 0.00008 ± 0.00003 0.00004 ± 0.00002 44 <0.01  
PE (34:2) 0.014 ± 0.003 0.008 ± 0.003 42 <0.01  
SPM (14:0) 0.00037 ± 0.00004 0.00026 ± 0.00002 31 <0.001  
SPM (16:0) 0.0046 ± 0.0003 0.0042 ± 0.0004 11 <0.05  
SPM (16:1) 0.15 ± 0.02 0.10 ± 0.02 31 <0.001  
SPM (22:0) 0.27 ± 0.03 0.19 ± 0.05 31 <0.001  
SPM (22:1) 0.0009 ± 0.0001 0.0010 ± 0.0001 17 <0.05  
SPM (23:0) 0.13 ± 0.01 0.09 ± 0.01 28 <0.001  
SPM (23:1) 0.00031 ± 0.00004 0.00027 ± 0.00002 13 <0.05  
SPM (24:0) 0.0095 ± 0.0008 0.0081 ± 0.0007 15 <0.001  
SPM (24:1) 0.0044 ± 0.0004 0.0034 ± 0.0003 22 <0.001  
SPM (24:2) 0.0018 ± 0.0001 0.0015 ± 0.0002 17 <0.01  
 
p values correspond to the mean difference between the SUB885C group and the control group. 
Note: lipids with p values marked in bold mean those remain significant after MTC. 
LPC-O: ether LPC; PC-O: ether PC;  
* Homogeneity of variance assumption is deviated of this lipid. Data was log transformed and the 










(mean ± SD) 
SUB885C 






 ()  
 () 
ChE (18:1) 0.30 ± 0.04 0.18 ± 0.02 40 <0.001  
ChE (18:2) 2.9 ± 0.6 1.2 ± 0.3 57 <0.001  
ChE (18:3) 0.0011 ± 0.0003 0.0004 ± 0.0001 65 <0.001  
ChE (20:4) 0.14 ± 0.03 0.10 ± 0.01 29 <0.05  
ChE (22:6) 0.015 ± 0.004 0.009 ± 0.002 38 <0.001  
ChE (18:1)-Dimeric 12 ± 2 7± 1 43 <0.01  
ChE (18:2)-Dimeric* 1.6 ± 0.5 0.7 ± 0.2 55 <0.001  
ChE (18:3)-Dimeric 0.0045 ± 0.0015 0.0011 ± 0.0005 75 <0.001  
ChE (22:6)-Dimeric 0.02 ± 0.01 0.007 ± 0.003 65 <0.01  
TG (46:0) 0.033 ± 0.004 0.027 ± 0.004 19 <0.05  
TG (46:1) 0.013 ± 0.004 0.007 ± 0.002 47 <0.01  
TG (48:0) 0.17 ± 0.06 0.06 ± 0.03 63 <0.01  
TG (48:1) 0.008 ± 0.003 0.003 ± 0.002 61 <0.01  
TG (48:2) 0.10 ± 0.03 0.04 ± 0.02 62 <0.01  
TG (50:0) 0.05 ± 0.02 0.015 ± 0.010 70 <0.01  
TG (50:1) 0.16 ± 0.07 0.06 ± 0.03 65 <0.01  
TG (50:2) 0.11 ± 0.04 0.05 ± 0.02 59 <0.01  
TG (50:3) 0.020 ± 0.006 0.009 ± 0.004 54 <0.01  
TG (50:4) 0.017 ± 0.004 0.011 ± 0.003 38 <0.05  
TG (52:0) 0.06 ± 0.03 0.02 ± 0.01 68 <0.01  
TG (52:1) 0.22 ± 0.11 0.07 ± 0.04 70 <0.01  
TG (52:2) 1.0 ± 0.4 0.4 ± 0.2 59 <0.01  
TG (52:3) 0.31 ± 0.11 0.14 ± 0.07 54 <0.05  
TG (52:4) 0.7 ± 0.3 0.3 ± 0.1 64 <0.01  
TG (52:5) 0.004 ± 0.001 0.0021 ± 0.0006 51 <0.01  
TG (52:6) 0.0025 ± 0.0008 0.0011 ± 0.0006 57 <0.01  
p values correspond to the mean difference between the SUB885C group and the control group. 
Note: lipids with p values marked in bold mean those remain significant after MTC. 
* Homogeneity of variance assumption is deviated of this lipid. Data was log transformed and the 
mean ± SD was shown as the normal data value for a reference.  
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(mean ± SD) 
SUB885C 






 ()  
 () 
TG (54:0) 0.025 ± 0.012 0.008 ± 0.006 67 <0.05  
TG (54:1) 0.12 ± 0.07 0.04 ± 0.03 68 <0.05  
TG (54:2) 0.32 ± 0.17 0.11 ± 0.06 66 <0.01  
TG (54:3) 0.9 ± 0.4 0.4 ± 0.2 58 <0.01  
TG (54:4) 0.18 ± 0.08 0.08 ± 0.04 57 <0.01  
TG (54:5) 0.05 ± 0.02 0.021 ± 0.009 55 <0.05  
TG (54:6) 0.012 ± 0.004 0.007 ± 0.002 47 <0.05  
TG (54:7) 0.0012 ± 0.0004 0.0007 ± 0.0002 40 <0.05  
TG (56:0) 0.0028 ± 0.0013 0.0011 ± 0.0007 61 <0.05  
TG (56:1) 0.012 ± 0.006 0.004 ± 0.003 64 <0.05  
TG (56:2) 0.021 ± 0.010 0.008 ± 0.004 61 <0.01  
TG (56:3) 0.10 ± 0.05 0.04 ± 0.02 55 <0.05  
TG (56:4) 0.08 ± 0.03 0.03 ± 0.02 55 <0.01  
TG (56:5) 0.12 ± 0.04 0.06 ± 0.03 48 <0.05  
TG (56:6) 0.05 ± 0.02 0.03 ± 0.01 49 <0.05  
TG (56:7) 0.37 ± 0.16 0.15 ± 0.06 60 <0.01  
TG (56:8) 0.0043 ± 0.0017 0.0022 ± 0.0006 48 <0.05  
p values correspond to the mean difference between the SUB885C group and the control group. 
Note: lipids with p values marked in bold mean those remain significant after MTC. 
* Homogeneity of variance assumption is deviated of this lipid. Data was log transformed and the 



















(mean ± SD) 
SUB885C 






 ()  
 () 
TG (58:1) 0.004 ± 0.002 0.002 ± 0.001 64 <0.05  
TG (58:2) 0.004 ± 0.002 0.0013 ± 0.0009 65 <0.05  
TG (58:3) 0.006 ± 0.003 0.002 ± 0.001 59 <0.01  
TG (58:4) 0.005± 0.002 0.003 ± 0.001 51 <0.01  
TG (58:5) 0.016 ± 0.007 0.008± 0.005 49 <0.05  
TG (58:6) 0.016 ± 0.006 0.008 ± 0.004 51 <0.01  
TG (58:7) 0.026 ± 0.009 0.013 ± 0.007 50 <0.01  
TG (58:8) 0.015 ± 0.005 0.007 ± 0.002 54 <0.01  
TG (58:9) 0.09 ± 0.04 0.04 ± 0.01 55 <0.05  
TG (60:1) 0.002 ± 0.001 0.0007 ± 0.0005 63 <0.05  
TG (60:2) 0.002 ± 0.001 0.0007 ± 0.0005 67 <0.05  
TG (60:3) 0.0011 ± 0.0006 0.0004 ± 0.0002 67 <0.01  
TG-O (50:0) 0.011 ± 0.006 0.003 ± 0.002 70 <0.05  
TG-O (50:1) 0.0035 ± 0.0016 0.0011 ± 0.0007 70 <0.05  
TG-O (50:2) 0.0008 ± 0.0003 0.0003 ± 0.0002 67 <0.05  
TG-O (52:0) 0.016 ± 0.008 0.005 ± 0.004 71 <0.05  
TG-O (52:1) 0.0037 ± 0.0017 0.0011 ± 0.0008 70 <0.05  
TG-O (56:2) 0.008 ± 0.004 0.003 ± 0.002 70 <0.05  
TG-O (56:3) 0.002 ± 0.001 0.0007± 0.0005 69 <0.05  
TG-O (58:2) 0.006 ± 0.004 0.002 ± 0.001 69 <0.05  
TG-O (58:3) 0.0023 ± 0.0012 0.0008 ± 0.0006 67 <0.05  
p values correspond to the mean difference between the SUB885C group and the control group. 
Note: lipids with p values marked in bold mean those remain significant after MTC. 
TG-O: ether TG 
* Homogeneity of variance assumption is deviated of this lipid. Data was log transformed and the 
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Table S3. Lipid molecular species are significantly influenced in liver tissue upon 
SUB885C treatment as compared to non-treated controls  
Lipid species 
control 
(mean ± SD) 
SUB885C 








LPC (18:1) 0.34 ± 0.04 0.29± 0.05 12 <0.05  
LPC (18:2) 0.11 ± 0.02 0.08 ± 0.02 28 <0.01  
PC (32:0) 0.29 ± 0.02 0.26 ± 0.02 10 <0.05  
PC (36:5) 0.55 ± 0.06 0.64 ± 0.08 16 <0.05  
PC-O (38:5)* 0.33 ± 0.04 0.25 ± 0.02 21 <0.05  
PC-O (40:6) 0.025 ± 0.002 0.020 ± 0.004 33 <0.05  
PE (34:2) 0.25 ± 0.05 0.20 ± 0.03 20 <0.05  
PE (36:2) 0.76 ± 0.11 0.63 ± 0.06 17 <0.05  
PE (36:3) 0.53 ± 0.13 0.39 ± 0.06 26 <0.05  
SPM (22:1) 0.63 ± 0.05 0.51 ± 0.05 19 <0.01  
SPM (24:1)* 0.86 ± 0.11 0.68 ± 0.07 21 <0.05  
ChE (18:2) 0.29 ± 0.06 0.16 ± 0.05 44 <0.01  
ChE (20:4) 0.14 ± 0.06 0.07 ± 0.01 50 <0.01  
TG (50:1) 1.4 ± 0.4 1.8 ± 0.3 30 <0.05  
TG (54:0) 0.04 ± 0.01 0.024 ± 0.004 50 <0.01  
TG-O (50:0) 0.038 ± 0.007 0.026 ± 0.005 30 <0.01  
TG-O (50:1) 0.065 ± 0.008 0.053 ± 0.004 29 <0.01  
TG-O (50:2) 0.016 ± 0.002 0.013 ± 0.002 50 <0.05  
TG-O (52:1) 0.11 ± 0.02 0.077 ± 0.008 28 <0.001  
TG-O (52:2) 0.12 ± 0.02 0.10 ± 0.01 17 <0.01  
TG-O (58:1) 0.015 ± 0.003 0.009 ± 0.002 40 <0.01  
TG-O (58:2)* 0.034 ± 0.006 0.024 ± 0.005 33 <0.05  
p values correspond to the mean difference between the SUB885C group and the control group. 
Note: lipids with p values marked in bold mean those remain significant after MTC. 
PC-O: ether PC; TG-O: ether TG 
* Homogeneity of variance assumption is deviated of this lipid.  
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Abstract 
Although a number of animal experiments and clinical trials have investigated the 
effects of ginseng roots on diabetes, the relationship between its therapeutic 
effects on diabetes and the quality and the growth age of this herb have not yet 
been reported. This study systematically investigated the effects of 3- to 6-y-old 
ginseng roots on glycemic and plasma lipid control in a rat model of type 2 
diabetes. Six groups of male Goto-Kakizaki (GK) rats received either metformin, 3- 
to 6-y-old ginseng root, or no treatment. The treatments were administered twice 
daily for 9 weeks. A combined approach was used that involved applying liquid 
chromatography–mass spectrometry-based lipidomics, measuring biochemical 
parameters and profiling the components of ginseng roots of different ages. 
Compared to the untreated controls, treatment with 4- and 6-y-old ginseng roots 
significantly improved glucose disposal, and 5-y-old ginseng treatment 
significantly increased high density lipoprotein cholesterol. Treatment with 
6-y-old ginseng significantly decreased total plasma triacylglyceride (TG) and 
very-low-density lipoprotein cholesterol and improved plasma glycated 
hemoglobin (HbA1c). In addition, treatment with 4- to 6-y-old ginseng influenced 
plasma lipidomics in diabetic GK rats by reducing TG lipid species. Metformin 
significantly reduced fasting blood glucose by 41% and reduced HbA1c by 11%, 
but showed no effects on the plasma lipid parameters. The present study 
demonstrates that ginseng roots show growth age-dependent therapeutic effects 
on hyperlipidemia and hyperglycemia in diabetic GK rats. These age-dependent 
effects may be linked with the variation in both the ratios and concentrations of 
specific bioactive ginsenosides in ginseng roots of different growth ages. This 
study introduced novel systems biology-based approaches for linking biological 




The incidence and prevalence of diabetes, particularly type 2 diabetes mellitus 
(T2DM), is increasing rapidly worldwide [1]. T2DM is a chronic metabolic disorder 
characterized by increased insulin resistance, impaired insulin secretion, and 
progressive -cell dysfunction leading to hyperglycemia [2, 3]. The majority (50–
70%) of T2DM patients have an atherogenic profile, manifested as an elevation in 
plasma triacylglyceride (TG) and apolipoprotein B levels, a decrease in 
high-density lipoprotein cholesterol (HDL-C) levels, and a preponderance of small, 
dense, low-density and very-low-density lipoprotein (LDL and VLDL) particles [2-4]. 
Individuals with T2DM have a substantial risk of morbidity and mortality from 
major coronary events, such as cardiovascular, cerebrovascular, and peripheral 
vascular diseases [5-7]. To this end, the prevention and treatment of diabetes is 
crucial to reduce the risk factors for diabetic complications. 
Clinical trials have provided adequate evidence that hyperglycemia and 
hyperlipidemia are fundamental risk factors for the vascular complications 
associated with diabetes [8, 9]. To reduce these two risk factors, proper diet and 
regular exercise have been emphasized as a high priority. Lipid-lowering and 
glycemia-lowering medications are currently used to treat diabetes and its 
associated complications in mainstream medical approaches [10]. However, the 
current drug treatments for diabetes have three major limitations: 1) the high 
frequencies of side effects, 2) the high rates of secondary failure, and 3) the 
rapidly increasing costs of new diabetic drug development. Due to these concerns, 
researchers have been searching for more effective and multi-targets therapies. 
This strategy differs from the ‘one drug fits all’ treatment concept and may reduce 
side effects.  
Natural products, such as herbs, have a much longer history of use in the 
treatment of diabetes, than modern pharmaceuticals. For example, in China, as 
early as the period from 1368 to 1644, the root of Panax ginseng C. A. Mey (often 
simply referred to as ginseng in this text) was reported to treat diabetic symptoms 
in an ancient medicinal textbook titled Compendium of Materia Medica (Ben Cao 
Gang Mu) by Shizhen Li (1518–1593). Since then, the popularity of treating 
illnesses like diabetes with ginseng has continued to grow worldwide. Reports 
obtained from in vivo animal experiments and clinical trials have demonstrated 
that radix ginseng, the dried root of Panax ginseng C.A. Meyer, has a wide range 
of therapeutic effects on the central nervous system, the cardiovascular system, 
and the immune system [11-13]. Pharmacological studies have indicated that 
radix ginseng can ameliorate diabetes by improving glucose homeostasis and 
insulin sensitivity and alleviate diabetes-induced oxidative stress by inhibiting lipid 
peroxidation [14-16]. However, the lack of standardization in quality control and 
Panax Ginseng therapy in GK rats 
 124 
quality assurance in producing ginseng and ginseng products often leads to 
inconclusive results when they are used to treat diabetes [17]. In part, this lack of 
standardization is due to the complex chemical composition of ginseng roots, 
which exhibit regional variation and age-dependent variation in growth that 
influence the compositional ratios of certain ginsenosides [18]. Sengupta et al. [17] 
observed that reconstituting a ginseng extract by adding two ginsenosides, Rg1 
and Rb1, in a defined ratio could alter the angiogenic outcome: the dominance of 
Rg1 led to angiogenesis, whereas the dominance of Rb1 exerted an opposing 
effect. These observations strongly suggest that quality control and quality 
assurance must be addressed when making ginseng products. 
Ginseng is a perennial herb that can grow for dozens of years. The major 
components in ginseng are ginsenosides, which are responsible for most of 
ginseng’s biological and pharmacological activities. Ginseng cultivators have long 
observed that the ginseng growth period is directly related to its therapeutic 
quality. Ginseng grown for  4 y is regarded to be for the appropriate quality for 
medicinal use [19]. Although ginseng has been demonstrated to have beneficial 
effects on diabetes management, no research has yet been performed to 
determine how the ginseng’s age and its related quality affect its therapeutic 
efficacy.  
With these considerations, we used systems biology based metabolomics 
approaches to evaluate the therapeutic effects of ginseng roots grown for 36 y 
on the regulation of hyperglycemia and dyslipidemia in a Goto-Kakizaki (GK) rat 
model with spontaneous T2DM. The GK rat model displays fasting hyperglycemia 
and has a non-obese phenotype [20]. Metformin, a widely used oral medicine in 
T2DM treatment to reduce hepatic gluconeogenesis and improve glucose uptake 
[21, 22], was administered as a positive control. We aimed to evaluate possible 
ginseng-induced effects on lowering glucose and improving glucose tolerance. We 
hypothesized that ginseng roots show growth age-dependent effects on 
improving glycemia and lipid metabolism in diabetic GK rats. We hypothesized 
that these age-dependent effects may be due to the fact that the ratios and 
concentrations of specific ginsenosides in the ginseng roots change during growth.  
 
Experimental Section 
Chemicals and Reagents 
Liquid chromatography grade dichloromethane (CH2Cl2), methanol (MeOH), 
isopropanol (IPA), and acetonitrile (ACN) were purchased from Tedia (Fairfield, 
USA). Distilled water was purified using a Milli-Q system (Millipore, Bedford, MA, 
USA). Analytical grade ammonium formate (AmFm) was obtained from 
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Sigma-Aldrich (St. Louis, USA). Analytical grade glucose was from Chengdu Kelong 
Chemical Reagent Plant (Chengdu, China). Chemical grade sodium 
carboxymethylcellulose was purchased from Tianjin Guangfu Fine Chemical 
Research Institute (Tianjin, China). Ginseng samples, harvested after 36 y of 
growth, were purchased as dried roots from Fusong Chengan Ecology Ginseng Co., 
Ltd. (Jilin, China). Nine ginsenoside standards, including Rb1, Rb2, Rb3, Rc, Rd, Re, 
Rf, Rg1, and Rg2, were purchased from Chengdu Cogon Bio-tech Co., Ltd. 
(Chengdu, China). Metformin was purchased from Shandong Linuo Kefeng 
Pharmaceutical Company Co., Ltd. (Shandong, China). Synthetic lipid standards 
were purchased from Avanti Polar Lipids, Inc. (Alabaster, Alabama, USA) and 
Sigma-Aldrich (Munich, Germany). Digoxin and leucine-enkephalin was obtained 
from Sigma-Aldrich (Munich, Germany).  
 
Ginseng Plant Cultivation 
Radix Panax ginseng C.A. Mey was used in this study. All of the ginseng plants 
were cultivated at one farm located GAP station in a village (Fusong Chengan 
Ecology Ginseng Co., Ltd) in Jilin Province (Northern China). Ginseng plants of 
different ages were cultivated at the same location and harvested at the same 
time (i.e., in autumn). After harvesting the plants, the ginseng roots were air dried 
in the sun. According to Chinese Pharmacopeia, the water content is not more 
than 12.0% and total ash is not more than 5.0% and acid-insoluble ash is not more 
than 1.0%. The main ginseng roots containing secondary roots without root hair 
were used in the present study. 
 
Animal Protocols and Ginseng or Metformin Administration 
All animal experiments were approved by an institutional ethical committee on 
animal care and experimentation under authorization number 113 (West China 
School of Pharmacy, Sichuan University, Chengdu, China). Four-week-old, male GK 
rats, weighing 260–320 g, were purchased from Shanghai Slac Laboratory Animal 
Co., Ltd. (Shanghai, China). All animals were housed in a temperature-controlled 
room with a 12-h light/dark cycle. Food and water was freely available, except 
during fasting periods before some experiments. 
After a one-week adaptive feeding period, 37 GK rats were randomly divided into 
six groups for a 9-week treatment intervention: group 1, non-treated control (n = 
5); group 2, positive control (n = 8) receiving intraperitoneal administration of 
metformin at a dosage of 75 mg/kg body weight/day, groups 3, 4, 5, and 6 (n = 4, 
5, 5, and 5, respectively), receiving intraperitoneal administration of 3-, 4-, 5-, or 
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6-y-old ginseng roots, respectively, at a dosage of 1.875 g/kg body weight/day, 
twice daily. Both ginseng and metformin were ground into powder and mixed 
with 0.5% sodium carboxymethylcellulose before administration. The non-treated 
animals were injected with 0.5% sodium carboxymethylcellulose at 2× 1 mL/100 g 
body weight/day without any herbal medicine or drug. No adverse effects were 
observed in animals after treatments with ginseng roots, metformin, or the 
vehicle.  
Notably, plasma biochemical parameters including total cholesterol (TC), TG, 
HDL-C, low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein 
cholesterol (VLDL-C), and plasma glycated hemoglobin (HbA1c) were measured at 
the end of the experiment. Fasting blood glucose (FBG) was measured at week 0 
and week 9. The intraperitoneal glucose tolerance test (IPGTT) was also 
performed at week 9. In addition, body weight and food intake were measured 
weekly throughout the experiment.  
 
Sacrifice and Sample Collection 
Animals were sacrificed with rapid asphyxiation with CO2 and opened 
longitudinally after the 9-week experiment (endpoint). Blood was collected via 
saphenous vein puncture before the start of the treatment (i.e., t = week 0) and 
via heart puncture after sacrifice (i.e., t = week 9) in CB 300 LH microvettes 
(Sarstedt, Nümbrecht, Germany), containing lithium heparin, and the samples 
were placed on ice immediately after collection. Plasma samples were obtained 
after centrifugation at 3000g for 5 min at 4C. Aliquots of plasma were frozen and 
stored at -80C until use.  
 
Plasma Lipid Biochemical Parameters 
Plasma TC and TG were measured by the fully automatic enzymatic method using 
enzymatic kits obtained from Shanghai Fosun Long March Medical Science Co., Ltd. 
(Shanghai, China). Plasma HDL-C, LDL-C, and VLDL-C were measured using 
enzymatic kits purchased from Wenzhou Dongou Jinma Bio-tech Co., Ltd. 
(Wenzhou, China). All measurements were carried out on plasma samples taken 
after animals were fasted for 4 h. 
 
Plasma Glycemic Metabolic Parameters 
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HbA1c was measured using an immune-based assay. After the animals were 
fasted for 4 h, FBG concentrations were measured before and after treatment. 
Blood glucose levels were determined in blood samples taken from the tail vein 
with a glucose assay kit using the GOD-PAP method (Sichuan Maker Bio-tech Co., 
Ltd., Chengdu, China). The IPGTT was performed on the final day of treatment on 
the 9th week using an intraperitoneal administration of glucose (1.25 g/kg body 
weight) after the animals were fasted for 4 h. Blood glucose levels were also 
determined in blood samples from the tail vein at 0 min (prior to glucose 
administration), and 30, 60, 120, 180 and 240 min after the glucose 
administration.  
 
Liquid Chromatography–Mass Spectrometry (LC-MS) Lipid Profiling  
Lipid Extraction 
Lipid extracts were obtained via a modified Bligh/Dyer extraction procedure, as 
described previously [23].  Briefly, 30 L of internal standard (IS) mixture were 
added to 30 L of plasma followed by the addition of 540 L of 2:1 CH2Cl2/MeOH. 
The mixture was thoroughly vortexed, and then 120 L of water was added to 
form a two-phase system. The lipids were dissolved in the bottom organic phase. 
After being centrifuged at 6000g for 10 min at 10C, 100 L of the lipid extracts 
from the bottom layer were transferred and diluted 5 times with ACN/IPA/water 
(65:30:5, v/v/v). Then 10 L of the lipid extracts were loaded for LC-MS lipid 
profiling analysis. Notably, each sample was prepared in duplicate and each 
prepared sample was injected once. 
 
LC-MS Analysis 
LC-MS lipidomics analysis was performed on a hybrid ion-trap time-of-flight mass 
spectrometer (IT-TOF-MS; Shimadzu, Kyoto, Japan). The mass spectrometer was 
coupled with an ultra fast liquid chromatography (LC) system (Shimadzu, Kyoto, 
Japan). An Ascentis Express C8 column (2.7 µm particle size, 90 Å, 2.1  150 mm; 
Sigma-Aldrich, Munich, Germany) was used for the LC separation. The LC 
separation conditions used were identical to the previously published methods 
[23]. The plates with diluted lipid extracts were maintained at 12C.  
Plasma lipid profiling was carried out on the Shimadzu IT-TOF-MS equipped with 
an electrospray ion source. MS survey scans were acquired in the positive ion 
mode. The voltages of the interface and the detector of the TOF analyzer were set 
to 4.5 kV and 1.6 kV, respectively. The temperatures of the curved desorption line 
and heat block were both set to 200C. The flow rate of the nebulizing gas was 1.5 
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L/min. The dry gas pressure was 0.2 MPa. The flight tube temperature was stable 
at 40C, and the ion trap pressure was maintained at 1.6  10-2 Pa. Ultra-high 
purity argon was used for collision and ion cooling. The data were collected at a 
mass range of m/z 4001500 with an ion scan duration of 20 ms using LCMS 
solution software (Shimadzu, Kyoto, Japan).  
All study samples were randomly analyzed. Quality control (QC) samples, 
prepared by pooling all of the plasma samples, were regularly measured in the 
sequence to monitor the response of the LC-MS system and assess the lipid 
profiling platform.  
 
LC-MS Ginsenoside Profiling 
Ginseng Extraction 
Thirty milligrams of powdered ginseng root were weighed in a new 2 mL 
Eppendorf vial followed by the addition of 1 mL MeOH/water (4:1, v/v) containing 
0.32 µg/mL digoxin, which was used as the IS for ginsenoside analysis. After 
thoroughly vortexing the mixture for 3 min, the resulted suspension was placed in 
a shaker and incessantly shaken for 1 h at room temperature. The suspension was 
then placed in an ultrasonic bath at 4C for 1 h. Next, the suspension was 
centrifuged at 10000g for 10 min at 20C. Subsequently, 600 L of supernatant 
was transferred and filtered using a Whatman polypropylene syringe filter with a 
0.2 µm pore size and a 25 mm diameter (Whatman, Netherlands B.V.). The 
filtered ginseng extracts were diluted 5 times with MeOH/water (1:1, v/v) before 
being analyzed by LC-MS. 
 
Ginsenoside Analysis 
The diluted ginseng root extracts were analyzed on an Acquity 
ultra-performance liquid chromatography/quadrupole time-of-flight mass 
spectrometry (UPLC/Q-TOF MS, Synapt G1 HDMS system, Water Corp., Milford, 
USA) equipped with an MS pump, an autosampler (Waters Corp., Milford, USA), 
and a Waters UPLC T3 column (2.1 mm × 100 mm, i.d., 1.8 µm, Waters Corp., 
Milford, USA). The separation was carried out with a binary solvent consisting of 
water (15 mM AmFm) and ACN. The binary gradient started with 20% B until 0.5 
min, increased to 21% B from 0.5 to 7 min, to 30% B from 7 to 10 min, to 40% B 
from 10 to 18 min, to 80% B from 18 to 20 min, and was maintained at 80% B 
from 20–23 min. Then from 23–23.1 min, solvent B was decreased to 20%, and it 
was then maintained for 4.9 min for column re-equilibration. The flow rate was 
0.50 mL/min. The column oven temperature was set to 35C, and the 
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temperature of the autosampler tray was maintained at 10C. The following 
parameters were used for mass spectrometry: capillary voltage, 2.5 kV; reference 
cone voltage, 50 V; sampling cone voltage, 35 V; extraction cone voltage, 4.0 V; 
source temperature, 80C; desolvation temperature, 400C; desolvation gas flow, 
700 L/h; cone gas flow, 20 L/h; reference scan frequency, 10 s; scan time, 1.0 s; 
interscan time, 0.02 s; and lock mass, 554.2615 (leucine-enkephalin). The 
ginsenoside profiling was acquired under negative ionization mode. The 
ginsenoside profiling data were recorded by using MassLynx™ (MassLynx V4.1 
SCN 639).  
Before carrying out the ginsenoside profiling of the ginseng root samples, a 
compact validation of the method was performed, and the analytical 
characteristics were evaluated in terms of linearity, repeatability, recovery, and 
limit of detection (LOD) for nine, representative ginsenoside standards. Digoxin 
was used as the IS The results of the compact method validation were satisfactory 
for the profiling analysis of complex herb mixtures [24]. 
 
Statistical Analysis 
All measured biological parameters are presented as means  SD. Univariate 
statistics were performed with SPSS (Statistical Product and Service Solutions) 
using one-way analysis of variance (ANOVA) with the two-sided Dunnett post hoc 
test for multiple comparisons to investigate the differences between the control 
and treatment groups. Differences among groups were considered statistically 
significant if p < 0.05. 
During the analysis of the lipid metabolism parameters, the appropriate lipid IS 
was used to correct the signal intensities of the lipids in each ionization mode (see 
Supplementary Table S1 for details). Thereafter, peak areas were calculated for 
each lipid species relative to the standards to account for the variability in MS 
signals among the different groups of samples. Principle component analysis (PCA) 




Treatment Effects on Biochemical Parameters  
Throughout the 9-week treatment period, neither food intake nor body weight 
was significantly changed in any of the treated rats when compared to the 
untreated controls. Within each group, food intake was comparable, and the body 
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weight of the animals showed a continuous increase from week 1 to week 9 (data 
not shown).  
The plasma biochemical parameters (i.e., TC, TG, HDL-C, LDL-C, and VLDL-C) were 
measured after 4 h fasting in all the GK rats at week 9. These results indicated that 
there was a significant decrease in the levels of TG (1.27 ± 0.33 vs. 0.85 ± 0.28 
mmol/L, p < 0.05) and VLDL-C (0.58 ± 0.15 vs. 0.39 ± 0.13 mmol/L, p < 0.05) in the 
GK rats that received the 6-y-old ginseng root treatment compared to the 
untreated control. There was a significant increase in HDL-C (1.27 ± 0.13 vs. 1.48 ± 
0.09 mmol/L, p < 0.05) in the GK rats that received the 5-y-old ginseng root 
treatment compared to the untreated controls. Additionally, there was a trend of 
improvement (i.e., 0.05 < p < 0.1) in TG (1.27 ± 0.33 vs. 0.90 ± 0.27 mmol/L), 
HDL-C (1.27 ± 0.13 vs. 1.39 ± 0.15 mmol/L), and VLDL-C (0.58 ± 0.15 vs. 0.41 ± 0.12 
mmol/L) levels in GK rats that received the 4-y-old ginseng root treatment vs. the 
untreated control. Interestingly, the metformin-treated animals did not show the 
above trends in the lipid biochemical parameters. The mean baseline (i.e., t = 
week 0) FBG in all of the treatment groups was comparable to that in the 
untreated control group (data not shown). At the end of the experiment, a 
significant reduction in FBG (9.36 ± 4.27 vs. 5.52 ± 1.26 mmol/L, p = 0.03) was 
observed only in the metformin treated group vs. untreated controls, but no 
reduction in FBG was observed in the ginseng treated groups.  
No reduction in HbA1c was observed in animals following the treatments with 3- 
to 5-y-old ginseng roots at the end of the study; however, animals receiving 
treatment with either 6-y-old ginseng root or metformin displayed a decrease 
tendency of –11% (p = 0.094) and –11% (p = 0.067), respectively (vs. untreated 
controls) (Figure 1). 
In addition, glucose tolerance was evaluated by IPGTT at week 9. Compared to the 
nontreated control group, significant glucose disposal was observed in GK rats 
responding to 4- and 6-y-old ginseng root treatments at 180 min (i.e., 19.91  4.73 
vs. 9.83  3.83 and 19.91  4.73 vs. 11.28  3.18, respectively; both p < 0.05) and 
at 240 min (i.e., 17.75  3.96 vs. 6.88  2.18 and 17.75  3.96 vs. 8.63  2.01, 
respectively; both p < 0.01) (Figure 2). In order to further evaluate the overall 
glucose exposure, the area under the curve (AUC) of glucose disposal was 
calculated. The glucose AUC corresponding to the 4- and 6-y-old ginseng 
treatments decreased by 15% and 8%, respectively, in comparison to the 
untreated rats. Meanwhile, the glucose AUC of the metformin-treated animals 
was comparable with the 3- and 5-y-old ginseng treatment groups, and there was 
no significant decrease when compared to that of the untreated rats. Collectively, 
the ginseng treatments displayed a similar glucose response curve to the 
metformin treatment. The treatments with 4- and 6-y-old ginseng induced better 




Figure 1. HbA1c levels in GK rats that received treatment with 3- to 6-y-old ginseng root or 
metformin, or nontreatment. The HbA1c levels exhibited a tendency to decrease (p < 0.1, for both) in 
the 6-y-old ginseng root and metformin treatment groups vs. untreated controls, respectively. 
Figure 2. Intraperitoneal glucose tolerance test results. The intraperitoneal glucose tolerance test 
was performed at the end of the experiment in untreated GK rats and in animals treated with 3- to 
6-y-old ginseng roots or metformin. Significantly higher rates of glucose disposal at 180 min and 240 
min were observed in GK rats after treatment with 4- and 6-y-old ginseng roots. *P < 0.05, **p < 0.01 
compared to untreated rats. 
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Relationship between efficacy and the growth ages of the ginseng roots 
A total of 96 individual lipids including lyso-phosphatidylcholine (LPC), 
phosphatidylcholine (PC), phosphoethanolamine (PE), sphingomyelin (SPM), 
diacylglyceride (DG), TG and cholesterol ester (ChE) were identified and quantified 
in the lipidomics study. In order to identify general clusters in the data from the 
nontreated controls and the rats undergoing the different treatments and to 
examine which lipids contributed most to the clusters, we carried out PCA on the 
plasma lipidomics data from all of the study samples, including the 3- to 6-y-old 
ginseng treatment, the metformin treatment, and the untreated control groups. 
Figure 3 displays the PCA score plot based on a PC2 vs. PC1 model. The score plot 
(consisting of the symbols ‘ ,’ ‘ ,’ ‘ ,’ and ‘ ’) showed a clear separation 
between the 6-y-old ginseng treated group (symbols connected with bold dashed 
lines) and the nontreated control animals (symbols connected with bold solid 
lines). The first two principal components accounted for 55.1% of the variance, i.e., 
more than half of the total variance in the model. In addition, there was a clear  
trend of separation between the 4-y-old ginseng treated group (symbols 
connected with gray bold solid lines in Figure 3) and the nontreated controls. No 
separation was found between the untreated controls and 3- or 5-y-old ginseng 
root treatment groups. Furthermore, the PCA score plot showed that 
metformin-treated animals (symbols connected with gray dot dashed lines in 
Figure 3) largely overlapped with that of the nontreated animals. The PCA biplot 
indicated that the TG lipids dominated the clustering patterns of the 6-y-old 
ginseng treatment group vs. the nontreated controls and of the 4-y-old ginseng 
treatment vs. nontreated controls (Supplementary Figure S1 in the Supporting 
Information). Interestingly, TG lipids were found to be even more abundant in 
metformin-treated rats than in the untreated rats according to the biplot, 
suggesting that metformin has very limited effects on plasma lipid metabolism in 
diabetic GK rats. In summary, this initial PCA suggested striking differences 
between the patterns depending on the growth age of the ginseng roots, in spite 
of the fact that the ginseng had the same genetic background, were planted in the 
same region, and were under identical harvesting and processing conditions.  
To further identify any potential underlying patterns causing the observed 
differences in the PCA model, we analyzed the content of individual lipid 
molecular species in the groups treated with 3- to 6-y-old ginseng vs. the 
untreated controls using one-way ANOVA with the 2-sided Dunnett post hoc test. 
In total, only TG (58:6) and TG (58:7) showed significant reductions (p = 0.021 and 
0.022, respectively), and TG (56:6) and TG (60:9) showed a decreasing trend (p = 
0.085 and 0.097, respectively) in the 6-y-old ginseng treatment group vs. the 
nontreated controls. Although rarely statistical significance was observed, most of 
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the TG lipids showed a decreasing trend in groups treated with 4- to 6-y-old 
ginseng roots (data not shown) compared to the nontreated controls, which 
suggests that the effects of ginseng root treatment on plasma lipid metabolism in 
diabetic GK rats are growth age-dependent.  
 
Figure 3. PCA score plot of lipidomics data. PCA score plot of plasma lipidomics data from 
all of the study samples revealed general clusters in the nontreatment and treatment 
groups. ‘ ’ connected with bold solid lines represents the nontreated control group, ‘ ’ 
connected with gray dot dashed lines represents the metformin-treated group, ‘ ’ 
connected with gray bold solid lines represents the 4-y-old ginseng root treatment group, 
and ‘ ’ connected with bold dashed lines represents the 6-y-old ginseng root treatment 
group.  
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Relationships between the Biologically Active Components in Ginseng 
Roots and the Biological Responses 
In order to find correlations between the biologically active components in 
ginseng roots and biological responses, we first investigated whether there were 
growth age-dependent differences in the ginsenosides of ginseng roots. PCA was 
performed on the mean-centered plus unit variance-scaled LCMS data from all 
the ginseng root samples with 36 y of growth. Figure 4A presents the PCA score 
plot (consisting of the symbols ‘ ,’ ‘ ,’ ‘ ,’ and ‘ ’) on the basis of the PC3 vs. 
PC1. The variation in PC3 may reflect the metabolites responsible for the 
age-dependent differences. The 3- to 6-y-old ginseng roots are discriminated in 
PC3, and the 6-y-old ginseng samples are located close to the 4-y-old ginseng 
samples. Meanwhile, the 5- and 3-y-old ginseng samples, which partially overlap 
with each other, are located relatively far away from the 6-y-old samples, but 
close to the 4-y-old ginseng samples. The age-dependent differences were also 
related to the sizes of ginseng roots, as shown in Figure 4B. 
In the next step, we analyzed the variation in the concentrations of the individual 
components in ginseng roots of different growth ages on a univariate basis. Figure 
5 displayed the concentration variation (in %) of 8 specific ginsenosides in the 3- 
to 6-y-old ginseng roots. In the 4-y-old ginseng roots, the most abundant four 
compounds were Rb2, notoginsenoside R1 (Noto-R1), malonly-Rb2 (mal-Rb2), and 
malonly-Rb3 (mal-Rb3). In the 5-y-old ginseng roots, the most abundant two 
compounds were Rb3 and Rd. In the 6-y-old ginseng roots, two compounds, 
namely Re and gypenoside XVII, were most abundant. Interestingly, Rb2, Noto-R1, 
mal-Rb2, and mal-Rb3 continued decreasing in abundance with age in the 4- to 
6-y-old ginseng roots, and Rb3 and Rd continued increasing with age in the 3- to 
5-y-old ginseng roots. The variation in the concentrations of these eight 
compounds with growth age may be account for the different therapeutic effects 
of 4- to 6-y-old ginseng roots. The concentrations and ratios of these compounds 
might serve as valuable markers for therapeutic quality control. 
 
Discussion 
Panax ginseng C.A. Mey root and its products have long been used as herbal 
treatments and dietary supplements with documented health benefits, including 
antioxidation, anti-hyperglycemia, anti-atherosclerosis, and anti-cancer effects 
[25-29]. For diabetes management, ginseng root extracts have been 
demonstrated to lower blood glucose [30], increase insulin sensitivity [31], and 




Figure 4. PC3 vs. PC1 score plot of extracted Panax ginseng roots and dry morphology of 
ginseng roots. (A) PC3 vs. PC1 score plot of all MeOH/H2O extracted Panax ginseng roots 
‘ ,’ ‘ ,’ ‘ ,’ and ‘ ’ represent 3-, 4-, 5- and 6-y-old ginseng roots, respectively. The PCA 
score plot reveals that 3- to 6-y-old ginseng roots are discriminated in PC3. The 6-y-old 
ginseng samples are located close to the 4-y-old ginseng samples, while the 5- and 3-y-old 
ginseng samples partially overlap with each other, but are located relatively far away from 
the 6-y-old ginseng samples and close to the 4-y-old ginseng samples. (B) Dry morphology 
of 3- to 6-y-old ginseng roots. 
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Figure 5. Concentration variation (in %) of 8 specific ginsenosides in the 3- to 6-y-old 
ginseng roots. The concentrations of the ginsenosides in the 4-y-old ginseng roots were set 
equal to 1. The concentrations values (g/mL) of the ginsenosides in the 4-y-old ginseng 
are given along the X-axis below the name of 8 ginsenosides. The ginsenosides Rb2, 
noto-R1, mal-Rb2 and mal-Rb3 were most abundant in 4-y-old ginseng, ginsenosides Rb3 
and Rd were most abundant in the 5-y-old ginseng, and ginsenosides Re and gypenoside 
XVII were most abundant in the 6-y-old ginseng. These 8 ginsenosides are responsible for 
the age-dependent differentiation of the ginsenoside profiles (*: p < 0.05, **: p < 0.01). 
Although the research investigating the effects of ginseng roots in diabetes is 
rapidly growing, researchers have not yet examined how the therapeutic effects 
of this ginseng are related to its quality and the growth age. The aims of this study 
were: (1) to evaluate the effects of ginseng roots grown for 3–6 y on regulating 
hyperglycemia and hyperlipidemia in a T2DM GK rat model, and (2) to link the 
biologically active components in ginseng roots to their biological effects. To this 
end, we first tested lipid- and glycemic-related biological parameters, and then 
incorporated two advanced technologies as part of a systems biology approach. 
These two technologies involved: (a) the application of lipidomics to a study of 37 
GK rats with T2DM that received 9-week, parallel interventions, which included a 
nontreatment control group, and (b) the application of profiling ginsenosides to 
identify the differences among ginseng roots of different growth ages. Our study 
presents three major findings. 
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Firstly, 4- to 6-y-old ginseng roots were observed to improve hyperlipidemia and 
hyperglycemia in diabetic GK rats. Six-year-old ginseng had the most beneficial 
effect on hyperlipidemia, followed by 5-year-old and then 4-y-old ginseng, based 
on the observation that 6-y-old ginseng significantly improved plasma TG and 
VLDL-C and 5-y-old ginseng significantly improved HDL-C in comparison to the 
untreated controls. Treatment with 4-y-old ginseng led to a trend of improvement 
in TG, HDL-C, and VLDL-C, although these improvements were not statistically 
significant. In contrast to the ginseng treatments, metformin showed very limited 
effects on these lipid-related biochemical parameters. However, in terms of 
glycemic control, metformin significantly improved FBG (reduced by 41%, p = 
0.030 vs. control) and produced a substantial improvement tendency in HbA1c 
(reduced by 11.2% vs. control). Our results are consistent with those reported in a 
previous review, which concluded that metformin has beneficial effect on 
glucose-lowering but rather limited effect on plasma lipid profile in T2DM [34]. 
Meanwhile, 4- to 6-y-old ginseng roots produced positive effects on glycemic 
control by improving glucose tolerance (4- and 6-y-old ginsengs in IPGTT) and a 
decreasing tendency of HbA1c (6-y-old ginseng). In our current study, the 
glycemic regulation effects produced by ginseng were equal to or better than 
those produced by metformin treatment. Accordingly, under the current 
experimental conditions, the treatments with 4- to 6-y-old ginseng roots, 
especially 6-y-old ginseng, were superior to metformin treatment in terms of 
producing beneficial effects on lipid regulation and glucose tolerance. Moreover, 
metformin is associated with adverse gastrointestinal effects, including taste 
disturbance, appetite loss, nausea or vomiting, abdominal pain, and diarrhea [21], 
which cause patients to become intolerant to metformin. Ginseng is commonly 
used as a dietary supplement and herbal medicine in China, and its adverse 
effects have been scarcely reported. Therefore, ginseng may be an effective and 
safe initial intervention to improve glucose- and lipid-related parameters in 
people with T2DM.  
Secondly, we identified distinct clusters in the lipid profiles, which demonstrate 
differences between the levels of lipid metabolites in the intervention groups 
after the 9-week parallel treatments. The PCA of the plasma lipidomics data 
revealed a clear difference between the 6-y-old ginseng-treated group and the 
nontreated controls. The TG lipids contributed the most to this difference. Four 
TG species were identified as discriminating lipids (i.e., TG 56:6, 58:6, 58:7, and 
60:9) in the total lipid pattern. In addition, a large number of TG molecules 
showed non-significant decreasing trends in the GK rats receiving 4- to 6-y-old 
ginseng treatments in comparison to the untreated controls, indicating that the 
TG-lowering effect of ginseng is growth-age dependent. The growth age of the 
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ginseng roots can account for the variation in the contents of specific biologically 
active components. 
Thirdly, we identified general growth and age-related trends by profiling 
components in ginseng roots, and we precisely defined changes in individual 
components. Through further integration with biological parameters, we 
predicted linkages between bioactive components in ginseng roots and the 
bioactivities related to growth ages. Ginsenosides (i.e. ginseng saponins) have 
been well recognized as major bioactive components, which are responsible for 
the biological and pharmacological activities of ginseng roots and tissues. In the 
present study, we examined the identified 27 ginsenosides found in all ginseng 
root extracts. We combined our biochemical and lipidomic results in the animal 
model together with the variations in the concentrations of specific ginsenosides 
in the 3- to 6-y-old ginseng roots. This method allowed us to link the 
improvements in lipid and glycemic metabolism due to treatment with 4-y-old 
ginseng root to Noto-R1, Rb2, mal-Rb2, and mal-Rb3. Meanwhile, the 
improvements due to treatment with 5-y-old ginseng root were linked to Rb3 and 
Rd, and the beneficial effects of 6-y-old ginseng root treatment were associated 
with Re and gypenoside XVII. However, it is possible that the efficacy of 6-y-old 
ginseng root treatment could be due to a combination of many different 
ginsenosides in a specific concentration ratio (e.g., high concentrations of 
gypenoside XVII and Re, and a low concentration of Noto-R1, see Figure 5). We 
observed that four ginsenosides were related to the 4-y-old ginseng root 
treatment effects, which is partially supported by the results of a previous study 
on the medicinal use of pure ginseng components to treat diabetes. Yang et al. 
provided experimental evidence on the clinical application of six representative 
notoginsenosides, including notoginsenoside R1, in the diabetic, obese KK-Ay 
mouse model and demonstrated that notoginsenosides improved insulin and 
leptin sensitivity [35]. Liu et al. reported that mal-ginsenosides, including mal-Rb1, 
mal-Rb2, mal-Rc, and mal-Rd, significantly lowered plasma glucose without 
changing the hepatic glycogen and cholesterol levels in streptozotocin-induced 
diabetic mice [36]. Moreover, ginsenoside Rb2 is reported to be capable of 
lowering TG levels in 3T3-L1 adipocytes cultured under high energy conditions by 
stimulating the expression of SREBP and leptin mRNA [37].  Although the present 
study could not precisely determine the beneficial actions of these four 
ginsenosides on glycemic and lipid control in diabetes, it provided experimental 
evidence on the hyperglycemic and hyperlipidemia regulation effects of Asian 
ginseng root and identified potential bioactive components.  
Although no relevant research on diabetes has been reported in literature for the 
two specific ginsenosides identified in the 5-y-old ginseng root (i.e. Rb3 and Rd), 
several studies indicated that these components play an important role in health 
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promotion and disease prevention. For example, a recent study demonstrated 
that ginsenoside Rb3 can significantly ameliorate myocardial injury and heart 
function impairment induced by isoproterenol in rats by increasing the activities 
of myocardial antioxidant enzymes and inhibiting myocardial lipid peroxidation in 
myocardial ischemia [38].  Ginsenoside Rd was considered to be a potential 
compound for cancer prevention due to its inhibitory action on 26S proteasome 
activity and its low toxicity [39].  
For the two ginsenosides identified in the 6-y-old ginseng root (i.e., Re and 
gypenoside XVII), there has been substantial research related to their biological 
effects in diabetic/diseased animal models and humans [40-42]. For instance, 
ginsenoside Re was demonstrated not only to exhibit a dose-dependent 
anti-hyperglycemic effect in diabetic ob/ob mice [25, 43], but it also had a 
significant anti-hyperlipidemic efficacy in streptozotocin-induced diabetic rats [44]. 
Gypenoside XVII has been reported to have a protective effect against oxidative 
stress in phagocytes, vascular endothelial cells, and liver microsomes, which 
indicates that it may play an important role in the prevention and treatment of 
atherosclerosis, liver disease, and inflammation [45]. Based on our findings and 
the reported effects of the above-mentioned ginsenosides in the literature, we 
summarized the observed ginseng therapeutic effects and the correlated 
ginsenoside biological effects in Figure 6. We considered only the ginsenosides 
with the highest concentrations for the ginseng of each growth ages. However, it 
is likely that combinations of different ginsenosides in various ratios will be the 
key to explain the observed multi-dimensional pharmacologic effects. By using the 
Matrigel implant model and reconstituting the extracts using distinct ratios of Rg1 
and Rb1, Sengupta et al.17 observed that different defined ratios led to opposing 
biological effects, which could alter angiogenic outcomes. In the future, additional 
pre-clinical and clinical experiments on the medicinal use of purified individual 
compounds or combination of specific ginsenosides will be necessary to confirm 
their efficacy on T2DM. These studies may provide an opportunity to develop a 
new class of agents for diabetes care. Furthermore, this line of research can also 




In conclusion, by applying LCMS-based lipidomics, measuring biochemical 
parameters, and profiling the components of ginseng roots of different ages, we 
demonstrate that ginseng roots show growth age-dependent therapeutic effects 
on hyperlipidemia and hyperglycemia in diabetic GK rats. These effects may be 
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linked with the age-dependent variations in concentrations of specific bioactive 
ginsenosides in the ginseng roots. The present study provides novel and valuable 
experimental evidence on the age-dependent biological actions of ginseng in the 
treatment of diabetes. The results demonstrate that 4- to 6-year-old (i.e.  4 y) 
ginseng roots contain bioactive ginsenosides that may prove to be valuable in the 
development of drugs or dietary supplements to regulate lipid levels and increase 
glucose tolerance. Our results suggest that future investigations should examine 
the biological effects of combinations of specific ginsenosides from ginseng roots. 
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Figure 6. Illustration of observed ginseng therapeutic effects and the correlated ginsenoside biological effects. The columns on the 
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Figure S1 Score and loading biplots of PCA of plasma lipidomics data from all study 
samples to reveal general clusters of rats of nontreatment and receiving different 
treatments (scores) and to examine which lipids contributed most to the clusters 
(loadings). Symbols of ‘ ’ connected with black bold solid lines stand for nontreated 
control group, symbols of ‘ ’ connected with square dot lines stand for metformin treated 
group, symbols of ‘ ’ connected with gray bold solid lines stand for 4 yr old ginseng 
treated group, symbols of ‘ ’ connected with black bold dashed lines stand for 6 yr old 
ginseng treated group. Symbols of ‘ ’, ‘ ’, ‘ ’, ‘ ’, ‘ ’, ‘ ’ and ‘ ’ in smaller size represent 
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Lipidomics has become a powerful tool to study phenotypes and changes in life 
style associated abnormalities such as obesity, diabetes type 2 and cardiovascular 
diseases.  A quick lipid profiling and the detection of changes in concentration of 
lipid classes in biological samples will provide valuable information for elucidating 
the mechanism of above mentioned diseases.  
Lipid profiling is often performed with LC/ MS or GC/MS (after fractionation). 
These methods are relatively time consuming. Direct nanospray infusion in 
combination with mass spectrometry has been established as a powerful 
technology for lipid analysis. The method is fast and enables high throughput of 
samples with low sample consumption. Following this idea, a method of direct 
nanospray infusion using a TriVersa chip-based infusion instrument in 
combination with high resolution LTQ-Orbitrap mass spectrometer has been 
developed as a tool for fast lipid analysis in serum and tissue after a very simple 
lipid extraction with isopropanol. However, this method cannot be applied to 
plasma due to clogging of the nanospray emitters caused by relatively high salt 
concentrations from the anti-coagulants (EDTA, citrate, heparin salts, etc). 
The standard Folch lipid extraction method was modified to solve the problem of 
salt (anti-coagulant) formation in the nanospray chip. The salts were removed and 
we have developed a fast lipid analysis method by direct nanospray infusion (DI 
method) for plasma. With the sample volume as low as 5 µL of plasma, a snapshot 
of all different lipid class can be obtained within 5 minutes per sample. The 
following lipid classes are covered: triacylglycerols, cholesterol esters, 
phosphatidylcholines, lyso-phosphatidylcholines and sphingomyelins. When 
compared with the validated LC/MS method, the DI method is equivalent to it for 
high abundance lipids. However, it is less precise than LC/MS method. However, it 
still holds promise for the fast lipids analysis for plasma samples and worth further 












Lipids, the fundamental components of biological membranes, play an important 
role in biological systems, energy metabolism and storage, and contribute in great 
deal to pathophysiological states such as diabetes mellitus, fatty liver, hepatotoxic 
induced insulin resistance and atheroslecrosis [1, 2]. Lipids comprise an enormous 
number of chemically distinct molecular species arising from the various 
combinations of fatty acids and a series of backbone structures [2]. Lipid profiling 
and measurement in biological samples, so called lipidomics research, is a lipid-
targeted metabolomics approach aiming at comprehensive analysis of lipids in 
biological systems [2]. It is regarded as an important technology to provide 
valuable information for investigating the effect of lifestyle, diet and drug 
intervention on lipid metabolism. However, a priori the characterization of 
complex lipids presents a considerable challenge for lipid profiling as they are 
characterized by a huge diversity of chemical structure with different 
physicochemical properties [3]. Once extracted, the lipids must then be 
fractionated, usually requiring a multi-step chromatography process to allow 
identification and quantitation of the individual molecular species [3]. These 
intricate operations are time consuming and it is often not possible to cover the 
whole lipidome by a single analytical method.  
Recently, direct infusion nano-electrospray with an LTQ/Orbitrap mass 
spectrometer (MS) has been established as a powerful technology for lipid 
analysis and identification [4-8]. The LTQ Orbitrap is a hybrid mass spectrometer 
consisting of two mass analyzers that can function in parallel or in series. The 
linear ion trap provides the MSn capability and the Orbitrap can acquire the 
spectra at high resolution (100.000) and high mass accuracy [9]. The LTQ/Orbitrap 
is able to make mass measurements with a resolving power of up to 100K (at m/z 
400) and mass accuracies of better than 2 ppm have been demonstrated [10]. 
Nanospray- electrospray ionization (ESI) is a development of ESI for spraying very 
low amounts of very low concentration samples (nmol/mL). The technique has an 
increased tolerance to high aqueous solvents and the spectra can be obtained 
from pg of material with very little clean up being required. This increased 
performance is the result of lowering the inner diameter of the spray needle and 
reducing potentials normally used in ESI. The nanospray chip system (TriVersa 
NanoMate) ( Figure 1) was developed by Advion Biosciences as an add-on to most 
ESI sources.  
In order to make a snapshot of a wide range of lipid classes, we have combined 
the TriVersa nanospray chip-based system with the LTQ/Orbitrap and developed a 
fast lipid analysis method by direct nanospray infusion (DI method). By a simple 
lipid extraction with isopropanol (IPA), the extracts of serum and tissue samples 
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can easily applied with the direct nanospray infusion to LTQ/Orbitrap. However, 
this method cannot be applied to plasma due to clogging of the nanospray 
emitters caused by high salt concentrations from the anti-coagulants (EDTA, 
citrate, heparin salts, etc). The Folch lipid extraction method was modified to 














Figure 1.  TriVersa NanoMate device and a nanospray chip holding 400 nanospray emitters. 
 
Method and materials 
A modified Folch lipid extraction method (Figure 2) was applied to extract the in-
house reference human plasma. Firstly 10µL human plasma was mixed with 30µL 
isopropanol (IPA) containing the internal standards (IS) including lyso-
phosphatidylcholine (LPC)_C17:0, phosphatidylcholine (PC)_C24:0, ceramide 
(CER)_C17:0, fatty acid (FA)_C16-D31, LCA-D4, triacylglycerol(TG)_C51:0, 
cholesterol ester (ChE) _C17:0. Afterwards add 400 µL methanol, 800 µL 
chloroform and 300 µL water (Milli Q) and vortex well in each step. After 5 min 
centrifuge at speed 2500RPM at 20ºC, the upper layer consists of water while the 
lower layer consists of methanol-chloroform containing the plasma lipids.  The 
upper aqueous layer was removed. The organic phase was evaporated with 
nitrogen at 45 ºC. The residue was reconstituted with 900 µL IPA. After being 
vortexed and 5 min centrifuged at speed 14000 RCF at 20 ºC, the extract was 
diluted 5 fold with IPA. And then being vortexed and 5 min centrifuged at the 
speed 14000 RCF at 20 ºC, the extract was diluted 1.5 fold with 2mM ammonium 




TriVersa NanoMate apparatus (Nanomate HD, Advion Bioscience Ltd., USA) fitted 
on a LTQ-Orbitrap MS (Thermo Fisher Scientific, Netherlands).  
Figure 2.  Modified Folch method for lipid extraction 
 
The TriversaNanomate was loaded with 5 µL of the extracts. Full scan data 
acquisition (m/z range 300-1200 in positive mode while 200-1200 in negative 
mode) was performed to obtain a global snapshot of the plasma lipids followed by 
SIM scans (m/z subranges for improved sensitivity) in both positive and negative 
modes. The SIM scanranges were defined (see below) to measure all members of 
the various lipid classes in a single SIM scan range (e.g. cholesterol esters from 
m/z 600 to 700). The total analysis time is only 10 minutes per extract. The 
instrumental method illustrated in table 1. 
 
 
10 ul plasma + 30 ul IPA with IS
Methanol : chloroform: MillieQ water
( 4:8:3)
Upper layer: water phase
water + salts + Methanol
Lower layer: organic phase
Lipids+ chloroform + Methanol
Dilute 5 V with IPA;
Dilute 1.5 fold with 2mM NH4Ac/MeoH
Evaporate 
Reconstitute in 900 ul IPA
Middle layer:
insoluble protein residues
Infuse  to TriVersa NanoMate
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Table 1. TriVersa- LTQ Orbitrap instrument method 
TriVersa- LTQ Orbitrap instrument method 
Infusion volume (µL) 5 
Polarity positive /negative 
Ionization nano-ESI 
Total MS run time (min)  5 
Number of scan events 1 
Resolution  100000 
San segment 1   
   duration (min) 1.5 
   san event info FTMS+ full scan 
   m/z range 300-1200 ( positive)/200-1200 (negative) 
San segment 2-8   
   duration (min)  0.5 
   scan event info FTMS + SIM scan 
   m/z range - segment 2 300-530 ( positive)/ 200-530 ( negative) 
   m/z range - segment 3 450-600 
   m/z range - segment 4 550-700 
   m/z range - segment 5 650-800 
   m/z range - segment 6 750-900 
   m/z range - segment 7 850-1000 
   m/z range - segment 8 950-1200 
 
Result and discussion 
The spectrum of the full m/z range (1.5 minutes) covers all lipid classes. Combined 
with SIM scans, 0.5 minute per m/z range, the sensitivity of the  method  for  the 
various lipid classes is increased. The following lipid classes are covered: TGs and 
ChEs (positive mode); PCs, LPCs and SPMs (positive/negative mode); FFAs 
(negative mode) (Figure 3A-B). 
 
Recovery 
Table 2 summarizes the extraction recovery of the general lipid classes. The 
recovery of the lipid extraction method was 100% for TG’s and ChE’s, 85% for PC’s 





Figure 3. Mass spectrum of lipids analyzed by DI method 
Table 2. Recovery of selected lipid classes 
 Lipid classes LPC PC ChE TG 
Recovery (%) 75% 85% 100% 100% 
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Relative standard deviation (RSD) 
RSD (5 replicates) for main lipid classes using DI method is 5-34%, which is lower 
than that by using LC/MS method (1-10%). (Table 3)  
 


















DI method 5% 9% 16% 20% 23% 24% 34% 8% 
LC/MS 
method 6% 1% 8% 5% 6% 6% 10% 8% 
 
Linearity 
The linearity of the method was investigated by analyzing different volumes of the 
same plasma sample. Triplicate samples were prepared and infused in two series: 
(1) 8 µL, 10 µL, 12 µL; and (2) 10 µL, 20 µL, 30 µL. The response versus plasma 
volume was linear for all lipid classes (R2 > 0.98).  Examples of LPC_C16:0 and 
ChE_C20:4 measured by the DI method and a validated LC/MS lipid method are 
shown in Figure 4 A-B respectively.  
 
Standard addition linearity 
Standards of high abundance plasma lipids (LPC_C18:0, PC_C36:2, TG_C54:3) and 
low abundance plasma lipids platelet-activating factor ((PAF) _C16:0, PC_C40:0 
and TG_C42:0) were added to plasma at 1.5, 2 and 10 times the native 
concentrations independently (determined with LC/MS method, denoted as 1.5*, 
2* and 10*). 
For high abundance lipids the method failed to accurately detect a concentration 
increase from 1.5* to 2*. The concentration increase from 2* to 10* for C54:3-TG 
can be accurately determined. However, the signal increase was less than 
proportional for C18:0_LPC and C36:2_PC, which indicates ion suppression (most 
likely by very abundant TG’s). For low abundance lipids, LC/MS can accurately 
detect concentration increases at 1.5*, 2* and 10* for PAF_C16:0 and TG_C42:0. 
The DI method is also linear, but the accuracy was not as good, especially for 
C16:0-PAF. The data quality for PC 40:0 was very poor (experimental failure) 




saturation, and as a consequence this resulted in very low concentrations of LPC 
and PC, which precluded their accurate analysis (very low signal to noise ratio).  
Figure 4. Plasma volume linearity. (A) First series, LPC_C16:0 measured by DI method and a 
validated LC/MS lipid method; (B) Second series, ChE_C20:4 measured by DI method and a 
validated LC/MS lipid method.  
 




This study showed that the modified Folch method effectively lowers the salt 
concentration of the final extracts. Clogging of nanospray emitters did no longer 
occur when analyzing large numbers of plasma samples. The DI method is fast and 
enables high throughput of samples with low sample consumption, without 
sample-to-sample carry-over effect. When compared with the validated LC/MS 
method, the DI method is equivalent for high abundance lipids. However, it is less 
precise than the LC/MS method. The DI method is not applicable to samples with 
high triglycerides levels because extracts needs to be diluted too much (poor 
detectability of low abundance lipids). For samples with high triglyceride 
concentrations additional fractionation, e.g. liquid–liquid extraction (LLE), solid-
phase extraction (SPE), or high-performance liquid chromatography (HPLC), 
should be a good remedy. The DI method is promising for the fast lipids analysis 
for plasma samples and worth further development and validation.  
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Figure 5. Standard addition linearity. (A) High abundance lipids DI method; (B) High abundance lipids LC/MS method; (C) Low 
abundance lipids DI method; (D) Low abundance lipids LC/MS method (The PC_C40:0 was not added to the spike solution for 
LC/MS method) 
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Conclusions 
Type 2 diabetes mellitus (T2DM) leads to a number of serious medical 
complications (e.g. retinopathy, neuropathy, myocardial infarction), which are a 
major cause of morbidity, hospitalization and mortality in diabetic patients; and 
resulting in a major threat and financial burden for public health internationally 
[1-3]. Due to its multi-factorial causes resulting from the interaction between a 
genetic predisposition together with behavioral and environmental risk factors, 
the diagnosis and treatment of T2DM remains unsatisfactory. A personalized and 
system based strategy applied in the pre-diabetic stage is vital for diabetic 
prevention and management. 
Emerging technologies have made it feasible to acquire high-throughput profiles 
of a whole organism’s metabolic status (metabolite profiling or metabolomics) [4]. 
These techniques, which allow assessment of large numbers of metabolites that 
are substrates and products in metabolic pathways, are particularly relevant for 
studying metabolic diseases such as T2DM [4]. Metabolomics has been 
increasingly applied to study complex disease mechanisms to discover health-
disease associated mechanistic biomarkers and is regarded as a unique bridge 
between different healthcare perspectives on personalized medicine [5, 6]. The 
concept of personalized health with system diagnostic principles has long been 
the basis of CM, in which the focus is on the overall maladjustments of functional 
status called ‘syndrome type’[7]. The essence of  ‘syndrome type’ is the human 
system imbalance resulting in the perturbation of the metabolic network [8]. If we 
can correlate the CM diagnosed syndrome types to the metabolomics quantified 
patterns, it may help us stratify the patients and push personalized medicine 
forward. 
In light of this idea, the aim of this thesis was to combine metabolomics and CM 
diagnostic strategy to search for the diagnostic makers to subtype T2DM.  The 
multi-component preparations or drugs to treat cardio-metabolic disorders were 
studied and assessed by metabolomics to understand the potential underlying 
multi-pathway effects, leading to a better understanding of the personalized 
health of T2DM. 
In Chapter 2, an explorative study of 50 pre-diabetic males was designed, 
combining urine metabolomics with CM diagnosis to identify metabolic patterns. 
Due to the fact that CM diagnosis is conceptual and relies entirely on clinical signs 
discerned by CM physicians, the inter-physician consistency on CM diagnosis is of 
importance to be investigated at the first place. Three CM physicians reached 85% 
diagnosis consistency when the diagnostic principles were standardized and 
symptom descriptions were clarified in advance. Based on 3 different CM 




metabolomics and had different urinary metabolic patterns; and one of which 
indicated more disturbances of carbohydrate metabolism and renal function. The 
identified urinary metabolites may be of special clinical relevance for easy 
screening for subtypes of pre-/diabetes, which may lead to a better 
understanding and improvement of personalized interventions for diabetics. This 
study set an example to combine non-invasive gas chromatography–mass 
spectrometry (GC-MS) urine metabolomics with CM personalized diagnosis to find 
metabolic subtypes in pre-diabetics; and proved that the improvement of 
diagnosis plays a key role in bridging between CM and western medicine on 
personalized healthcare.  
Obesity is one of the major risk factors for T2DM. Compliance with lifestyle 
modifications such as reduced caloric intake and increased physical activity has 
proved to be difficult for the general population, meaning that pharmacological 
intervention may be the only recourse for some people with obesity [9]. 
Therefore, in Chapter 3 and 4, the effects of rimonabant and a multi-component 
preparation (SUB885C), both with effects of regulating weight and the 
improvement on cardio-metabolic risk factors, were assessed  by lipidomics on 
mildly over-weight ApoE*3Leiden.CETP Mice. Rimonabant is a selective 
cannabinoid-1 receptor antagonist for treatment of obesity and targets the 
endocannabinoid system. SUB885C is developed according to the principles of CM 
containing eight natural ingredients. The core formula is used in China for 
treatment of metabolic syndrome and early stage T2DM with obesity. For 
rimonabant and SUB885C, little is known about the impact on the regulation of 
lipid metabolism in the early stage of obesity.  A 4-week rimonabant intervention 
brought a significant reduction of the body weight, yet a moderate effects on lipid 
profile and limited lipid metabolism changes in the ApoE*3Leiden.CETP mice. 
Although no weight reduction was observed, SUB885C was able to produce 
multiple anti-atherogenic changes in lipids of the mice to improve metabolic 
parameters and lipid patterns, manifesting as decreased plasma cholesterol, 
(V)LDL,  and triglycerides, increased HDL-C and a change in wide range of neutral 
lipids. These effects were comparable to those obtained with compounds 
belonging to known drugs (e.g. atorvastatin, niacin). In vitro, SUB885C extract 
caused adipolysis stimulation and adipogenesis inhibition in 3T3-L1 cells. These 
two studies successfully illustrated the power of lipidomics in unraveling 
intervention effects and can help researchers pinpoint novel ways to treat 
lifestyle-related metabolic abnormality.  
Panax ginseng C. A. Mey (often simply referred to as ginseng) is reported to have 
effects to treat diabetic symptoms and is widely used in China as the dietary or 
drug ingredient for daily health maintenance. So far no research has been 
performed to determine how the ginseng’s growth year and its related quality 
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affect its therapeutic efficacy. In Chapter 5, lipidomics was applied to evaluate the 
effects of the root of ginseng grown for 3–6 years on the regulation of 
hyperglycemia and dyslipidemia in a diabetic Goto-Kakizaki (GK) rat model. By 
applying liquid chromatography–mass spectrometry (LC-MS) based lipidomics, 
measuring biochemical parameters, and profiling the components of ginseng 
roots of different ages, we demonstrate that ginseng roots show growth age-
dependent therapeutic effects on hyperlipidemia and hyperglycemia in diabetic 
GK rats. These effects may be linked with the age-dependent variations in 
concentrations of specific bioactive ginsenosides in the ginseng roots. The  4 
year ginseng roots contain bioactive ginsenosides that may prove to be valuable in 
the development of drugs or dietary supplements to regulate lipid levels and 
increase glucose tolerance. This study introduced novel systems biology-based 
approaches for linking biological activities with potential active components in 
herbal mixtures. 
Chapter 6 reports the preliminary development of a fast plasma lipid analysis 
platform by direct nanospray infusion using a TriVersa chip-based instrument in 
combination with high resolution LTQ-Orbitrap mass spectrometer. The modified 
Folch method was applied for the plasma lipid extraction. With the sample 
volume of 5 µL plasma, a snapshot of the following lipid classes can be obtained 
within 5 minutes per sample: triacylglycerols, cholesterol esters, 
phosphatidylcholines, lyso-phosphatidylcholines, sphingomyelins and fatty acids. 
When compared with the validated LC-MS method, the fast method is equivalent 
to it for high abundance lipids; yet it is less precise than LC-MS method. However, 
it still holds promise for the fast lipids analysis for plasma samples and worth 
further development and validation.  
To sum up, the early metabolomics studies carried out in this thesis set an 
example to combine analytical bioscience, clinical approach and other health 
system perspectives such as CM to provide the systems biology view on the 
metabolism patterns of T2DM and the intervention effects of possible drug and 
dietary approaches. It is promising to fusion metabolomics and CM diagnosis to 
search for subtypes of T2DM. Metabolomics, lipidomics in specific, is able to 
investigate multi-dimensional pharmacological effects and detect potential 
biomarkers related to these effects. These findings can be used to develop future 
new research strategies and products at the nutrition-pharma interface to 
manage T2DM and related metabolic risk factors.  However, it will only be realized 
when analytical methods will further improve, and system biology based 






Improved diagnosis to stratify patients is important to push personalized 
medicine forward 
The only one human study reported in this thesis (Chapter 2) showed the promise 
to fuse metabolomics and CM diagnosis to search for subtypes of T2DM. However, 
it is an early phase investigation on subtypes of pre-diabetes based on a small 
number of study subjects and CM physicians. As such whilst this data is very 
promising, there needs to be larger investigations using more subjects and CM 
physicians to demonstrate the further reliability and external validity/ 
generalization ability of this novel approach to diagnosing pre-diabetic subtypes. 
Future studies are needed to validate the subtypes yielded in the current study 
and to assess the time dependent response of these subtypes to challenge test or 
metabolic drug intervention.  
This study proved that the understanding and improvement of diagnosis plays a 
key role in bridging between CM and Western medicine (WM) on personalized 
healthcare.  Stratifying patients on molecular biomarker profiles is a key step 
towards treatment responder/nonresponder differentiation and personalized 
medicine. The CM method of qualitative subtyping could be of use to help decide 
the course of treatment for patients in modern medicine, and provide momentum 
for the move towards personalized medicine [13]. A diagnostic tool such as a 
questionnaire can be designed, combing CM symptoms and WM quality of life 
items, to search for patients subtypes based on different health and disease 
related manifestations.  
 
Interventions for T2DM 
It is obvious that multiple mechanisms are involved in T2DM development, and so 
far no universal cure exists for all of the metabolic abnormalities that are 
embodied in this disease. For example, drugs aimed at metabolic targets, such as 
the enhancement of fatty acid oxidation, may have desirable effects on hepatic 
insulin action and steatosis, but possible deleterious effects in muscle or islet β‑
cells [9]. Moreover, drugs that stimulate insulin secretion beyond the already 
elevated levels of the obese and insulin-resistant state may eventually cause β‑
cell stress and permanent damage [9]. It is unlikely that effective treatments will 
be based on single bioactive compounds. These complexities may force a focus on 
combined drug/nutrition therapies with individualized optimization.  
To restore energy balance and improve metabolic risks, rimonabant, a 
cannabinoid-1 receptor antagonist which regulates central appetite control in 
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response to endogenous ligands, used to show promise. However, it has 
incompletely characterized peripheral effects, and has been associated with 
psychic (neurologic, mental) side-effects such as depression and even suicide 
attempt. Moreover, the lipidomics response to an intervention of rimonabant in 
transgenic mice, as reported in Chapter 3, only showed moderate effects in early 
stage obesity. Projects are underway to develop cannabinoid-1 receptor blockers 
that do not pass the blood-brain barrier (to prevent mental side effects) are non-
brain penetrant and act only on peripheral cannabinoid-1 receptor [10]. 
Metabolomics can again be a good method to investigate the effects and 
mechanism of such agents.  
Meanwhile, pharmacological strategies for primary prevention are increasingly 
focusing on the use of low-dose drug combinations. An example is the 
development of “polypill” concepts with a statin, one or more anti-hypertensive 
compounds and acetylsalicylic acid to reduce risks for cardiovascular disease in 
middle-aged individuals [11]. While at the same time it has been shown that 
dietary measures such as “polymeal” may be of comparable efficacy or even 
provide a “more natural, safer and probably tastier alternative” than a polypill 
[12]. Therefore, T2DM prevention through nutritional intervention is realized to 
be crucial for increased human quality of life. Metabolomics based nutritional 
profile is useful to give indications for personalized intervention that can influence 
on multiple targets in the human system with fewer side-effects. For example, an 
intervention with selected dietary products affected inflammatory processes, 
oxidative stress, and metabolism in humans, as shown by large-scale profiling of 
genes, proteins, and metabolites in plasma, urine, and adipose tissue [13]. To 
make it possible for health-care and nutrition practitioners to give nutrition 
recommendations, more trials using metabolomics and a suitable database based 
on a large number of measurements of accurate metabolite concentrations from 
healthy people might be necessary [14]. Furthermore the concept of health 
promotion alongside disease management will help to improve the current 
healthcare system [11] 
Such new insights and leads for dietary prevention or intervention can also be 
acquired from CM where the gap between food and drugs is small. The study 
results of the muti-components preparation SUB885C and ginseng reported in 
Chapter 4 and 5 [15, 16] may shed light on this approach. Both SUB885C and 
ginseng showed beneficial effects on dyslipidemia and may have influence on 
multiple pathways, which need further investigation. In China a remarkable high 
number of preparations have been handed down over the centuries with 
documented activity related to clinical features of what is now described as 
metabolic syndrome. The diabetic regulation health claims of these Chinese herbs 




metabolism, stimulating pancreatic function, and alleviate diabetes-induced 
oxidative stress by inhibiting lipid peroxidation [17-19]. Only a few side effects of 
Chinese herbs used in treating diabetes have been reported, however, further 
comprehensive studies are warranted as evidence is still scarce with likely 
underreporting [19]. 
The use of Chinese herbal medicines, either as food ingredients or drug therapy, 
in diabetes seems promising but still far from proven. First of all, the lack of 
standardization in quality control and quality assurance in producing the herb and 
herbal products often leads to inconclusive intervention results. Chapter 5 clearly 
illustrated the age-dependent effects of ginseng intervention and these age-
dependent effects may be due to the fact that the ratios and concentrations of 
specific ginsenosides in the ginseng roots change during growth [15]. The 
possibilities to evaluate the quality control and analyze the subtle and multiple-
pathway effects of Chinese herb or/and preparations have increased by the 
developments in systems biology-based metabolomics and specific animal models, 
as shown in Chapter 4 and 5.  
In addition, many of the herbs are still untested or tested only in limited trials, 
thus further clinical trials are needed to evaluate their effects and mechanisms 
[19]. To avoid the underestimation of the Chinese herb intervention, it is 
suggested that study subjects in such clinical trials should at first be stratified 
according to CM diagnosed subtypes as the CM diagnosis is on the syndrome 
types instead of a disease in WM perspective. Therefore, improved diagnosis and 
intervention go hand in hand, and metabolomics can certainly contribute to find 
and understand the molecular phenotypes.  
 
The challenge of metabolomics study and the future direction 
With respect to the technology of metabolite profiling, further progress is 
required to determine the chemical identity of peaks that can be determined with 
metabolite-profiling methods. Given the fact that the phenotype of any biological 
system is largely determined by its metabolite composition, the future 
development of metabolite-profiling technologies is of crucial importance to 
biomedical research [20].  
It seems wise to combine the untargeted metabolomics platform with targeted 
platforms in the same study. As for an untargeted global metabolite analysis, so 
many of the changes detected are possibly associated with high concentration 
metabolites. Many of the metabolites detected in studies by GC-MS are involved 
in amino acid metabolism, the Krebs cycle, glycolysis and β-oxidation, and thus it 
is perhaps not so surprising that the approach detects changes in these pathways 
[21].  To additionally apply a targeted approach where a number of predefined 
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metabolites are targeted, this has the advantage that this type of approach can 
also be readily made quantitative by nature and more biological interpretation of 
results can be drawn.  
Lipidomics measures all or subsets of lipids and provides a thorough perspective 
to study intervention induced lipid changes and metabolism in the complex 
biological system. To study more in-depth the involvement of specific lipid species 
and pathways, more understanding of lipid metabolism is needed. T2DM is not 
only a disorder of glucose metabolism, but also associated with a cluster of 
interrelated plasma lipid and lipoprotein abnormalities. Combining lipidomics with 
biochemically measured lipid profiles (e.g. total cholesterol, triglycerides, HDL-Cl, 
etc) can provide us with a better understanding of lipid metabolism. Chapter 3-5 
describes the successful application of this approach, using LC-MS based 
lipidomics, to investigate the changes in the lipidome of animal models following 
interventions and illustrated possible underlying mechanism how lipid were re-
distributed in the biological system after intervention.  
The amount of information generated with metabolomics studies does not in 
itself a guarantee for the discovery of a biomarker or a metabolic pattern. It is 
important to carry out biomarker validation and follow-up studies to complete the 
cycle of hypothesis generation and hypothesis testing. Approaches can be like 
MolPAGE  project [22],  using large cohorts and extensive statistical material from 
clinical settings will enable the method to expand into a better understanding of 
the disease pathophysiology, which could lead to the biomarkers for clinical 
settings.  
Another obstacle to progress in biomarker research resides as much in the culture 
and organization of academic research as in deficiencies in collaborative 
approaches. To become clinically useful, biomarker research must operate more 
like the large, collaborative networks mobilized for international genome-wide 
association studies and the multi-institution, multi-investigator big-science 
projects, involving industry and experts in molecular biology, genetics, analytical 
chemistry, computation, engineering, clinical-trial design, epidemiology, statistics, 
regulation and health-care economics [23]. To reach this, organizational and 
funding reforms should persuade the research community to adopt common 
standards and a cross disciplinary, systems-based approach to biomarker 
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The incidence of Type 2 diabetes mellitus (T2DM) and its cardio-metabolic 
complications continues to increase globally. This epidemiological reality 
heightens the urgency for gaining a deeper understanding of the complex 
molecular pathogenesis and genetic basis of this disease. Treatment focusing on 
glycaemic control is not enough to reduce the cardiovascular morbidities. A more 
personalized and system based strategy should be applied for diabetic prevention 
and management. 
Systems biology based metabolomics is regarded as a promising approach to 
provide an overview at a system level. It has been increasingly applied to study 
complex disease mechanisms to discover health-disease associated biomarkers. It 
also creates a possibility to study and evaluate the system based diagnosis and 
intervention of other healthcare systems such as Chinese Medicine (CM). The 
concept of personalized health with system diagnostic principles is the basis of 
CM which focuses on the ‘disease subtype’. If we can correlate CM diagnosed 
subtypes to quantitative metabolomics patterns, it may help us stratify the 
patients and find the related pattern of changes in metabolites, namely diseased 
related metabolic profile/fingerprint. 
The aim of this thesis was to combine metabolomics and CM diagnosis to search 
for diagnostic makers or metabolic profiles to subtype T2DM.  The multi-
component preparations or drugs to treat cardio-metabolic disorders were 
studied and assessed by metabolomics to understand the potential underlying 
multi-pathway effects and move further to personalized health of T2DM. 
In Chapter 2, an explorative study of 50 males with pre-diabetes was designed, 
combining urine metabolomics with CM diagnosis to identify metabolic patterns. 
Three CM physicians reached 85% diagnosis consistency resulting in the 
classification of 3 pre-diabetic groups. Based on 3 different CM diagnosed groups, 
two pre-diabetic subtypes (A and B) could be identified by urine metabolomics 
with different metabolic patterns. The majority of metabolites (51%), mainly 
sugars and amino acids, showed higher urine levels in subtype B compared with 
subtype A. This indicated more disturbances of carbohydrate metabolism, the 
Krebs cycle and renal function in subtype B. No differences were found for 
hematological and biochemical parameters except for levels of glucose and γ-
glutamyltransferase that were significantly higher in subtype B. This study proved 
that combining metabolomics with CM diagnosis can reveal the metabolic 
fingerprint for pre-diabetic subtypes. The identified urinary metabolites may be of 




which could lead to an improvement of personalized interventions for diabetics. 
However, due to the relatively small number of subjects, future studies with more 
subjects are needed to validate the subtypes yielded in the study and to 
demonstrate the further reliability and generalization of this novel approach to 
diagnose pre-diabetic subtypes. 
In Chapter 3 and 4, the effects of rimonabant and a multi-component preparation 
(SUB885C), both with reported effects of regulating weight and the improvement 
on cardio-metabolic risk factors, were assessed by lipidomics on mildly over-
weight ApoE*3Leiden.CETP Mice. Mice with 4-week intervention, either 
rimonabant or SUB885C, were compared with the ones without. Rimonabant is a 
selective cannabinoid-1 receptor antagonist for treatment of obesity and targets 
the endocannabinoid system. SUB885C is developed according to the principles of 
CM containing eight natural ingredients. The core formula is used in China for 
treatment of metabolic syndrome and early stage T2DM with obesity. Little is 
known about the impact of these two therapeutics on the regulation of lipid 
metabolism in the early stage of obesity.  A 4-week rimonabant intervention 
brought a significant reduction of the body weight, and moderate effects on lipid 
profile in mildly obese ApoE*3Leiden.CETP mice. Though no weight reduction was 
observed, SUB885C was able to produce multiple anti-atherogenic changes in 
lipids of the mice to improve metabolic parameters and lipid patterns, manifesting 
as decreased plasma cholesterol, triglycerides, increased HDL-C and a change in 
wide range of neutral lipids. These effects were comparable to those obtained 
with compounds belonging to known drugs (e.g. atorvastatin, niacin). In vitro, 
SUB885C extract caused adipolysis stimulation and adipogenesis inhibition in 3T3-
L1 cells. These two studies successfully illustrate the power of lipidomics in 
unraveling intervention effects and to help finding new targets or ingredients for 
lifestyle-related metabolic abnormality.  
Panax ginseng C. A. Mey (often simply referred to as ginseng) is reported to have 
effects to treat diabetic symptoms in China. However, the relationship between 
its therapeutic effect on diabetes and the quality and the growth age of this herb 
has not yet been reported. In Chapter 5, a combined approach involving 
lipidomics, biochemical parameters and herbal component profiling was used to 
evaluate the effects of the ginseng roots grown for 3–6 years on the regulation of 
hyperglycemia and dyslipidemia in a diabetic Goto-Kakizaki (GK) rat model. Six 
groups of GK rats received either metformin, 3- to 6-y-old ginseng root, or no 
treatment. The treatments were administered twice daily for 9 weeks. Compared 
to the untreated controls, treatment with 4- and 6-y-old ginseng roots 
significantly improved glucose disposal, and 5-y-old ginseng treatment 
significantly increased HDL-cholesterol. Treatment with 6-y-old ginseng 




improved plasma glycated hemoglobin (HbA1c). In addition, treatment with 4- to 
6-y-old ginseng influenced plasma lipidomics in diabetic GK rats by reducing TG 
lipid species. Metformin significantly reduced fasting blood glucose by 41% and 
reduced HbA1c by 11%, but showed no effects on the plasma lipid parameters. 
This study demonstrates that ginseng roots show growth age-dependent 
therapeutic effects on hyperlipidemia and hyperglycemia in diabetic GK rats. 
These age-dependent effects may be linked with the variation in both the ratios 
and concentrations of specific bioactive ginsenosides in ginseng roots of different 
age. The ≥ 4 year ginseng roots contain bioactive ginsenosides that may prove to 
be valuable in the development of drugs or dietary supplements to regulate lipid 
levels and increase glucose tolerance. This study introduced novel systems 
biology-based approaches for linking biological activities with potential active 
components in herbal mixtures.  
In Chapter 6 we reported the preliminary development of a fast plasma lipid 
analysis platform by direct nanospray infusion using a TriVersa chip-based 
instrument in combination with high resolution LTQ-Orbitrap mass spectrometer. 
The modified Folch method was applied for the plasma lipid extraction. With a 
volume of 5 µL plasma, a snapshot of   the following lipid classes can be obtained 
within 5 minutes per sample: triacylglycerols, cholesterol esters, 
phosphatidylcholines, lyso-phosphatidylcholines, sphingomyelins and fatty acids. 
When compared with the validated liquid chromatography–mass spectrometry 
(LC-MS) method, the fast method is equivalent for high abundance lipids; yet it is 
less precise than LC-MS method. However, it still holds promise for the fast lipids 
analysis for plasma samples and worth further development and validation.  
To conclude, the early systems biology based metabolomics investigations 
performed in this thesis converged analytical bioscience, clinical approach and the 
diagnostic perspectives in other health system such as CM to provide the systems 
biology view on the pre-stage of T2DM. It is promising to fusion metabolomics 
and CM diagnosis to search for subtypes of T2DM. Metabolomics, lipidomics in 
specific, is able to investigate multi-dimensional pharmacological effects and 
detect potential biomarkers related to these effects. These findings can be used to 
develop new research strategies and products at the nutrition-pharma interface 
to manage T2DM and related metabolic abnormalities.  However, it will only be 
realized when analytical methods will further improve, and the system biology 
based metabolomics approaches are more integrated in the medical research 





































De incidentie van type 2 diabetes mellitus (T2DM) en de daaraan verbonden 
cardio-metabole complicaties blijft wereldwijd toenemen. Deze epidemiologische 
werkelijkheid verhoogt de urgentie voor het verkrijgen van een beter begrip van 
de complexe moleculaire pathogenese en de genetische basis van deze ziekte. 
Behandeling gericht op  glykemische controle is veelal niet genoeg om de 
cardiovasculaire morbiditeit te verminderen. Een meer persoonlijke en systeem-
gebaseerde strategie heeft de voorkeur  voor diabetische preventie en therapie. 
Systeembiologie op basis van metabolomics wordt beschouwd als een 
veelbelovende aanpak om van een patient een beeld op systeemniveau  te geven 
en daarmee gepersonaliseerde geneeskunde mogelijk maakt. De systeembiologie 
wordt in toenemende mate toegepast om complexe ziektes en de onderliggende 
mechanismen te bestuderen, en voor de gezondheid-ziekte relatie biomarkers te 
ontdekken. Het creëert ook de mogelijkheid om het systeem te bestuderen en 
evalueren van op basis van diagnose en tussenkomst van andere medische 
systemen zoals Chinese Geneeskunde (CM). Het concept van gepersonaliseerde 
gezondheidszorg met diagnostische principes is de basis van CM die zich richt op 
het 'ziekte subtype'. Als CM gediagnosticeerde subtypes gecorreleerd kunnen 
worden met kwantitatieve metaboliet-patronen, kan het helpen patiënten  te 
stratificeren en het bijbehorende patroon van veranderingen in 
metabolietconcentraties, het ziekte gerelateerde metabolietprofiel te 
identificeren. Het doel van het onderzoek beschreven in dit proefschrift was om 
metabolomics en CM diagnostiek te combineren om te zoeken naar de 
diagnostische markers of metabolietprofielen voor T2DM subtypes. De multi-
component preparaten of medicijnen om cardio-metabole stoornissen te 
behandelen werden bestudeerd met  metabolomics om de onderliggende 
multifactoriele effecten te begrijpen, en daarmee de persoonlijke therapie van 
T2DM te versterken. 
Hoofdstuk 2 beschrijft een studie aan 50 mannen met pre-diabetes waarin een 
combinatie van urine metabolomics met CM diagnose is gedaan met als doel de 
metabolietpatronen te identificeren die correleren met de CM diagnose. Drie CM 
artsen bereikten 85%  overeenkomst in de diagnose wat resulteerde in de indeling 
van de proefpersonen in drie pre-diabetische subgroepen. Op basis van de 
metabolietprofielen in urine konden twee pre-diabetische subtypes A en B 
geïdentificeerd woorden. De meerderheid van de metabolieten (51%), vooral 
suikers en aminozuren, hadden hogere urineconcentraties voor subtype B in 
vergelijking met subtype A. Dit duidt op grotere verstoringen van het koolhydraat 
metabolisme, de Krebs-cyclus en de nierfunctie bij subtype B. Er werden geen 




voor het gehalte aan glucose en γ-glutamyltransferase die significant hoger waren 
in subtype B. Uit dit onderzoek blijkt dat de combinatie van metabolomics en CM 
diagnose resulteert in een metabole vingerafdruk voor pre-diabetische subtypen. 
De geïdentificeerde metabolieten in de urine zijn potentieel klinisch relevant voor 
niet-invasieve screening op subtypen van pre-diabetes, en kunnen leiden tot een 
verbetering van gepersonaliseerde interventies voor diabetici. Vanwege het 
relatief kleine aantal proefpersonen in studie zijn toekomstige studies met meer 
deelnemers noodzakelijk om de betrouwbaarheid en generalisatie van deze 
nieuwe benadering voor pre-diabetische subtypering te onderbouwen en te 
valideren.  
In hoofdstuk 3 en 4 is onderzoek gedaan naar de effecten van Rimonabant en een 
multi-component CM geneesmiddel (SUB885C), beiden met gerapporteerde 
effecten op de regulering van gewicht en de verbetering van cardio-metabolische 
risicofactoren, op het plasmalipidenprofiel in ApoE * 3Leiden.CETP muizen met 
licht overgewicht. De muizen kregen een 4-weken durende interventie, hetzij 
Rimonabant of SUB885C, en werden vergeleken met een controlegroep. 
Rimonabant is een selectieve cannabinoïde-1 receptor antagonist voor de 
behandeling van obesitas en richt zich op het endocannabinoïdsysteem. SUB885C 
is ontwikkeld volgens de principes van CM en bevat acht natuurlijke ingrediënten. 
De kernformulering van SUB885C wordt in China gebruikt voor de behandeling 
van metabool syndroom en T2DM bij obese patienten in een vroeg stadium. Er is 
weinig bekend over de impact van deze twee geneesmiddelen op de regulering 
van het vetmetabolisme in de vroege fase van obesitas. De behandeling  met 
Rimonabant gedurende 4 weken leidde tot een aanzienlijke vermindering van het 
lichaamsgewicht en had een geringe invloed op het plasmalipiden profiel in licht 
obese ApoE * 3Leiden.CETP muizen. Hoewel er geen gewichtsverlies werd 
waargenomen na behandeling met SUB885C, leidde dit CM geneesmiddel tot 
meerdere anti-atherogene veranderingen in het plasmalipidenprofiel van de 
muizen. De verbetering van metabole parameters en lipidenpatronen 
manifesteerde zich als een verlaagd plasma cholesterol, triglyceriden, verhoogde 
HDL-C en een verandering in een scala van neutrale lipiden. Deze effecten waren 
vergelijkbaar met die verkregen met bekende geneesmiddelen (bijv. atorvastatine, 
niacine). In vitro, stimuleert  een SUB885C extract adipolysis en remt adipogenese 
in 3T3-L1 cellen. Deze twee studies met illustreren de kracht van lipidomics in het 
ontrafelen van interventie-effecten en kan daarmee helpen bij het vinden van 
nieuwe targets en/ of ingrediënten voor interventies bij lifestyle-gerelateerde 
metabole aandoeningen. 
Panax ginseng CA Mey (vaak simpelweg aangeduid als ginseng) wordt in China 
gebruikt als een middel om diabetische symptomen in China behandelen. Echter, 




samenstelling (kwaliteit en leeftijd) is nog onduidelijk. In hoofdstuk 5 is een 
gecombineerde aanpak  van lipidomics, biochemische parameters en 
samenstellings analyse van Panax toegepast om de effecten van de ginseng 
wortels,  variërend in leeftijd van  3-6 jaar, op hyperglycemie en dyslipidemie in 
een diabetisch Goto-Kakizaki (GK) rat model te evalueren. Zes groepen van GK 
ratten kregen ofwel metformine, 3  tot 6 jaar oude ginseng wortel, of geen 
behandeling. De behandelingen werden tweemaal daags toegediend gedurende 9 
weken. Vergeleken met de onbehandelde groep gaf  zowel  4 als 6 jaar oude 
ginsengwortel een aanzienlijk verbeterd glucosemetabolisme, en de 5 jaar oude 
ginseng-behandeling gaf een significant verhoogd HDL-cholesterol. De 
behandeling met 6 jaar oude ginseng leidde tot een significante daling van 
plasma-triacylglyceriden (TG) en VLDL-cholesterol en een verbetering van  
geglycosyleerd hemoglobine (HbA1c) in plasma. Bovendien, resulteerde de 
behandeling met 4, 5 en 6 jaar oude ginseng in een verlaging van plasma-
triglyceriden in diabetische GK. Metformine verminderde de bloedsuikerspiegel 
na vasten met 41% en verlaagde de HbA1c-waarde met 11%, maar toonde geen 
effecten op de plasmalipiden. Deze studie toont aan dat ginseng een 
leeftijdsafhankelijke (groei) therapeutisch effect op hyperlipidemie en 
hyperglycemie in diabetische GK ratten heeft. Deze leeftijdsafhankelijke effecten 
kunnen worden gerelateerd aan de variatie in zowel de verhoudingen als 
concentraties van specifieke bio-actieve ginsenosiden in ginseng wortels. De ≥4 
jaar oude  ginseng wortels bevatten bioactieve ginsenosiden die waardevol zijn 
voor de ontwikkeling van medicijnen of voedingssupplementen om dyslipidemie 
te reguleren en glucose tolerantie te verhogen. Deze studie heeft nieuwe 
systeembiologische benaderingen geïntroduceerd voor het koppelen van 
biologische activiteit met actieve componenten in kruidenmengsels. 
In hoofdstuk 6 is de ontwikkeling beschreven van een snelle plasmalipiden 
analyseplatform door middel van directe nanospray infusie met behulp van een 
TriVersa nanospraychip systeem in combinatie met een hoge resolutie LTQ-
Orbitrap massaspectrometer. Een aangepaste Folch methode werd toegepast 
voor de extractie van lipiden uit plasma. Met een volume van slechts 5 µl plasma, 
kan binnen 5 minuten per monster data verkregen worden van de volgende 
lipidenklassen: triacylglycerolen, cholesterol esters, fosfatidylcholines, lyso-
fosfatidylcholines, spingomyelinen en vetzuren. In vergelijking met de 
gevalideerde vloeistofchromatografie-massaspectrometrie (LC-MS)-methode, is 
deze snelle methode ondanks een mindere nauwkeurigheid  nagenoeg 
gelijkwaardig voor plasmalipiden met een hoge concentratie. Deze methode is in 
principe bijzonder geschikt voor high-throughput plasmalipiden analyse maar 




Tot slot, het systeembiologie-metabolomics onderzoek verricht in dit proefschrift 
convergeerde analytische biowetenschappen, klinisch onderzoek en de 
diagnostische concepten in andere gezondheidszorgsystemen, zoals CM om een 
systeembiologisch beeld van de pre-fase van T2DM te verkrijgen. Het is 
veelbelovend om met een combinatie van  metabolomics en CM 
diagnosemethodieken te zoeken naar subtypes van T2DM. Metabolomics, en i.h.b. 
lipidomics, is in staat om multi-dimensionele farmacologische effecten te 
onderzoeken en potentiële biomarkers die verband houden met deze effecten op 
te sporen. Deze bevindingen kunnen worden gebruikt om nieuw 
onderzoekstrategieën en/of producten op het voeding-farma grensvlak te 
ontwikkelen voor T2DM behandeling en de daarmee samenhangende metabole 
afwijkingen te beheren. Dit zal echter alleen worden gerealiseerd als analytische 
methoden verder  verbeteren, en  systeembiologie en  metabolomics beter 
geïntegreerd zijn binnen biomedisch onderzoek. 
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List of abbreviations 
 
ACN, acetonitrile 
ALT, alanine aminotransferase  
ANOVA, analysis of variance 
ApoE*3Leiden, Apolipoprotein E3 Leiden 
BHT, butylated hydroxytoluene  
CB1, cannabinoid 1 
CETP, cholesteryl ester transfer protein  
CER, ceramide 
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CM, Chinese medcine 
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DG, diacyglyceride 
DI: direct infusion 
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(V) LDL, (very) low density lipoprotein 
*/ ×,  times  
WM, Western medicine 
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